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Abstract 
Maintaining redox homeostasis is crucial for normal cellular functions. Electron leak by the 
cytochrome P450 enzymes renders steroidogenic tissues acutely vulnerable to redox imbalance and 
oxidative stress is implicated in several potentially lethal adrenal disorders. This thesis aims to 
further delineate the role of oxidative stress in triple A syndrome and familial glucocorticoid 
deficiency (FGD).  
Triple A syndrome incorporates adrenal failure and progressive neurodegenerative disease. The 
AAAS gene product is the nuclear pore complex protein ALADIN, of unknown function. Patient 
dermal fibroblasts are sensitive to oxidative stress, with failure of nuclear import of DNA repair 
proteins and ferritin heavy chain protein. To provide an adrenal and neuronal-specific disease 
model, I established AAAS-knockdown in H295R human adrenocortical tumour cells and SH-SY5Y 
human neuroblastoma cells. This had effects on cell viability, exacerbated by hydrogen peroxide 
treatment. Redox homeostasis was impaired in AAAS-knockdown H295R cells, with depletion of key 
components of the steroidogenic pathway and a significant reduction in cortisol production, with 
partial reversal following treatment with N-acetylcysteine.  
Mutations in the mitochondrial antioxidant, nicotinamide nucleotide transhydrogenase (NNT), 
causing FGD, have recently highlighted the importance of redox regulation in steroidogenesis. I 
investigated seven individuals from a consanguineous Kashmiri kindred, mutation negative for 
known causes of FGD. A stop gain mutation, p.Y447* in TXNRD2, encoding the mitochondrial 
selenoprotein thioredoxin reductase 2 segregated with the disease trait; with complete absence 
of the 56 kDa TXNRD2 protein in patients homozygous for the mutation.  TXNRD2-knockdown led to 
impaired redox homeostasis in H295R cells. This is the first report of a homozygous mutation in any 
component of the thioredoxin antioxidant system leading to inherited disease in humans. 
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Antioxidant defence within the adrenal gland warrants further investigation and abnormalities of 
other components within these pathways may prove to be causative in as yet unaccounted for cases 
of primary adrenal insufficiency. 
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Chapter 1 Introduction 
1.1 Hypothalamic-pituitary-adrenal axis 
The adrenal glands are responsible for the production of several classes of steroids. The central 
adrenal medulla contains neural crest-derived chromaffin cells that release catecholamines in 
response to stimulation by the sympathetic nervous system. The outer part of the gland, the cortex, 
is further subdivided into 3 functionally distinct sections comprising the outer zona glomerulosa 
which produces aldosterone, the middle zona fasciculata which secretes glucocorticoids and the 
inner zona reticularis which produces adrenal androgens. The hypothalamus and pituitary tightly 
regulate the production of glucocorticoids enabling an appropriate stress response and the 
maintenance of a diurnal rhythm of cortisol secretion. Emotional and physical stresses excite 
brainstem catecholamine producing circuits which in turn stimulate parvocellular neurons of the 
hypothalamic paraventricular nucleus. These secrete corticotropin-releasing hormone (CRH) and 
arginine vasopressin (AVP) into the hypophyseal portal circulation. CRH and AVP synergistically 
trigger secretion of adrenocorticotropic hormone (ACTH) from the anterior pituitary. ACTH is formed 
by cleavage of proopiomelanocortin (POMC), from which α-, β- and γ-melanocyte-stimulating 
hormones are also produced. ACTH has physiological actions in several peripheral sites, namely the 
adrenal glands where it stimulates glucocorticoid release. Glucocorticoids exert their effects in a 
range of tissues. Furthermore they exert negative feedback, regulating the release of CRH and AVP 
from the hypothalamus and ACTH from the anterior pituitary. This constitutes the hypothalamic-
pituitary-adrenal pathway (Figure 1.1).  
1.2 Cortisol production 
ACTH exerts its effects in the adrenal zona fasciculata by binding to the melanocortin 2 receptor, 
MC2R. This stimulates production of intracellular cyclic adenosine monophosphate (cAMP) which in 
turn stimulates cAMP-dependent protein kinase (protein kinase A). This process induces the import 
of cholesterol esters into the cell, by the scavenger receptor B1, which are hydrolysed by hormone   
22 
 
 
Figure 1.1. Schematic overview of the HPA axis. CRH and AVP at the hypothalamus stimulate ACTH 
production in the anterior pituitary gland. ACTH released into the circulation acts on the adrenal 
cortex to produce glucocorticoids (cortisol in humans and corticosterone in rodents). Glucocorticoids 
negatively feedback to regulate the release of CRH and AVP at the hypothalamus and ACTH at the 
pituitary. 
 
sensitive lipase. Cholesterol is then taken up into the mitochondrion, a process activated by 
steroidogenic acute regulatory protein (STAR) and mediated by the translocator protein (TSPO)-
associated multi-component complex [1]. This is the first and rate limiting step in cortisol synthesis. 
ACTH stimulates the synthesis of several steroidogenic enzymes, including STAR, via a variety of 
mechanisms. These include activation of the cAMP response element binding protein (CREB) and 
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furthermore ACTH induces STAR transcription by cAMP inhibition of salt induced kinase (SIK), which 
allows phosphorylation of the transducer of regulated CREB activity (TORC), which in turn activates 
CREB thereby inducing STAR transcription [2]. Plasma cortisol increases almost within minutes of the 
adrenal cortex being stimulated by ACTH, largely dependent on pre-existing STAR stores [3]. 
Following the acute response a longer term response to ACTH involves maintenance of steroidogenic 
enzyme level, including STAR, regulated by cAMP [4]. The biosynthesis of glucocorticoid from 
cholesterol involves the sequential actions of the cytochrome P450 enzymes in the mitochondria 
and smooth endoplasmic reticulum and the hydroxysteroid dehydrogenases (Figure 1.2). The 
cytochrome P450 enzymes are divided into the Type I mitochondrial enzymes (P450scc, P450c11β, 
and P450c11AS) and Type II microsomal enzymes (P450c17 and P450c21) [5]. Both sets of enzymes 
require the transfer of electrons from reduced NADP (NADPH) for activity; for the Type I enzymes 
this occurs via ferredoxin and ferredoxin reductase, and for the Type II enzymes, via P450 
oxidoreductase.  
In healthy individuals cortisol secretion is pulsatile with circulating cortisol concentrations fluctuating 
in a circadian fashion, with highest levels in the early morning, between 0600h and 0800h and 
lowest around midnight. Whilst there is diurnal variation in cortisol synthesis, levels tend to remain 
similar through all stages of life.  
1.3 Androgen production 
The adrenal androgens, androstenedione, dehydroepiandrosterone (DHEA) and the sulphur ester of 
dehydroepiandrosterone (DHEAS) are produced in the zona reticularis, under the regulation of ACTH 
(Figure 1.2). The precise mechanisms responsible for the control of androgen synthesis and the 
development of the zona reticularis remain unclear. Unlike cortisol production, androgen production 
varies though life. Typically high levels are seen in the neonatal period with a decline during the first 
few months of life. Thereafter there is a steady increase during adrenarche between the ages of 6 
24 
 
and 10 years. Peak levels are found during the 3rd decade of life followed by a steady decline from 
the 5th decade. 
1.4 Aldosterone production 
The regulation of aldosterone production is a separate entity to the ACTH-induced production of 
glucocorticoids and androgens. Instead aldosterone production is predominantly controlled by the 
renin-angiotensin-aldosterone system. 
The juxtaglomerular cells of the kidney produce renin in response to a number of stimuli, including 
hyponatraemia, hyperkalaemia, low renal arteriolar pressure, upright position, vasodilatory drugs 
and β-adrenergic stimulation. Renin cleaves Angiotensinogen to Angiotensin I, which is converted to 
Angiotensin II by the angiotensinogen converting enzyme. Angiotensin II causes an increase in blood 
pressure via actions mediated through the AT1 receptor. In the first instance Angiotensin II 
stimulates arteriolar vasoconstriction, a process that occurs within seconds. Secondly, Angiotensin II 
stimulates increased transcription of CYP11B2 encoding the cytochrome P450 enzyme, P450c11AS, 
within the zona glomerulosa, thereby increasing aldosterone synthesis. Increased plasma potassium 
also stimulates aldosterone production through membrane depolarisation and calcium channel 
alteration leading to CYP11B2 transcription. Aldosterone causes renal sodium retention and 
potassium loss, increasing intravascular volume and therefore blood pressure. 
As regulation of aldosterone synthesis is not ACTH-induced, certain disorders of adrenal 
insufficiency, such as classical familial glucocorticoid deficiency involving disrupted ACTH signalling, 
may occur in the absence of hypoaldosteronism. Other conditions involving adrenal hypoplasia or 
destruction can affect both systems.  
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Figure 1.2. The adrenal steroidogenesis pathway. Enzymes required for steroidogenesis are shown 
in italics. Those requiring electron transfer by ferredoxin reductase and ferredoxin are outlined in 
red (Type I mitochondrial enzymes). The microsomal enzymes are outlined in blue, these include the 
Type II microsomal P450 enzymes (P450c17 and P450c21) which accept electrons from P450 
oxidoreductase, and the hydroxysteroid dehydrogenases (3βHSD, 17β-HSD3). 
 
1.5 Inherited primary adrenal insufficiency 
Perturbations in the hypothalamic-pituitary-adrenal (HPA) axis can be caused by several 
physiological mechanisms and pathological conditions. Adrenal insufficiency is classified according to 
the underlying mechanism; with primary relating to disease at the level of the adrenal glands, 
secondary relating to pituitary disease impairing the release of ACTH and tertiary caused by impaired 
synthesis or action of CRH and/or AVP from the hypothalamus. 
The prevalence of primary adrenal insufficiency is increasing, with autoimmune adrenal insufficiency 
as the primary cause accounting for 80-90% of cases in the developed world, of which 40% are 
isolated and 60% occur in the context of autoimmune polyendocrinopathy syndrome [6]. In 
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idiopathic autoimmune adrenal disease, cell-mediated immune mechanisms lead to destruction of 
the adrenal cortex and may involve antibodies against 21-hydroxylase and other autoantigens [7]. 
Additionally, increased susceptibility to autoimmune Addison’s disease has been identified in 
association with the MHC haplotypes DR3-DQ2 and DR4-DQ8, protein tyrosine-phosphatase non-
receptor type 22, cytotoxic T lymphocyte antigen 4 and MHC class II transactivator. Autoimmune 
adrenal insufficiency is also described in the context of autoimmune polyendocrinopathy syndromes: 
Type 1 (APECED; autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy), Type 2 
(autoimmune adrenal insufficiency, autoimmune thyroid disease, with or without type 1 diabetes 
mellitus) and Type 4 (autoimmune adrenal insufficiency with one or more minor component 
autoimmune disease) [8]. Both Types 1 and 2 have a strong genetic component with Addison’s 
disease as a prominent feature of the disorder. Additionally, 40-50% of patients with Addison’s 
disease will go on to develop an associated endocrinopathy. Aetiologies of acquired primary adrenal 
insufficiency include infection, haemorrhage and drug-induced disease. Infectious causes include 
tuberculosis-associated adrenalitis which was once the most prevalent cause of primary adrenal 
insufficiency.  
In childhood, genetic causes of primary adrenal insufficiency are the most common. Most frequently 
seen is congenital adrenal hyperplasia, which in the main is caused by mutations in CYP21A2 leading 
to 21-hydroxylase deficiency and more rarely by deficiency in 11β-hydroxylase, 17α-hydroxylase, 17, 
20-lyase, 3β-hydroxysteroid dehydrogenase or P450 oxidoreductase. Classic 21-hydroxylase 
deficiency is characterised by glucocorticoid deficiency but a large proportion also have 
mineralocorticoid deficiency and adrenal hyperandrogenism leading to virilisation. Impaired 
development and activity of the adrenal medulla can also occur. Several other inherited causes of 
primary adrenal insufficiency are described including X-linked adrenoleukodystrophy (ALD). ALD is an 
inherited neurometabolic disorder incorporating progressive demyelination in the central nervous 
system, axonopathy in the spinal cord and adrenal insufficiency [9]. The disease is caused by 
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mutations in the ABCD1 gene on Xq28, encoding the adrenoleukodystrophy protein (ALDP), a 
member of the peroxisomal ATP-binding cassette (ABC) transporters. The clinical phenotype is 
variable, from a late onset, slowly progressive disease adrenomyeloneuropathy (AMN) to cerebral 
inflammatory demyelinating forms which can be fatal [9]. Adrenal insufficiency occurs in 
approximately two thirds of patients with AMN, presenting with both hypocortisolism and a 
reduction in adrenal androgen production [10]. Other causes of inherited primary adrenal 
insufficiency are listed below in Table 1.1. 
 
Genetic Disorder Clinical features in addition to adrenal 
insufficiency 
Pathogenetic mechanism 
Adrenoleukodystrophy 
or 
adrenomyeloneuropathy 
Weakness, spasticity, dementia, blindness, 
quadriparesis 
ABCD1 and ABCD2 
mutations 
Congenital adrenal hyperplasia 
21-hydroxylase 
deficiency 
Hyperandrogenism CYP21A2 mutations 
11β-hydroxylase 
deficiency 
Hyperandrogenism, hypertension CYP11B1 mutations 
3β-hydroxysteroid 
dehydrogenase type 2 
deficiency 
Ambiguous genitalia in boys, postnatal 
virilisation in girls 
HSD3B2 mutations  
17α-hydroxylase 
deficiency 
Pubertal delay in both sexes, hypertension CYP17A1 mutations 
P450 oxidoreductase 
deficiency 
Skeletal malformation (Antley-Bixler 
syndrome), abnormal genitalia 
POR mutations 
P450 side-chain cleavage XY sex reversal CYP11A1 mutations 
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deficiency 
Congenital lipoid 
adrenal hyperplasia 
XY sex reversal STAR mutations 
 
Smith-Lemli-Opitz 
syndrome 
Craniofacial malformations, mental 
retardation, growth failure, hyponatraemia, 
hyperkalaemia, cholesterol deficiency 
DHCR7 mutations 
Adrenal hypoplasia congenita 
X-linked Hypogonadotropic hypogonadism in boys NROB1 mutations 
Xp21 contiguous gene 
syndrome 
Duchenne muscular dystrophy, glycerol 
kinase deficiency, psychomotor retardation 
Deletions of genes for 
muscular dystrophy 
(DMD), glycerol kinase 
(GK), NROB1 
SF-1 linked XY sex reversal NR5A1 mutations 
 
IMAGe syndrome Intrauterine growth retardation, 
metaphyseal dysplasia, adrenal hypoplasia 
congenital, genital abnormalities 
CDKN1C mutations 
Kearns-Sayre syndrome External ophthalmoplegia, retinal 
degeneration, cardiac conduction defects, 
other endocrine disorders 
Mitochondrial DNA 
deletions 
Wolman’s disease Bilateral adrenal calcification, 
hepatosplenomegaly 
LIPA mutations 
Sitosterolaemia Xanthomata, arthritis, premature coronary 
artery disease, short stature, gonadal and 
adrenal failure 
ABCG5 and ABCG8 
mutations 
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Familial glucocorticoid deficiency 
Type 1 Hyperpigmentation, tall stature, 
characteristic facial features such as 
hypertelorism and frontal bossing, lethargy 
and muscle weakness but normal blood 
pressure 
MC2R mutations 
Type 2 Hyperpigmentation, normal height, 
hypoglycaemia, lethargy and muscle 
weakness, but normal blood pressure 
MRAP mutations 
FGD variant: MCM4 Growth failure, increased chromosomal 
breakage, natural killer cell deficiency 
MCM4 mutations 
FGD variant: NNT Hyperpigmentation NNT mutations 
 
Triple A syndrome Achalasia, alacrima, deafness, mental 
retardation, hyperkeratosis 
AAAS mutations 
 
Table 1.1. Genetic causes of primary adrenal insufficiency adapted from Charmandari et al, Lancet, 
2014 [6]. 
 
The contents of this thesis relate to triple A syndrome and familial glucocorticoid deficiency (FGD). 
ACTH resistance occurs in both conditions causing glucocorticoid deficiency. Both conditions are 
inherited in an autosomal recessive manner. Clinical features in triple A syndrome can be variable 
and neurodegenerative features can arise together with adrenal insufficiency, similar to ALD. 
Classically in FGD, isolated glucocorticoid deficiency is seen, however in the newly described FGD 
variants due to MCM4 mutation, extra-adrenal manifestations are described. In both triple A 
syndrome and more recently FGD, oxidative stress is implicated in the pathogenesis. 
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1.6 The triple A syndrome 
Triple A syndrome (OMIM #231550) was initially described in two pairs of siblings by Allgrove and 
colleagues in 1978 [11]. It is classically characterised by a triad of alacrima (an inability to produce 
tears), achalasia of the oesophageal cardia and adrenal failure. In approximately 70% of patients a 
highly disabling neurodegenerative process ensues. It is an autosomal recessive disorder linked to a 
mutation in AAAS (Achalasia-Addisonianism-Alacrima Syndrome) encoding the protein ALADIN 
(Alacrima Achalasia aDrenal Insufficiency Neurologic disorder) of unknown function. Mutations of 
AAAS have also been identified in patients presenting with just one of the classical features. In fact, 
only 58% of patients described in the largest case series to date (215 patients in 173 families from 37 
countries) present with all three ‘A’s: alacrima, achalasia, adrenal insufficiency (Huebner, personal 
communication). 
1.6.1 Epidemiology of triple A syndrome 
Triple A syndrome is a rare condition with just over 200 cases reported worldwide from over 30 
different countries. Families reported in the literature have been of European, Asian, North African, 
Arab and North American origin [12-14] . Consanguinity is described in 30% of families and the age 
of presentation is relatively heterogeneous (Huebner, personal communication). Male to female 
ratios are approximately equal. There are no founder effects for triple A syndrome. 
1.6.2 Clinical manifestations of triple A syndrome and current management of triple A syndrome 
patients 
1.6.2.1 Alacrima 
The earliest and most consistent manifestation of triple A syndrome is alacrima, an inability to 
produce tears, which affects the majority of patients. This is often described retrospectively 
following diagnosis, and is reported to develop in the first year of life [13, 15]. Alacrima is confirmed 
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by Schirmer’s test in which the deficiency of tear production is observed. Small lacrimal ducts have 
been observed on MRI scanning in one case and autonomic dysfunction at the level of the lacrimal 
glands has also been suggested as the cause of the failure of tear production [16].  
Additional ophthalmic features described include optic atrophy, identified by pathological visual 
evoked responses, and optical coherence tomography [17]. Normal electroretinograms suggest that 
the retina is not involved. Interfamilial variability relating to the extent of optic atrophy is described. 
1.6.2.2 Achalasia 
Approximately 80% of triple A patients present with achalasia of the oesophageal cardia. Symptoms 
include dysphagia, vomiting and failure to thrive [13, 18]. Management includes repeated 
endoscopic balloon dilatation with some patients requiring surgical intervention, for instance Heller 
cardiomyectomy combined with Nissen fundoplication. 
The pathophysiology of the achalasia is unclear. The absence of ganglion cells and nerve fibres was 
described following necropsy in one adult with triple A syndrome [11]. A recent study of 
myomectomy specimens from ten children with triple A syndrome revealed fibrosis of the 
intermuscular plane (between the circular and longitudinal musculature) in all patients [19]. This was 
postulated to impair the mechanical properties together with electrical coupling between the two 
muscle layers, contributing to the pathogenesis. In addition, there was a marked reduction of the 
number of myentric ganglia and myentric neurons suggesting a lack of intrinsic innervation. Similar 
to achalasia of other causes, a lack of nitrergic inhibition with preservation of cholinergic excitation 
is observed, contributing to the sphincter hypertonicity seen in the disease [19].  
1.6.2.3 Adrenal Insufficiency 
The adrenal failure observed in triple A syndrome is ACTH-resistant. It most commonly occurs in the 
first decade of life, although the age at presentation can vary from birth to 35 years of age. Adrenal 
insufficiency can manifest as hypoglycaemic seizures, frequent fainting and in some patients, when 
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the cortisol deficiency is unrecognised, death as a result of acute adrenal crisis [20]. 
Hyperpigmentation as a consequence of raised POMC products is also observed. The adrenal 
insufficiency is predominantly glucocorticoid deficiency (75% patients) however mineralocorticoid 
deficiency also occurs in 27% of these patients (Huebner, personal communication). 
Glucocorticoid insufficiency is diagnosed by a failed response (inability to show an appropriate rise in 
cortisol) to a low dose synacthen (ACTH) test [13].  A high baseline ACTH in the face of normal 
cortisol is also characteristic. Given the devastating consequences of adrenal insufficiency, 
glucocorticoid deficiency should be screened for in all patients with a potential diagnosis of triple A 
syndrome. Those patients with glucocorticoid deficiency are commenced on physiological 
replacement therapy, with some also requiring additional mineralocorticoid replacement. 
Necropsy carried out in one of the pairs of original siblings published revealed atrophy of the adrenal 
cortical zona fasciculata and zona reticularis, suggesting a degenerative process [11]. 
1.6.2.4 Neurodegenerative dysfunction 
The neurological features of triple A syndrome are highly variable, even amongst members of the 
same kindred [12]. Pathology often occurs in a patchy distribution and can encompass autonomic 
neuropathy with or without central and peripheral nervous system involvement. The most 
commonly associated features are that of a pyramidal syndrome, peripheral neuropathy and bulbar 
dysfunction [15]. 
Autonomic neuropathy symptoms include impotence, postural hypotension and bladder dysfunction 
[12, 15]. The alacrima commonly seen in the disease may also be related to a lack of 
parasympathetic innervation of the tear glands [12]. Upper and lower motor neuron abnormalities 
are also observed with hyper-reflexia presenting in the first decade [13]. The neuropathy 
predominantly involves motor fibres with a few patients also exhibiting sensory deficits. Some 
patients can present with Parkinsonian features and others may have dementia [12, 15].  
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The pathophysiology of the neurodegenerative aspects of the disease is unclear. MRI images of the 
brain and spinal cord of five families presenting with significant neurodegenerative disease have 
been reported as normal [12]. There have been no consistent histological features reported; some 
reports describe normal sural nerve biopsies whilst others describe changes suggestive of axonal 
degeneration with loss of both myelinated and unmyelinated fibres [12, 21]. 
The neurodegenerative aspects of the disease are progressive and can be highly disabling with little 
room for therapeutic intervention. Those patients presenting late with the triple A syndrome often 
have predominantly neurodegenerative features and the syndrome should be considered in patients 
with a multisystem neurological disorder [15, 21]. 
1.6.2.5 Other clinical features 
Several dermatological features are also described and these include xerostomia, palmo-plantar and 
punctate hyperkeratosis [15]. Other features such as microcephaly and short stature are also 
reported [22]. Additionally, 27.5% of patients are reported to have delayed puberty, particularly 
amongst male patients (Huebner, personal communication). For some this was demonstrated to be 
secondary to hypogonadotropic hypogonadism.  Amenorrhoea is reported in 4.1% of female patients 
and impotence in 13.2% of male patients (Huebner, personal communication).  
1.6.3 Genetics of triple A syndrome 
A systematic genome linkage scan in eight triple A families, of whom three were consanguineous, 
showed evidence for linkage of the triple A syndrome to markers on chromosome 12q13, with no 
evidence of genetic heterogeneity in these families. Haplotype and multipoint analyses suggested 
that the gene was located on a chromosomal segment flanked by the markers D12S1629 and 
DS12S312 (6cM apart) [23]. The novel gene, named AAAS, encoding a 547 amino acid protein was 
subsequently identified using fine-mapping based on linkage disequilibrium in 8 North African inbred 
families, with homozygous mutations in affected individuals [24].  This was corroborated by a second 
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group who also identified mutations in AAAS following refinement of the critical region on 
chromosome 12q13 and a positional genomics approach [25].  
Since then, over 60 different mutations have been described in the literature in AAAS, scattered 
throughout the gene. In the majority of patients these are frameshift and nonsense mutations. In 
the largest case series to date which encompasses 175 families and 215 patients, 31 of these families 
do not have mutations in the AAAS gene suggesting that genetic heterogeneity exists (Huebner, 
personal communication). This finding has also previously been reported in the literature [12, 26, 
27]. 
1.6.4 Genotype-phenotype correlation 
Three mutations have recently been identified as most commonly causing the disease; p.G14fs 
(c.43C>A), p.S263P (c.787T>C), c.1331+IG>A. Genotype-phenotype correlation has been investigated 
in these and other mutations [12, 13, 28] (Huebner, personal communication). Interestingly there is 
a lack of correlation, indicating that modifying factors related to other genes or the environment 
could be important. Triple A syndrome patients with AAAS mutations are reported to present with a 
higher frequency of adrenal insufficiency in comparison to those without identified AAAS mutations. 
1.6.5 GMPAA mutations causing achalasia, alacrima and neurological deficits 
Mutations in guanosine diphosphate (GDP)-mannose pyrophosphorylase A (GMPPA) have recently 
been described in a cohort of patients with a disease characterised by achalasia, alacrima and 
neurological deficits [29]. The condition, inherited in an autosomal recessive manner, shows many 
similarities to triple A syndrome. Importantly, none of the individuals with GMPPA mutations have 
adrenal insufficiency. GMPPA is thought to serve as a regulatory unit of GMPPB which catalyses the 
formation of GDP-mannose, an essential precursor of glycan moieties of glycoproteins and 
glycolipids, associated with congenital and limb-girdle muscular dystrophies with hypoglycosylation 
of α-dystroglycan. The authors propose that individuals presenting with a triple A syndrome-like 
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phenotype in the absence of adrenal insufficiency should primarily be investigated for mutations in 
GMPPA. 
1.6.6 Expression of AAAS 
AAAS expression has been investigated using a multiple human tissue expression array. Abundant 
AAAS expression was demonstrated in the adrenal gland, gastrointestinal structures, pituitary gland, 
cerebellum and foetal lung [25]. Expressed sequence tags or ESTs homologous to AAAS were also 
identified in cDNA libraries of a diverse range of adult human tissues (Hs 125262) and whole embryo 
(AA330197), suggesting ubiquitous expression of AAAS [25]. 
In situ hybridisation studies in the adult rat reveal high levels of AAAS mRNA in the adrenal cortex, 
peripheral and central nervous systems [30]. CNS expression was found to be the highest in neurons 
of the cerebral cortex, cerebellum, hippocampus, motor-associated nuclei of the brainstem and the 
ventral horn of the spinal cord. Non-neuronal cells such as fibrous astrocytes also expressed high 
levels of AAAS mRNA. Relatively little or no detectable AAAS mRNA was seen in the hepatocytes, 
enteric smooth muscle and fibroblasts. The highest level of expression in the developing embryo was 
found in the neural tissues [30]. 
1.6.7 Triple A syndrome gene product, ALADIN 
The triple A syndrome gene product is the protein ALADIN (Alacrima Achalasia aDrenal Insufficiency 
Neurologic disorder) of unknown function. 
1.6.7.1 Structure of ALADIN and WD family of proteins 
ALADIN’s sequence predicts a central domain composed of four WD-repeats producing a β-propeller 
structure [24, 25]. WD repeats comprise a domain of approximately 40-60 amino acids, initiated by a 
glycine-histidine (GH) dipeptide 11-24 residues from the N-terminus ending with a tryptophan-
aspartic acid (WD) peptide at the C terminus [31]. 
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The repeating unit is referred to as the GH-WD repeat or WD-40 repeat. Most proteins belonging to 
this family have between 4 (the minimum number of repeats reported) and 16 repeats [32]. The 
crystal structure of this repeat unit has been studied in the β-subunit of the GTP-binding protein 
transducin, in which this domain was originally described [33]. The G protein β-subunit adopts a β-
propeller fold made up of WD-repeats, which is highly symmetrical. These folds act as stable 
platforms for protein-protein interactions, the residues on the top and bottom of the propeller 
forming interacting surfaces, together with a circumferential surface available for binding. Given the 
conservation of the WD-repeat domain, it is likely that all WD-repeat proteins adopt a similar 
structure [31]. There are over 136 WD-repeat proteins described in humans [32]. These are thought 
to differ in the variable region within the WD-repeat, by the number of repeats and by the sequence 
outside the WD-repeat domain. Localisation signals can sometimes be found external to the WD-
repeat domain. 
The WD-repeat domain has no catalytic activity, therefore, the function of this family of proteins are 
dependent on the interactions achieved with other proteins/protein complexes [34]. The cellular 
functions of WD-repeat proteins described are extremely diverse [32].  Gβ protein and LIS1 are 
examples of proteins that are involved in signal transduction. Intracellular vesicular trafficking is 
conducted by another group of WD-repeat proteins, the α and β-CoP proteins, which comprise the 
Golgi-derived coated vesicles. These are involved in vesicular budding, translocation and fusion with 
target membranes [35]. Dynein intermediate chains, responsible for targeting various dyneins to the 
specific cell organelles to which they associate, are WD-repeat proteins and play a part in 
cytoskeletal assembly [36, 37]. WD-repeat proteins also have roles to play in the de novo 
nucleosome assembly pathway as part of the chromatin assembly complex (CAC) [38]. Additionally, 
other key roles including gene regulation, cell cycle regulation are described together with roles in 
programmed cell death [39-44].  
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Thus the WD-repeat family of proteins are involved in several key cellular pathways. The functions of 
several of these proteins, including ALADIN, are yet to be determined [32].  
1.6.7.2 WD proteins and disease 
Several other human diseases, in addition to triple A syndrome, arise as a consequence of mutations 
in WD-repeat proteins. Whilst triple A syndrome is alone in causing adrenal insufficiency, mutations 
in several WD-repeat proteins are associated with neurological conditions. Mutations in LIS1 have 
segregated with lissencephaly (absence of convolutions or gyri in the brain) [45, 46]. Autosomal 
recessive primary microcephaly with cortical malformations is caused by mutations in WDR62 which 
results in disordered cerebral cortical development [47, 48]. Mutations in WDR36 have been 
associated with primary open-angle glaucoma, one of the leading causes of blindness worldwide [49, 
50]. The WDR36 null mouse shows defects in axonal growth with progressive degeneration at the 
peripheral retina [51]. 
Suboptimal response to oxidative stress is associated with mutations in other WD-repeat proteins. A 
subtype of the premature aging syndrome Cockayne syndrome, in which patients also present with 
dwarfism, mental retardation, optic atrophy, deafness, pigmentary retinopathy and skeletal 
abnormalities, is caused by mutations in the CSB protein. This WD-repeat protein is involved in 
several biological processes including DNA repair and transcription, regulating several genes post 
oxidative stress [52].  
All the WD-repeat proteins described above exert their role as members of macro-molecular 
complexes with mutations impacting on various key biological processes.   
1.6.7.3 ALADIN in the nuclear pore complex (NPC) 
ALADIN was identified as one of 30 nucleoporins of the mammalian nuclear pore complex (NPC) by 
detailed proteomic analysis in 2002. A fractionation procedure was used to enrich the NPC fraction 
of rat liver, and the supernatant for analysis identified by a panel of anti-nucleoporin antibodies [53]. 
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Characterisation of the nucleoporins in this fraction was then undertaken by mass spectrometry 
analysis.  
NPCs are present throughout the nuclear envelope and are the sole site of nuclear–cytoplasmic 
transport. They are relatively well conserved between species [54]. ALADIN is not present in yeast 
but is observed in all higher eukaryotes [55]. 
1.6.7.4 Nuclear pore complex structure 
The vertebrate NPC is postulated to form an 8 fold symmetrical structure creating a transport 
channel across the nuclear envelope, with a molecular mass of 60-90 mDa [53, 55]. The NPC 
comprises a nuclear basket, central core and asymmetrically arranged cytoplasmic fibrils [56-58]. 
The nucleoporins that form this structure can roughly be divided into 3 categories: the 
transmembrane proteins, the scaffold proteins and finally the nucleoporins residing at the nuclear 
basket. The nucleoporins POM121 and gp210, are transmembrane proteins important in nuclear 
pore formation in the nuclear pore complex [59, 60]. NDC1 has been shown to be integral to the 
formation of the NPC in yeast has alternately been described as a transmembrane and a scaffold 
nucleoporin [61]. All these nucleoporins are postulated to be involved in the early phase of NPC 
development [60, 62]. Interestingly studies also suggest that these proteins are not absolutely 
essential for NPC formation implying that NPC formation is a relatively fault tolerant process [63, 
64]. The scaffold proteins, of which ALADIN is believed to be a member, constitute the second 
category of nucleoporins providing the stable structure of the NPC in 2 large sub-complexes; the 
Nup107-160 and the Nup 93-205 [65]. These are WD- and α- solenoid protein rich, with β propeller 
platforms, important for their role in establishing macro-molecular complexes. These proteins are 
postulated to be relatively stable in their residence time at the nuclear pore complex with very low 
turnover rates [57, 65, 66]. A study using GFP-tagged ALADIN demonstrated that ALADIN was 
present at the NPC for approximately 57 hours, with other nucleoporin residence times at the NPC 
varying between a few seconds and several days [66]. This suggests relatively stable expression of 
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ALADIN at the NPC. Interestingly absence of ALADIN at the NPC has minimal or no effect on NPC 
structure [67, 68]. 
The third category of nucleoporins comprise the FG repeat-(repetitive stretches of Phe-Gly residues) 
containing Nups residing at the nuclear basket, that mediate selectivity and permeability of the 
nuclear pore [69]. The non-FG domains of these Nups have β–propeller, coiled-coil and β sandwich 
structures, presumably allowing them to assemble onto the β-propeller and α-solenoid platforms of 
the scaffold nucleoporins [70, 71]. These FG Nups are believed to provide low affinity binding sites 
for transport receptors and mediate the passage of these receptors and their cargo through the 
nuclear pore [72, 73]. Some only spend a few seconds at the NPC, shuttling between the cytoplasm 
and nucleoplasm [66]. 
1.6.7.5 Nuclear pore complex and nuclear-cytoplasmic transport 
Whilst small molecules (less than 40 kDa) are capable of traversing the nuclear pore by passive 
diffusion, the transport mechanisms of larger macro-molecular complexes remain controversial. In 
contrast to the initial theories that NPC proteins provide stable docking sites for rapidly trafficking 
transport receptors, current concepts are moving towards a more dynamic model. Active NPC 
transport involves interactions directly with the NPC or association with several types of transport 
receptors. The karyopherins comprise the largest class of these transport receptors and include 
importins, exportins and transportins which are highly specialised for import or export. Directionality 
at the NPC is maintained by the small GTPase Ran which organises cargo binding and release in a 
compartment specific manner [57]. Certain FG Nups, for instance Nup98 and Nup50, have active 
roles in establishing disassembly of transport receptor-cargo complexes [74-76]. Several members of 
the NPC are also involved in mRNA export [77]. 
Selectivity across the NPC is believed to be maintained by the dynamic FG Nups which bind to 
specific transport receptors [78]. Differential expression of various transport receptors have been 
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demonstrated in different cell types. Each FG Nup may interact with only a subset of transport 
receptors allowing for selective pathways across the NPC [79-81]. Interestingly, depletion of nearly 
half the FG mass of the NPC does not affect cell viability or impact on NPC active transport 
suggesting an importance of the core/scaffold Nups in maintaining the permeability barrier [79]. 
Consistent with this, several tissue-specific diseases related to human mutations of nucleoporins 
involve core / scaffold components of the NPC [78, 82].  
Variation in NPC conformation between cell types is postulated given the differential tissue 
expression of several Nups [78, 82]. Enrichment of certain Nups, including ALADIN, in specific tissues 
may occur depending on tissue-specific requirements. The Mlp1 and Mlp2 proteins, which bind to 
ribonucleoproteins and associate with the nuclear pore complex, are not equally distributed along 
the nuclear envelope [83]. These proteins bind preferentially to some NPCs, mainly those associated 
with active chromatin, suggesting that NPCs are not identical even within an individual cell. 
Furthermore, within each cell type, conformational changes in the NPC are thought to occur during 
transport [84]. This suggests that the NPC is a dynamic system, able to model depending on the 
requirements of the cell. 
1.6.7.6 Transport independent roles of the nuclear pore complex  
Conformational changes in the NPC are thought to occur during the various stages of the cell cycle 
[84]. During mitosis the nuclear envelope breaks down and the NPCs divide into several sub-
complexes which serve as NPC building blocks during telophase [84]. Several Nups localise to 
kinetochores during mitosis, including members of the Nup 107-160 subcomplex and Nup358; these 
steps are thought to be integral to entry into mitosis [85]. Depletion of certain Nups also lead to 
defects in spindle formation [86]. 
The NPC is proposed to be involved in chromatin organisation, also suggesting a role in transport 
independent gene regulation. A ChIP approach in yeast demonstrates the NPC binding to the 3’ end 
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of genes whilst other studies suggest NPC binding to the promoter and 5’ ends [87, 88]. A model of 
chromatin looping has been proposed, in which active chromatin localises to nuclear pore 
structures. [89]. High resolution images of the NPC show heterochromatin interspersed by NPC 
pores in a periodic manner [78]. Therefore, the NPC could act as boundary elements which prevent 
communication between active and silent chromatin and the stable core component of the NPC 
could be integral in this function [90]. 
NPCs may also have a more dynamic involvement in gene regulation as suggested by the 
transcription dependent mobility of Nup153 and Nup98, which can move away from the NPC to 
interact with transcribing genes and mRNA [91]. Efficient coordination of transcription and mRNA 
export may, thus, be achieved by these dynamic nucleoporins. 
1.6.7.7 ALADIN localisation to the nuclear pore complex 
ALADIN does not have a nuclear localisation signal (NLS). Immunocytochemistry has demonstrated 
that ALADIN co-localises with the nucleoporin Nup358 (RanBP2) to the cytoplasmic face of the NPC 
[68]. Interaction of ALADIN with the scaffold nucleoporin NDC1 has also been demonstrated [92, 93]. 
ALADIN appears to require the presence of NDC1 for appropriate docking onto the NPC, with 
depletion of NDC1 resulting in mislocalisation of ALADIN to the cytoplasm [92]. In contrast, depletion 
of the other core Nups, POM 121 and GP210, have no effect on the localisation of ALADIN [92]. 
The effect of naturally occurring AAAS mutations on ALADIN subcellular localisation has been 
investigated by transiently transfecting wild-type and several GFP-tagged mutant AAAS constructs 
into Hela cells. These mutants are demonstrated to predominantly mislocalise to the cytoplasm 
suggesting that localisation of ALADIN to the nuclear pore complex is necessary for its function [68, 
94]. 
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1.6.7.8 The nuclear pore complex and human disease 
Tissue specific requirements for Nups are supported by human mutations that lead to tissue-specific 
human pathologies [82]. A missense mutation in human NUP155, which forms part of the scaffold 
complex, has been associated with an inherited form of atrial fibrillation [95]. Homozygous mice 
carrying the knockout Nup155 allele die in mid-embryogenesis whilst heterozygous mice show an 
atrial fibrillation specific phenotype [95]. Interestingly the drosophila homologue of NUP 155, Nup 
154, has been shown to be involved in gametogenesis demonstrating both tissue-specific and 
species-specific roles of the Nups [96, 97]. 
The NPC is implicated in the regulation of gene expression and this is supported by multiple genomic 
translocations of NUP98 and NUP214 genes which result in fusions of the Nups to ‘partner genes’ 
leading to the generation of leukemogenic fusion proteins. For instance, the oncogenic fusion of 
NUP98 to the transcription factor HOXA9 induces aberrant expression of HOXA9 target genes 
leading to acute myelogenous leukaemia [98]. Fusion of NUP98 to PHD-finger proteins, containing 
nuclear protein interaction-domains, similarly lock target genes to an aberrant state leading to 
leukaemic transformation [99]. Furthermore, fusion of NUP214 to the tyrosine kinase ABL1 is seen in 
a proportion of acute lymphoblastic leukaemia [100, 101]. 
Aside from triple A syndrome, two other diseases involving the central nervous system have been 
associated with mutations in nucleoporins. A missense mutation of human Nup358/RANBP2 was 
identified in familial cases of infection triggered acute necrotizing encephalopathy [102]. RANBP2 
has been described to have several roles in mitosis and nucleocytoplasmic transport. More recently 
it has been identified as a SUMO E3 ligase interacting with RanGAP1/SUMO1 complex and Ubc9. This 
complex is described to have multiple roles  in nucleocytoplasmic transport, cell-cycle progression, 
and protein sumoylation [103]. Additionally, it has been detected with mitochondria and 
microtubules in primary neurons with a potential role in intracellular trafficking, implying a role 
outside the NPC [104].   Missense mutations in the FG-repeat containing nucleoporin, Nup62, cause 
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degeneration of the basal ganglia in the autosomal recessive infantile bilateral striatal necrosis. This 
mutation does not affect localisation of the mutant protein to NPCs, and the precise mechanism by 
which basal ganglia disease is caused is unclear [105]. Furthermore, antibodies against nucleoporins 
have also been associated with human disease. These include antibodies against human Nup62 and 
human Gp210 which have been demonstrated in approximately 50% of patients with primary biliary 
cirrhosis [106].   
All current known human mutations in nucleoporins display tissue specific pathology, yet the precise 
pathological mechanisms in some, including triple a syndrome, remain elusive. 
1.6.8 Proteins interacting with the triple A syndrome gene product 
As a WD-repeat protein at the nuclear pore, ALADIN would be predicted to be involved in several 
protein-protein interactions. Identifying protein partners of ALADIN is crucial for further 
understanding the function of ALADIN and mutations of genes encoding these proteins may account 
for the genetic heterogeneity observed in the disease. 
1.6.8.1 ALADIN and NDC1 
ALADIN has been shown to interact with the NPC protein NDC1 which is described as a ‘scaffold’ NPC 
protein [92, 93]. ALADIN’s localisation appears to be dependent on the presence of NDC1 in the NPC; 
depletion of NDC1 by siRNA results in the mislocalisation of ALADIN to the cytoplasm [92]. 
Interestingly, the presence of ALADIN at the NPC appears to be required for NDC1 to localise 
appropriately. Fluorescence resonance energy transfer (FRET) measurements demonstrate the 
association between NDC1 and ALADIN. GFP-tagged ALADIN has also been demonstrated to co-
immunoprecipitate with NDC1 [93]. No human mutations have been identified in NDC1 however in 
yeast, NDC1 has been demonstrated to be necessary to establish the biosynthesis and the integrity 
of the NPC [61]. 
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1.6.8.2 ALADIN and Ferritin Heavy Chain (FTH1) 
Ferritin Heavy Chain (FTH1) was identified as an interacting protein partner of ALADIN from 2 
separate human cDNA libraries (HeLa cell and cerebellar cDNA libraries) using the full length human 
ALADIN sequence as bait in bacterial two-hybrid screening [107]. This interaction was validated by 
co-immunoprecipitation following transfection of tagged FTH1 and ALADIN. Additionally, GFP-tagged 
ALADIN was found to co-immunoprecipitate with endogenous FTH1. FRET studies confirmed this 
interaction in vivo [107]. 
1.6.8.3 Ferritin Heavy Chain: Structure and function 
The 24 unit ferritin heteropolymer is described as a hollow protein shell capable of sequestering free 
iron. Ferritin is comprised of ferritin light chain, a 19 kDa protein of 175 amino acids (encoded by 
FTL, on chromosome 19) and the 21 kDa ferritin heavy chain of 183 amino acids (encoded by FTH, on 
chromosome 11) [108]. The ferritin light and heavy chains are multi-helical and share a 55% identical 
sequence. However, they are functionally distinct with the light chain playing an important role in 
iron storage and heavy chain having potent ferroxidase activity [109, 110]. The ratio of heavy to light 
chain in the intracellular environment is dependent on the cell type, with those tissues more 
abundant in free iron having a greater heavy chain component whilst those that have an iron storage 
role have a higher light chain ratio [108, 111].  Intracellularly, both FTH1 and ferritin light chain 
localise mainly to the cytoplasm. Both FTH and FTL possess IREs (iron regulatory element) in the 5’ 
UTR region. These IREs bind iron responsive proteins (IRP), which act as transcription repressors 
[111, 112]. Intracellular levels of iron and variations in redox haemostasis modulate IRP binding and 
subsequent transcription of the ferritin subunits. FTL is more tightly regulated by intracellular iron 
than FTH [113]. Both FTH and FTL also have upstream antioxidant responsive element (ARE) and are 
upregulated by the transcription factors NRF2 and JunD in conditions of oxidative stress [114]. Hence 
cytosolic FTH and FTL levels are tightly controlled. 
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In 2001, a novel member of the ferritin family was described: mitochondrial ferritin [115]. This is 
encoded by the intronless FTMT gene on chromosome 5. This is highly similar to ferritin heavy chain 
and can also be incorporated into a homopolymer ferritin shell and functionally has potent 
ferroxidase activity. It has a specific leader sequence for targeting to the mitochondria which is 
cleaved on entry into the mitochondria, reducing the 30kDa precursor to 22kDa. It is postulated to 
have a role in iron homeostasis in this organelle. Approximately, 79% of the coding regions overlap 
with FTH (with conservation of the amino acids required for ferroxidase activity) and 63% overlap 
with FTL [115, 116]. However, unlike FTH and FTL, mitochondrial ferritin does not have an IRE.  
1.6.8.4 Evidence for nuclear localisation of ferritin heavy chain 
Nuclear FTH1 has been observed in avian corneal epithelial cells in response to ultraviolet-induced 
damage [117, 118]. In addition, the presence of nuclear FTH1 has been described in human 
hepatocytes and astrocytoma cells in response to oxidative stress, with a dose related increase 
response seen in the latter cell type [119]. The bulk of nuclear ferritin in human astrocytoma cells is 
within the soluble nuclear fraction with some associating with the nuclear matrix [120]. In avian 
corneal epithelial cells nuclear ferritin is found throughout the nucleus but not in the nucleolus 
[118]. 
Only FTH1 has been observed in the nucleus. Studies using a variety of constructs for FTH1 and light 
chain describe only the FTH1 constructs localising to the nucleus [120]. This preferential 
translocation is postulated to be related to the presence of O-glycosylation sites in FTH1 and alloxan 
blocking of these sites in astrocytoma cells reduced the presence of nuclear ferritin heavy chain 
[120]. It is not clear whether the heteropolymer is able to pass through the nuclear pore or whether 
it is broken into its constituent parts and then translocated. The intact ferritin complex would be of 
approximately 450kDa with an estimated external diameter of 13 nm. Although the resting nuclear 
pore diameter is an estimated 9nm, during active transport a diameter of approximately 39 nm can 
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be achieved [121]. siRNAS targeting FTH1 deplete both cytoplasmic and nuclear FTH1 indicating that 
nuclear FTH1 is not distinct from that observed in the cytoplasm [120]. 
FTH1 was demonstrated to be transported into the nucleus via the nuclear pore; wheat germ 
agglutinin (which blocks the nuclear pore) prevents nuclear translocation of FTH1 [119]. This 
translocation is an energy dependent process as apyrase ATP-depletion prevents the nuclear 
translocation of FTH1 [119]. FTH1 does not have a nuclear localisation signal and translocation into 
the nucleus is an importin-independent process [122]. In the avian corneal epithelium a nuclear 
transport molecule named ferritoid (which contains a SV40-type nuclear localisation signal and a 
second region similar to ferritin heavy chain) has been identified [117, 123]. SV40 nuclear 
localisation signals are classic nuclear localisation signals, named after their initial description in the 
SV40 large T antigen. Ferritoid is highly specific to avian corneal epithelium and no other chaperone 
proteins have been identified in human cells. 
Supercoil relaxation assays in human astrocytoma cells demonstrate that nuclear FTH1 protects 
against DNA fragmentation in response to oxidative stress [119]. Similarly, avian corneal epithelial 
cells with nuclear ferritin had significantly less DNA breakage than the other cells types examined 
[117]. 
1.6.8.5 Ferritin Heavy Chain in disease 
There have been no identified conditions associated with human mutations in ferritin heavy chain. A 
knockout mouse model results in lethality in the embryonic stage [124]. Heterozygous mice are 
healthy and do not differ significantly from their litter mates. Studies have been conducted on a 
conditional Fth-knockout mouse using a Cre-inducible system [125]. Complete loss of ferritin heavy 
chain was achieved in the liver, spleen and bone marrow (adrenal and neural tissue were not 
studied). On an iron-rich diet, irreversible hepatocyte damage was observed associated with 
significant DNA strand breaks demonstrated on TUNEL assays. Furthermore, Fth-knockout mouse 
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embryonic fibroblasts demonstrated a significant increase in the free iron pool and reactive oxygen 
species (ROS). The mitochondrial depolarisation which preceded cell death in this model appeared 
to occur as direct consequence of iron-mediated ROS formation [125]. 
Hereditary ferritinopathy in humans is associated with mutations in ferritin light chain [126]. The 
associated clinical phenotype includes a severe movement disorder and histopathology reveals the 
presence of nuclear and cytoplasmic inclusion bodies in glia and neurons. 
1.6.8.6 Localisation of FTH1 in triple A syndrome patient dermal fibroblasts 
Unlike control cells, no nuclear FTH1 is apparent in triple A syndrome patient dermal fibroblasts or 
lymphocytes [107]. Additionally, when cells are transfected with His-tagged FTH1, very little nuclear 
immunofluorescence was seen. However, when SK-N-SH neuronal cells (which express very low 
levels of endogenous AAAS mRNA) are co-transfected with both FTH1 and ALADIN, FTH1 is readily 
visible in the nucleus, implicating ALADIN in the nuclear localisation of FTH1 (Figure 1.3). 
 
Figure 1.3. FTH1-V5-His localises to the nucleus in cotransfected SK-N-SH cells. SK-N-SH cells were 
either transfected with the pcDNA3.1-FTH1-V5-His vector alone (A–D) or cotransfected with the 
pcDNA3.1-FTH1-V5-His and pEGFP-AAAS vectors (E–H). Images show the localisation of DAPI nuclear 
stain (blue, A and E) and localisation of the V5-His-tagged FTH1 (red, B and F). The V5-His-tagged 
FTH1 has a mainly cytoplasmic localisation when transfected alone (B–D) but is clearly visualised in 
the nucleus when coexpressed with GFP-ALADIN (F–H) (arrows). Images are 73.1 × 73.1 μm. Scale 
bars, 10 μm. Images reproduced with authors’ permission (Storr et al, 2009). 
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1.6.9 Oxidative stress and the triple A syndrome 
Several studies to date indicate that oxidative stress may be involved in the pathogenesis of triple A 
syndrome. The first of these involves study of cultured dermal fibroblasts from a triple A syndrome 
patient with the mutation, 1482Sf, by Hirano and colleagues [127]. The mutant protein failed to 
target appropriately to the NPC. The patient fibroblasts were demonstrated to be hypersensitive to 
oxidative stress (treatment with L-buthionine-(S,R)- sulfoximine) with increased frequency of DNA 
single-strand breaks [127]. Additionally, decreased nuclear accumulations of aprataxin (DNA repair 
protein for DNA single strand breaks) and DNA ligase I were noted in the I482Sf fibroblasts. 
Transfection of wild-type AAAS restored the nuclear import of these DNA repair proteins [127]. 
Fusion of classic nuclear localisation signals (SV40 nuclear localisation signals) to these DNA repair 
proteins also allowed successful nuclear import of these proteins in patient dermal fibroblasts with 
reduced oxidative stress-induced cell death [128]. However, successful nuclear import of both 
aprataxin and DNA ligase I did not fully restore the survival of patient fibroblasts to the level of the 
positive control of wild-type ALADIN suggesting the presence of other proteins that may be 
selectively imported by ALADIN. 
A lack of FTH1, which has potent ferroxidase activity, was noted in the nuclear fractions of triple A 
syndrome patient dermal fibroblasts suggesting ALADIN-dependent nuclear import of FTH1 [107]. 
Co-transfection of human neuronal cells with AAAS and FTH1 allowed successful nuclear import of 
FTH1 (Figure 1.3). Protection against oxidative stress was demonstrated in this neuronal cell line 
with transfection of AAAS or FTH1, with maximal protection conferred with transfection of both 
proteins [107] (Figure 1.4). 
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Figure 1.4. FTH1 and ALADIN are protective against oxidative stress. Densitometric analysis of 
Western blot of SH-SY5Y cells transfected with pEGFP-AAAS, pcDNA3.1-FTH1, or pEGFP-AAAS and 
pcDNA3.1-FTH1 and treated with or without hydrogen peroxide (H2O2). H2O2 treatment causes an 
increase in PARP cleavage relative to untreated controls, and cotransfection of pEGFP-AAAS and 
pcDNA3.1-FTH1 reduces the amount of PARP cleavage relative to untransfected cells. Analysis 
showed a significant (p = 0.01) decrease in cleaved PARP between untransfected cells and cells 
cotransfected with pEGFP-AAAS and pcDNA3.1-FTH1. Values are intensities of cleaved PARP relative 
to GAPDH relative to untreated controls (dark bars). *, p < 0.05; **, p < 0.01; n = 4. Images 
reproduced with authors’ permission (Storr et al, 2009). 
 
Triple A syndrome dermal fibroblasts have a significant baseline increase in reactive oxygen species 
(ROS) in comparison to wild-type fibroblasts [129]. This is further exacerbated by the inducer of 
oxidative stress paraquat. Mitochondrial networks were found to be more extensive in triple A 
syndrome fibroblasts, though the metabolic activity and maximum ATP synthesis were unchanged. 
The importance of this change in mitochondrial morphology is unclear. The mRNA expression of 
several well-known anti-oxidant enzymes was also studied with equivocal results [129]. A significant 
increase in superoxide dismutase 1 was seen in comparison to wild type fibroblasts, whilst catalase 
levels were decreased in triple A patient fibroblasts. There were no clear differences observed in 
superoxide dismutase 2 or glutathione reductase levels compared with controls. Triple A syndrome 
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patient fibroblasts exhibited features of senescent cells suggesting they may undergo stress-induced 
premature senescence [129].   
1.6.10 Other research to date 
1.6.10.1 Aaas-knockout mouse 
Aaas-knockout (Aaas-/-) mice have been established by Angela Huebner’s group using standard 
homologous recombination in mice from a 129/01a-C57Bl/6 mixed background [67].  Aaas was 
inactivated by integration of a neomycin resistant cassette replacing the start codon by homologous 
recombination. 
With regards to phenotype, the Aaas-/- mutants were largely indistinguishable from wild-type. The 
knockout mice were observed to have a slightly lower body weight at 10 weeks postnatally in the 
males and 8 weeks postnatally in the females. Achalasia was not observed in the knockout animals. 
The development appeared normal with the oldest male Aaas-/- mutant being 2.9 years and the 
oldest female 2.7 years.  Neurological observations were made in those mice above 7.5 months. 
Reflexes were described as the same as wild type with no significant difference in motor 
coordination. The Aaas-/- null mutants were observed to be slightly less active than wild-type, 
spending more time resting. Interestingly, the female Aaas-/- mice were infertile. 
Hormonal analysis conducted included baseline ACTH and corticosterone measurements in both 
Aaas-/- and wild type mice at 11 months, with no significant difference observed. Histology revealed 
no gross abnormality of the any of the organs studied. The adrenals, ovary, testes, oesophagus, 
pituitary and peripheral nerves had similar features to the wild-type. Infertility in the female Aaas-/- 
mice was postulated to be related to problems with the maturation of oocytes. Ultra structurally, 
there were no observable differences to the NPC (using kidney and liver tissue). In addition, no NPC 
structural differences were seen by immunocytochemistry of embryonic dermal fibroblasts. 
51 
 
In summary, the Aaas-/- mice failed to show a phenotype analogous to triple A syndrome patients. 
Possibilities to consider include functional redundancy of ALADIN in mice. ALADIN’s function at the 
NPC may be species-specific, certainly species-specific function(s) of nucleoporins have been 
demonstrated with other Nups [96, 97]. One also needs to consider that these mice were 
maintained in pathogen-free conditions and it is possible that phenotypic features could emerge 
with stress particularly if oxidative stress is imposed. Finally, complete absence of ALADIN, as would 
be the case in the Aaas -/- mouse model, may be less harmful than the presence of a mutant, 
mislocalised protein. This could potentially be tested using ‘knock-in’ approaches where mutations 
are inserted in the mouse Aaas gene, allowing for a more faithful genetic model of the human 
condition. However, two naturally occurring mutations leading to triple A syndrome suggest that a 
toxic gain of function is unlikely; 43C>A in exon 1,  leads to aberrant splicing and hence a predicted 
complete absence of the protein and L25P which leads to normal localisation of the protein to the 
NPC, still cause the disease phenotype and [94]. 
1.6.11 Triple A syndrome summary 
Triple A syndrome is a rare autosomal recessive condition incorporating adrenal insufficiency with 
neurodegenerative disease. In the main, the condition is caused by mutations in AAAS, encoding the 
nuclear pore complex protein ALADIN, of which relatively little is known. The expression of AAAS is 
enriched in the tissues affected by the disease. Interestingly, the Aaas-/- mouse does not recapitulate 
the human phenotype, suggesting functional redundancy in the mouse model and perhaps a 
species-specific role for this nucleoporin. In vitro studies using patient dermal fibroblasts suggest 
nuclear import of specific cargo-(es) may be defective, rendering ALADIN deficient cells susceptible 
to oxidative stress. The precise impact of ALADIN loss of function in the adrenocortical and neuronal 
environment, tissue types affected by the disease, is not known. 
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1.7 Familial glucocorticoid deficiency (FGD) 
Familial glucocorticoid deficiency was first described in 1959, in a report of 2 sisters with Addison’s 
disease without hypoaldosteronism, and involves a hereditary unresponsiveness to ACTH [130]. This 
rare autosomal recessive disorder manifests in most cases as glucocorticoid and adrenal androgen 
deficiency.  
1.7.1 FGD clinical features, diagnosis and patient management 
Affected individuals in the case of FGD type 1, 2 and 3 commonly present in the first 2 to 3 years of 
life [131]. Typically they have deficient production of cortisol in the presence of high ACTH levels. 
Adrenal androgen production is also affected. Mineralocorticoid production is relatively unaffected 
and renin and aldosterone levels are normal as patients have an intact renin-angiotensin axis. 
Clinical features are reflective of the low cortisol and raised ACTH levels. Hypoglycaemia is a 
common feature, which, if untreated, can lead to neurological sequelae [132, 133]. Clinical 
presentation includes failure to thrive in the neonatal or early childhood periods and an increased 
susceptibility to infections. This disorder can lead to significant morbidity and is potentially fatal if 
untreated. Patients commonly present with hyperpigmentation, a consequence of overstimulation 
of melanocortin 1 receptor (MC1R) by proopiomelanocortin products. This hyperpigmentation may 
be present at birth or may develop over time. Interestingly, lack of hyperpigmentation was seen in a 
recent case of FGD involving the coexistence of a homozygous, inactivating MC1R variant which has 
previously been associated with red hair and fair skin [134]. Indeed genetic variants in MC1R are 
detected in over 80% of individuals with red hair and fair skin who tan poorly [135]. Thus one must 
consider that hyperpigmentation seen in FGD may be less common in affected individuals from 
white ethnicities more predisposed to mutations in MC1R. A lack of adrenarche in affected 
individuals is seen as a consequence of adrenal androgen deficiency, although puberty and fertility 
are unaffected as the hypothalamic-pituitary-gonadal axis remains intact [136]. Other clinical 
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features can be specific to a particular FGD subtype depending on the underlying aetiology. These 
are described further below. 
At diagnosis, ACTH levels are extremely high, often greater than 1000 pg/ml (normal range <80 
pg/ml). A standard ACTH stimulation test will confirm an impaired cortisol response (<500 nmol/l) 
and verify adrenal insufficiency. Treatment involves glucocorticoid replacement usually with 
hydrocortisone. In children doses of 8 to 10 mg/m2/day and in adults 20 mg hydrocortisone are 
given daily in three to four divided doses. Importantly, ACTH levels often remain high during the 
treatment of FGD and it is essential that only physiological replacement doses are given rather than 
higher doses in an attempt to suppress ACTH. Overzealous replacement can have adverse effects 
particularly in children, where the impact of steroid therapy on growth needs to be considered. It is 
also essential that hydrocortisone dosing is increased 2 to 3-fold during times of stress. It is crucial to 
ensure the patient and their family have adequate education about when and how to increase 
hydrocortisone doses and in the administration of emergency intramuscular hydrocortisone or 
hydrocortisone suppositories. 
1.7.2 FGD type 1; MC2R gene mutations 
The isolated nature of the adrenal defect in FGD, appearing to predominantly affect the ACTH 
dependant zones of the adrenal, indicated that a receptor defect was responsible. Cloning of the 
ACTH receptor gene (melanocortin 2 receptor, MC2R), in 1992, allowed this theory to be addressed 
[137]. In 1993, the first mutation in MC2R was discovered in two siblings with FGD, by direct 
sequencing of the gene [138]. A single base change causing an amino acid substitution (p.S74I) in the 
receptor was associated with the disease. Since this initial discovery, over forty mutations in MC2R 
have been described [139] (Figure 1.5). The MC2R mutations, identified in cases of FGD, result in loss 
of receptor function. Only one activating mutation of MC2R has been reported (p.F278C); a rare 
mutation discovered in an individual with cyclical Cushing’s syndrome [140]. 
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Figure 1.5. Schematic diagram demonstrating all mutations in MC2R associated with FGD type 1. 
These comprise missense mutations (in orange), likely benign polymorphisms (in blue) and nonsense 
or frameshift mutations (in green). Image reproduced with authors’ permission [141]. 
 
MC2R, together with the other melanocortin receptors (1, 3, 4 and 5), form a distinct subfamily of 
transmembrane G-protein coupled receptors. These mediate the signalling of hormones derived 
from the cleavage of proopiomelanocortin (POMC). Five MCRs with varying roles have so far been 
described. MC1R is found in the skin and hair where it is an important regulator of pigmentation, 
responsible for the production of dark eumelanin pigment and the tanning response [135]. MC3R 
and MC4R contribute significantly to the regulation of food intake and energy homeostasis [142-144] 
and MC5R, whilst highly expressed in embryogenesis, is thought to be involved in exocrine function 
in adults [145, 146]. MC1, 3, 4, 5R respond to all POMC products (ACTH, α-, β- and γ-MSH) with 
varying preference. MC2R however responds to ACTH alone [147]. 
MC2R is the smallest member of the family, encoded by an intron-less gene mapped to the distal 
end of chromosome 18 and comprising 297 amino acids. MC2R mRNA is present in all three 
adrenocortical zones but ACTH predominantly activates receptors in the zona fasciculata [137]. In 
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response to ACTH binding, MC2R becomes active and in turn activates the heterotrimeric G-protein 
complex which activates adenylase cyclase. This in turn catalyses cAMP generation with subsequent 
activation of protein kinase A, required for expression of steroidogenic enzymes and consequently 
cortisol production in the zona fasciculata. ACTH activation in the zona reticularis results in the 
production of adrenal androgens [136]. Several cAMP responsive element (CRE)-like sequences are 
found in the promoter region of MC2R and ACTH is thus able to upregulate its own receptor, 
increasing receptor numbers in the zona fasciculata and reticularis. Interestingly some studies 
suggest a rare involvement of MC2R in cortisol-secreting adrenal tumours [148].  
Postmortem histological analysis of adrenal glands of affected individuals reveals atrophy of the 
ACTH-dependant zona fasciculata and reticularis. Where these zones normally comprise 90% of the 
adrenal cortex, only a narrow band of fibrous tissue remains [149, 150]. This is unsurprising given 
the important trophic effect ACTH has on the adrenal cortices. The angiotensin II-dependent zona 
glomerulosa is relatively well preserved. Similar histological findings are seen in the Mc2r-/- mouse 
[151]. Knockout resulted in neonatal lethality in three quarters of the mice, thought to be a 
consequence of hypoglycaemia. Similar to affected human patients, knockout of Mc2r in mice leads 
to high levels of ACTH, unresponsiveness to ACTH, and hypoglycaemia after prolonged fasting. 
However in contrast to the human phenotype, these mice are also found to be aldosterone 
deficient. A mild salt-losing phenotype has been described in patients with severe loss of function 
mutations in MC2R, however this tends to be a transitory phenomenon [152, 153].  
An additional feature seen in the FGD 1 phenotype is tall stature, the mechanism for which is unclear 
[154]. It is possible that either ACTH or cortisol deficiency is responsible for excessive growth. It has 
been suggested that excess ACTH stimulates melanocortin receptors in the growth plate, stimulating 
growth [155]. Hypertelorism, marked epicanthic folds and frontal bossing are also noted [154]. 
Another proposal is that cortisol inhibits the synthesis of IGF (insulin-like growth factor) binding 
protein 6 (IGFBP6), which binds to and prevents the actions of IGF II in the osteoblast [156]. Thus it is 
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possible that cortisol deficiency could result in a lack of IGFBP6 inhibition and hence increased 
growth. Early diagnosis and glucocorticoid replacement in patients appears to prevent excess 
growth. 
Mutations in MC2R account for 25% of cases of FGD, indicating that the condition is genetically 
heterogeneous [131]. The majority of MC2R mutations lead to defective trafficking of the receptor 
from the endoplasmic reticulum to the plasma membrane [157]. 
1.7.3 FGD type 2; MRAP gene mutations 
Defective trafficking of MC2R to the cell surface results in disrupted ACTH signalling and it became 
apparent that a further factor was required for this process, as evidenced by the difficulty in 
expressing MC2R in cells of a non-adrenal origin (heterologous cells) [158]. These studies implied 
that an adrenal-specific factor was required. To identify this factor a whole genome scan by single 
nucleotide polymorphism (SNP) array genotyping was carried out in one consanguineous FGD family 
and mapped a locus to chromosome 21q22.1 [159]. RT-PCR of candidate genes within the region 
identified a single adrenal specific gene, C21ORF61. Further genetic screening of an FGD patient 
cohort who did not carry MC2R mutations identified several nonsense and splice site mutations in 
C21ORF61 [159]. These mutations were predicted to result in complete absence or a short truncated 
version of the gene product. This protein, named fat tissue-specific low molecular weight protein, of 
unknown function, had previously been identified in differentiating adipocyte cells [160]. It was seen 
to be predominantly expressed in the adrenal and to a lesser extent expression was also seen in 
other tissues including the brain, thyroid, ovary, testis and breast [159]. It was demonstrated to 
interact with MC2R and furthermore its co-expression with MC2R in heterologous cells allowed for 
delivery of a significant proportion of the ACTH receptor to the cell membrane [159]. This protein 
was renamed melanocortin receptor 2 accessory protein (MRAP) and mutations in MRAP account for 
a further 20% of cases in FGD, FGD type 2 [131]. Patients with FGD 2 tend to present with disease in 
early infancy. Clinically, unlike FGD 1 patients, FGD 2 patients do not have tall stature and this is 
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thought to be related to the earlier diagnosis and earlier institution of replacement glucocorticoids. 
The first missense mutations, p.V26A and p.Y59D, in MRAP have also been described leading to a 
later onset, milder form of the disease [131]. Altogether twelve mutations in MRAP have been 
described [131]. 
MRAP comprises 172 amino acids and forms a stable anti-parallel homodimer at the plasma 
membrane and endoplasmic reticulum (ER) [161]. It is a small single transmembrane protein which 
forms a stable heterodimer with MC2R at the plasma membrane [162]. Further functional analysis 
has demonstrated that this dual topology of MRAP is essential to its function since deletion of the 
residues responsible for the antiparallel dimerization result in failure of trafficking of MC2R to the 
cell surface.  MRAP directly interacts with MC2R at the ER and is responsible for correct folding or 
trafficking of the receptor to the plasma membrane. mRNA levels of MC2R and MRAP are regulated 
by ACTH [163, 164]. Two isoforms of MRAP ( MRAP-α and MRAP-β) have been described with 
differing C terminals. Exons 3, 4 and 5 encode the 172 amino acid MRAP-α with alternative splicing 
of exons 3, 4 and 6 resulting in the 102 amino acid MRAP-β isoform. The importance of the variation 
in C terminal and the precise role of the two isoforms remains unclear. It has been suggested that 
the C-terminus may determine the localisation of MRAP; the α-isoform localising mainly to the ER 
and the β isoform exhibiting strong localisation to the plasma membrane [165]. An MRAP-knockout 
mouse model has yet to be described in the literature. A homologue of MRAP has recently been 
described, MRAP 2, sharing 39% sequence identity within the N-terminus [166]. MRAP 2 is seen in 
the developing adrenal but in very low levels in adulthood, as demonstrated in rodents [167]. It also 
forms a heterodimer with MC2R [166], although the role of this heterodimer needs to be fully 
elucidated and its importance in the adrenal has yet to be determined. 
The predominant mechanism of disease in FGD, causing 50% of cases, is therefore related to 
defective ACTH signalling in the adrenal, a consequence of mutations of MC2R or its accessory 
protein encoded by MRAP. 
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1.7.4 FGD type 3; Non-classical lipoid congenital adrenal hyperplasia 
A locus on chromosome 8 had previously been linked to the FGD-disease phenotype in 3 families 
who were mutation negative for MC2R and MRAP mutations. Analysis by single-nucleotide 
polymorphism array of the genotype of one of these individuals revealed a large region of 
homozygosity encompassing the steroidogenic acute regulatory protein gene, STAR. A homozygous 
STAR mutation, p.R192C, was identified in this patient and his 3 siblings [168]. Screening of 79 
families within the FGD cohort revealed the presence of a previously described homozygous p.R188C 
STAR mutation in a further nine individuals from four other families [168]. STAR mutations have 
accounted for approximately 10% of cases within our FGD cohort [131]. 
 
Figure 1.6. Schematic diagram demonstrating mutations in STAR associated with adrenal 
insufficiency. The mutations in red are those that have been identified in association with FGD. 
 
STAR in conjunction with a multi-component complex facilitates the transport of cholesterol across 
the inner mitochondrial membrane, following which cholesterol is metabolised along the 
steroidogenic pathways [1]. Over 40 mutations have been described in STAR, mainly located in the C 
terminal domain of the protein encoded by exons 5, 6 and 7 (Figure 1.6). These mutations cause 
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lipoid congenital adrenal hyperplasia (LCAH; OMIM #201701), an autosomal recessive disorder 
characterised by adrenal insufficiency in early infancy together with gonadal insufficiency. The 
absence of foetal testosterone/ dihydrotestosterone production can lead to a failure of 
androgenisation and a female phenotype in 46, XY individuals. Whilst affected females can undergo 
normal puberty, they develop a progressive hypergonadotropic hypogonadism. With regards to 
pathological mechanism, Miller’s two hit hypothesis describes mutations in STAR ablating the acute 
steroidogenic response, leading to low circulatory steroid levels and a compensatory increase in 
ACTH, angiotensin II and LH [169]. This in turn leads to increased cellular uptake of LDL cholesterol 
and de novo lipid deposition in steroidogenic cells which gradually have an impact on normal cell 
function over time [169]. The zona glomerulosa and fasciculata accumulate cholesterol esters after 
birth and the foetal testis is affected early in gestation due to chorionic gonadotropin stimulation. In 
contrast, the foetal and childhood ovary are relatively protected until after puberty when cholesterol 
deposits accumulate with LH and FSH stimulation of steroidogenesis. Investigation of Star-/- mice 
demonstrates the hierarchy of involvement of the different steroidogenic organs and pathological 
findings recapitulate the human phenotype [170]. Newborn knockout mice lack normal adrenal 
gland architecture with abundant lipid deposits although they still demonstrate some residual 
capacity for corticosteroid production. Progressive changes are seen and the zona fasciculata and 
glomerulosa are particularly affected, with relative preservation of the zona reticularis. By 16 weeks, 
adrenocortical hyperplasia akin to the human phenotype is seen. Whilst ovaries are normal at birth, 
worsening histopathology is seen with age, beginning at the time of puberty with stromal cells 
particularly affected. In males, residual biosynthesis of androgens is suggested with normal 
appearances of the epididymis and vas deferens (both derived from the wolffian ducts) and mature 
spermatids within the epididymis. However at 4 weeks of age, delayed germ cell maturation is seen 
with increased apoptosis in developing spermatocytes. In contrast, the seminal vesicles and prostate 
are markedly hypoplastic with absence of virilisation of the external genitalia; suggesting a more 
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significant impairment of the endocrine actions of the androgens compared to the paracrine actions 
in the structures closer to the testes.  
The p.R192C and previously described p.V187M and p.R188C mutations in humans confer a milder 
isolated adrenal phenotype, specifically involving glucocorticoid deficiency [168, 171]. The relative 
sparing of mineralocorticoid production is believed to reflect the lower rate of production of 
aldosterone in comparison with cortisol, thereby sparing the zona glomerulosa from excessive lipid 
accumulation. Whilst preserved gonadal function has allowed for normal male and female pubertal 
development in the patients, some of the adults have progressed to compromised fertility. The 
Val187 and Arg188 contribute to the sterol-binding pocket of the protein and modelling suggests a 
steric inhibition of cholesterol binding in the case of the p.V187M mutation [172]. With regards to 
the p.R188C mutation, the formation of the normal salt bridge present between residues R188 and 
E169 is prevented, instead a weaker bond between residues T167 and C188 is formed. This may be 
sufficient to preserve the shape of the binding pocket for cholesterol transport and functional 
analysis of the p.R188C and p.V187M mutants revealed preservation of greater than 20% normal 
cholesterol binding activity [172].  
STAR mutations associated with the FGD-like phenotype demonstrate the spectrum of clinical 
phenotype associated with STAR mutations, ranging from LCAH through to a phenotype of adrenal 
dysfunction, similar to FGD, with or without disorders of sexual development. 
1.7.5 FGD type 4; defects in DNA replication 
A variant of FGD has recently been described in a genetically isolated Irish traveller population by 
Hughes and colleagues [173]. Affected individuals, seven children from three kindreds, had the 
characteristic finding of isolated glucocorticoid deficiency with normal renin and aldosterone levels. 
Patients however appeared to have a period of normal adrenal function, with onset of disease in 
childhood rather than infancy as is classical in FGD. Additional features described included low birth 
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weight and short stature (short for mid-parental height standard deviation score (SDS)) in 
association with an intact growth hormone/IGF1 axis.  In addition, a specific natural killer cell 
deficiency is described, with one individual demonstrating an increased susceptibility to infection, in 
particular respiratory infections. Chromosomal fragility is also described. Patients were mutation 
negative for known causes of FGD. In common with other inherited causes of FGD, an autosomal 
recessive pattern of inheritance was seen. SNP genotyping in 8 patients followed by targeted exome 
sequencing in 1 patient identified a variant (c.71-1insG) in minichromosome maintenance-deficient 4 
(MCM4) that segregated with the disease. MCM4 is a DNA replicase and forms a highly conserved 
hexameric complex with MCM2, MCM3, MCM5, MCM6 and MCM7. This complex, known as the 
minichromosome maintenance complex, is required for the initiation and elongation phases of 
eukaryotic DNA replication. The mutation identified was predicted to result in a severely truncated 
protein (p.Pro24ArgfsX4), however western blotting of patient lymphocytes revealed conservation of 
the minor 86 kDa form of the protein with absence of the major 96 kDa isoform [173]. Further 
investigation suggested that this smaller isoform may be produced by an alternative translation start 
site, the third in frame ATG, leading to absence of the N terminus of the full length protein, but 
leaving essential conserved C-terminal domains intact. Independently, Gineau and colleagues also 
identified the same mutation in six other related patients from the Irish traveller population who 
presented with a similar clinical phenotype; the patients described in this study were however all 
immune compromised [174]. Their work demonstrated conservation of formation of the MCM2-7 
complex, indicating that the N terminal domain is not necessary for formation of the MCM2-7 
complex and DNA binding. However SV40-immortalised human fibroblasts from controls and 
patients demonstrated an effect on DNA replication with an impact on the mitotic phase. 
Furthermore with compromise of replication, DNA becomes more prone to breakage and increased 
genomic instability was demonstrated in patient-derived cells (as determined by the assessment of 
chromatid breaks and chromosomal exchanges).  
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Interestingly, genetic knockout of Mcm4 in mice is embryonically lethal [175]. It is proposed that the 
relatively mild phenotype seen in humans is a consequence of preservation of the smaller isoform of 
MCM4. For further interrogation of the adrenal phenotype a viable Mcm4 depleted mouse model 
was used; mice with a hypomorphic Chaos3 mutation [176]. The F345I mutation in this model affects 
a well conserved amino acid located close to the zinc finger motif, important for interactions 
between MCMs but represents a viable, defective allele of Mcm4. This Mcm4 depleted mouse 
model, demonstrated abnormal adrenal morphology with atypical spindle shaped cells populating 
the zona fasciculata with reduced expression of steroidogenic cells [173]. These spindle shaped cells 
were positive for GATA-4 (a transcription factor not usually present in the adult adrenal) and Gli1 
(characteristic of cells from the mesenchymal adrenal capsule).  The normal architecture of the 
capsule was lost and it is hypothesised that these cells are of capsular origin, entering the cortex but 
failing to differentiate into steroidogenic cells instead activating GATA-4 expression. This population 
of cells displace normal steroidogenic cells thus compromising steroidogenic output. The Mcm4 
depleted mice demonstrate severe growth failure and increased susceptibility to the development of 
mammary tumours, histiocytic sarcomas and lymphomas [176]. So far no form of cancer has been 
detected in patients. 
MCM4 may therefore play a role in adrenal stem cell differentiation and defective function may 
prevent adrenal capsular cells from differentiating into steroidogenic cells. This cohort of patients 
presenting with an FGD-like phenotype has highlighted the potential role of replicative stress on 
primary adrenal insufficiency. 
1.7.6 FGD type 5; defects in antioxidant pathways  
In 2012, linkage to a locus on chromosome 5 was identified in 3 consanguineous families by SNP 
genotyping with discovery of a mutation in nicotinamide nucleotide transhydogenase (NNT, OMIM 
#614736) [177]. NNT encodes nicotinamide nucleotide transhydrogenase, a proton pump located in 
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the inner mitochondrial membrane [177]. Mutations in NNT are estimated to account for 10% of 
disease within our FGD cohort (Figure 1.7).  
 
Figure 1.7. Schematic diagram demonstrating NNT mutations identified so far; 9 homozygous (in 
orange) and 7 compound heterozygous (delineated by matching colours). Image reproduced with 
authors’ permission[131]. 
 
NNT uses energy from the mitochondrial proton gradient to regenerate NADPH from NADP+, using 
NADH produced in the tricarboxylic acid (TCA) cycle. NNT couples the production of NADPH to the 
rate of mitochondrial metabolism and the production of ROS generated by the electron transport 
chain. High concentrations of NADPH are required by both the glutathione (GSH) and thioredoxin 
(TXN) systems for detoxification of mitochondrial ROS (Figure 1.8; this system is discussed in further 
detail in section 1.9 and 1.10). NADPH is also utilised by the electron transfer proteins ferredoxin 
reductase and ferredoxin, critical for the reduction of the P450 enzymes in steroidogenesis [178]. 
Thus there are several mechanisms by which NNT deficiency may impact on steroidogenesis. NNT is 
widely expressed with high levels apparent in the adrenal glands of both humans and mice [177]. 
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Figure 1.8. Detoxification of mitochondrial superoxide species produced during electron leak from 
the mitochondrial electron transport chain. The superoxide radical O2.-, produced from electrons   
(e-) leaked at complex I and III of the mitochondrial electron transport chain, can be protonated to 
form H2O2, this process of dismutation is catalysed by MnSOD (manganese superoxide dismutase). 
Mitochondrial H2O2 is detoxified by the thioredoxin and glutathione systems, which require high 
concentrations of NADPH (reduced nicotinamide adenine dinucleotide phosphate) provided by NNT 
(nicotinamide nucleotide transhydrogenase). The flow of electron transfer from NADPH to 
peroxiredoxin 3 (PRDX3) and glutathione peroxidase (GPX), through the various components of the 
thioredoxin and glutathione systems are shown in the figure. GSR, glutathione reductase; GSH, 
reduced glutathione; TXNRD2, thioredoxin reductase 2; TXN2, thioredoxin 2; GLRX2, glutaredoxin 2. 
 
A substrain of C57BL6/J mice carries a spontaneous Nnt mutation leading to a 5-exon deletion; 
partial-deletion of the first domain of NNT, which binds NADH, and four of the fourteen 
transmembrane domains which comprise the proton channel [179]. This substrain of C57BL6/J mice 
show an increased sensitivity to O2.-/ H2O2  particularly in the absence of mitochondrial MnSOD 
(SOD2) and a deficiency in both antioxidants results in death within 1 to 2 days [180] due to dilated 
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cardiomyopathy. Introduction of a normal copy of Nnt in the Sod2-/- mice with the C57BL6/J 
background confers improved cardiovascular function during foetal development [181]. Adrenals 
from the Nnt-mutant substrain are noted to have slightly disorganised zonae fasciculata with higher 
levels of apoptosis than wild-types [177]. No differences in P450scc (CYP11A1) and P450c11β 
(CYP11B1) distribution were seen between the two substrains, however the mutant mice had lower 
basal and stimulated levels of corticosterone, though the deficiency was not as marked as that seen 
in the human disease [177]. Lentiviral shRNA-knockdown of NNT in the human adrenocortical H295R 
cell line leads to increased levels of mitochondrial ROS, a decrease in the reduced to oxidised 
glutathione  (GSH/GSSG) ratio and increased apoptosis [177].  
Extra-adrenal features have also been demonstrated in this substrain of mice. Nnt-mutant mice have 
impaired glucose tolerance with loss of glucose dependent insulin secretion and ATP production in 
isolated pancreatic islet cells, reminiscent of a type 2 diabetes mellitus model [179, 182]. When fed 
on a high fat diet, C57BL/6J mice develop obesity, hyperglycaemia and insulin resistance [183]. 
Interestingly, it has been demonstrated that the C57BL/6J mice expressing the truncated protein 
have comparable insulin secretion and glucose tolerance to the C57BL/6N mice expressing the full 
length wild type protein, but  lower levels than other strains (C3H/HeH and DBA/2) with higher 
expression of Nnt [184]. This suggests that it is low levels of NNT rather than the specific 5 exon 
deletion that has the impact. This also raises the possibility that another enzyme is able to 
functionally compensate for the loss of NNT in the C57BL/6J mice, this could explain the relative 
preservation of steroidogenesis in this strain in comparison to the human phenotype. C57BL/6J mice 
have also been shown to have a higher sensitivity to neurotoxic agents [185]. There are currently no 
published reports of extra adrenal clinical manifestations in patients with NNT mutations, however 
careful clinical surveillance is required for these patients given the ubiquitous expression of NNT. 
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1.7.7 Familial glucocorticoid deficiency summary 
FGD is a rare autosomal recessive disorder of primary adrenal insufficiency leading to ACTH 
resistance, glucocorticoid and adrenal androgen deficiency. Mutations in the ACTH receptor MC2R 
have been associated with disease. Further study of aetiology within the patient cohort, negative for 
MC2R mutations, led to the discovery of the melanocortin receptor accessory protein (MRAP) 
providing further valuable understanding of the mechanism of ACTH signalling in the adrenal cortex. 
Mutations of MC2R and MRAP account for half of the disease, therefore, classically FGD involves 
disruption of ACTH signalling in the adrenal. More recently novel pathways have been implicated, 
including defective DNA replication and mitochondrial antioxidant defence, widening the spectrum 
of causative mechanisms. 
1.8 Steroidogenesis and reactive oxygen species (ROS) production 
Reactive oxygen species (ROS) are derived from O2 and comprise molecules with varying oxidant 
properties.  At low concentrations ROS modulate many cellular processes through redox dependent 
signalling, including proliferation, differentiation, apoptosis, immune regulation and cellular 
adaptation to stress [186, 187]. A critical balance in redox status needs to be maintained and this is 
achieved by numerous interacting antioxidant pathways. Oxidative stress occurs when this balance is 
disturbed. ROS can then have deleterious effects on proteins, lipids, and nucleic acids, ultimately 
leading to cell damage and death. Oxidative stress is implicated in a plethora of conditions including 
neurodegenerative disorders, diabetes mellitus, cardiovascular disease and aging. Antioxidant 
defence mechanisms are complex and can be specific to cell type and furthermore to sub-cellular 
compartment. In comparison to many other tissues, including those with high metabolic demand 
such as the liver and brain, the adrenal cortex has high levels of several antioxidants, both enzymatic 
and non-enzymatic [188]. This investment is necessary given the high turnover of lipid within the 
mitochondria and ROS production during steroidogenesis. Disturbances in redox homeostasis within 
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the adrenocortical environment could therefore have an impact on steroidogenesis. This is 
corroborated by several disorders of adrenal insufficiency, including most recently FGD.  
1.9 Reactive oxygen species generation in mitochondria 
Mitochondria are responsible for the majority of cellular ROS production secondary to electron leak 
as a consequence of respiration. During respiration, electrons are transferred across to molecular 
oxygen to generate water via the four complexes of the electron transport chain. The electron 
proton gradient established during this process is used to generate energy in the form of adenosine 
triphosphate (ATP). As a result of electron leak at complexes I (NADH dehydrogenase) and III 
(cytochrome c reductase) a small percentage of the molecular oxygen is converted to superoxide 
anions (O2.-) (Figure 1.8). These superoxide anions can be protonated to form strongly oxidant 
hydroxyl radicals (.OH) which can cause oxidative modification of proteins and membrane lipids. ROS 
can also modify key components of the electron transport chain thereby further exacerbating 
electron leak and superoxide production. Dismutation, catalysed by the superoxide dismutases 
(SODs), reduces superoxide ions to hydrogen peroxide (H2O2).   H2O2 can also contribute to oxidative 
stress by reacting with free metals to form .OH. Additionally, in comparison to O2.-  which tends to 
remain at the site of production, H2O2 readily traverses membranes into other subcellular 
compartments where it may impact on signalling pathways. 
Several compartment specific antioxidant mechanisms are in place to target superoxide production. 
Cytoplasmic copper/zinc dependent SOD1 (CuZnSOD), mutations of which are associated with the 
neurodegenerative disorder amyotrophic lateral sclerosis (ALS) and mitochondrial matrix manganese 
dependent SOD2 (MnSOD) catalyse the conversion of superoxide anions into H2O2 (Figure 1.8). H2O2 
has preferential reactivity towards (seleno) cysteine residues in target proteins and is detoxified by 
members of the glutathione peroxidase (GPX) and peroxiredoxin (PRDX) families, discussed later in 
section 1.10. The relative contribution of each of these enzymes may be tissue and compartment 
specific and determined by the source of H2O2 and the expression levels of each individual enzyme. 
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In addition to electron leak during respiration, other sources of superoxide production within the 
mitochondria include reactions catalysed by xanthine/xanthine oxidase, uncoupled nitric oxide 
synthases (NOS), NADPH-dependent oxidases (NOXs) and most pertinent to the adrenal cortex, 
cytochrome P450 isoforms. The P450 enzymes are involved in the biosynthesis of cholesterol 
derived steroidal compounds [5]. In steroidogenic tissues, the expression of P450 enzymes are 
approximately ten times higher than other electron transport chain proteins and electron leak in the 
P450 system can also contribute to ROS production [178, 189]. P450 groups are represented by 
microsomal cytochrome P450s present in the endoplasmic reticulum, and mitochondrial cytochrome 
P450s, present in the inner mitochondrial membrane.  Type 1 P450 isoforms present in the 
mitochondria include P450scc (side chain cleavage; CYP11A1), which catalyses the conversion of 
cholesterol to pregnenolone, and P450c11β responsible for the β-hydroxylation of 11-
deoxycorticosterone to cortisol (Figure 1.9). The reactions catalysed by these P450 enzymes require 
NADPH as a reducing agent, in addition to molecular oxygen. NADPH donates two electrons which 
are transferred to P450 enzymes via 2 electron transfer proteins, ferredoxin reductase (adrenodoxin 
reductase) and then ferredoxin (adrenodoxin) [190, 191]. Ferredoxin reductase is a FAD (flavin 
adenine dinucleotide) containing flavoenzyme and is able to accept both electrons from NADPH. 
These are then passed one at a time to ferredoxin and finally to the P450 enzymes for hydroxylation 
of substrates, the order of electron transfer as seen below (Hanukoglu 2006): 
 
NADPH  → ferredoxin reductase  → ferredoxin →P450 
 
In a tightly coupled system, all electrons from NADPH are used in substrate hydroxylation however 
electron transfer within the P450 system can be relatively 'uncoupled' or 'leaky,' with the rate of 
electron leak variable depending on P450 subtype [178]. Up to 40% of total electron flow in the 
P450c11β system, catalysing the final step in cortisol synthesis, are directed to ROS formation in 
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comparison to the 15% in the P450scc system [192]. Thus steroidogenesis, particularly glucocorticoid 
production, contributes significantly to cellular ROS production (Figure 1.9). Type 2 microsomal P450 
isoforms, catalysing all the other steps in steroidogenesis, are present in the endoplasmic reticulum 
and are reliant on P450 oxidoreductase and NADPH for reduction [5]. 
 
 
Figure 1.9.  Reactive oxygen species production during steroidogenesis. The import of cholesterol 
from the outer mitochondrial membrane (OMM) to the inner mitochondrial membrane (IMM) is 
activated by STAR and mediated by the translocator protein (TSPO)-associated multi-component 
complex. This is followed by cholesterol side chain cleavage to pregnenolone by P450scc (CYP11A1). 
The other steps in the steroidogenic pathway are catalysed by P450 cytochrome isoforms in the 
endoplasmic reticulum (ER). The final step in cortisol synthesis is catalysed by P450c11β (CYP11B1) 
in the mitochondria, converting 11-deoxycortisol to cortisol. Electron leak during this process results 
in reactive oxygen species production. 
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1.10 Adrenal cortex antioxidant defence mechanisms 
The adrenal cortex is particularly equipped to handle the increased risk of oxidative stress. Several 
antioxidants, both enzymatic and non-enzymatic, are highly expressed in comparison to other 
tissues.  Ascorbic acid (vitamin C), which recycles α-tocopherol (vitamin A) radicals, is present at the 
highest levels in the adrenal cortex [188], indeed endogenous ascorbic acid was first isolated from 
adrenal tissue [193, 194]. Depletion of ascorbic acid secondary to vitamin A deficiency in rats leads 
to adrenocortical degeneration [195]. Other non-enzymatic antioxidants present in high levels within 
the adrenal cortex include vitamin A and vitamin E [196]. 
As previously described O2.- radicals are converted by SODs to H2O2. Mitochondrial H2O2 is further 
reduced by two major thiol antioxidant systems dependent on reduced glutathione (GSH) and the 
small protein thioredoxin 2 (TXN2), each system having several associated proteins (Figure 1.8).  
Reduced GSH and components of the TXN2 system are seen in abundance in the adrenal cortex [196, 
197]. Both TXN2 and GSH systems are dependent on the reducing power of NADPH. NADPH supply 
within the mitochondria is maintained by the proton pump NNT, mutations of which have recently 
been associated with FGD [177]. Mitochondrial NADPH stores can also be restored by mitochondrial 
dehydrogenases including malate dehydrogenase and isocitrate dehydrogenase.  
GSH contributes significantly to maintaining a reduced cellular environment. In physiological 
conditions a high reduced (GSH) to oxidised glutathione (GSSG, glutathione disulphide) ratio is 
maintained. GSH, synthesised in the cytosol, is transported into the mitochondria by dicarboxylate 
and 2-oxoglutarate carriers [198]. Within the mitochondria, GSH is regenerated from GSSG by the 
enzyme glutathione reductase with NADPH as a cofactor. GSH acts as an electron donor for the 
glutathione peroxidases (GPXs), members of the selenoprotein family, which incorporate 
selenocysteine in their enzymatic catalytic site. These selenocysteine residues are highly redox 
reactive and GPXs play an important role in reducing H2O2 to water. Selenium (Se) content in the 
adrenal is high and Se is preferentially retained in this organ during selenium deficiency [199]. Se 
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deficiency results in a significant depletion of GPX activity and a reduction in steroidogenesis in an 
adrenal cell line [200]. Eight GPX isoforms have been identified in humans, GPX1 being the major 
isoform in most tissues, present primarily in the cytosol but also in small amounts in the 
mitochondria. Our unpublished data shows particularly high expression in the adrenal cortex. In the 
testes and spermatozoa, the mitochondrial isoform of GPX4 is the most prevalent form with 
depletion causing male infertility in mice [201]. 
Mammalian peroxiredoxins (PRDXs) also catalyse the reduction of H2O2 and lipid peroxides, albeit 
less efficiently than the GPXs. They comprise a family of 6 members, most of which (PRDX 1 to 5) use 
TXN as an electron donor. PRDX 3 and 5 are present within the mitochondria; PRDX3 is 
mitochondrial-specific and is seen in particular abundance within the adrenal cortex, with a 
significant role in H2O2 detoxification within the mitochondrial matrix. It is estimated that PRDX3 is 
the target for up to 90% of H2O2 generated within the matrix [202]. During H2O2 elimination, two 
reduced PRDX3 subunits are converted to an oxidised disulphide-linked dimer that is reduced again 
by the mitochondrial TXN2 system [203] (Figure 1.8 & 1.10). TXN2 in turn is maintained in reduced 
form by the mitochondrial selenoprotein, thioredoxin reductase 2 (TXNRD2) (Figure 1.8). In parallel, 
GSH can work together with glutaredoxin 2 (GLRX2) in the mitochondria to also reduce 
peroxiredoxins [204] (Figure 1.8).    
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Figure 1.10. Maintenance of reduced peroxiredoxin 3 (PRDX3-SH) by thioredoxin 2 (TXN2) and 
sulfiredoxin (SRX). PRDX3, in its reduced form, detoxifies H2O2 in the mitochondria. This process 
induces the formation of disulphide PRDX3 which in turn is reduced back to PRDX3-SH by TXN2. With 
excessive H2O2 PRDX3 is hyper oxidised to an inactive sulfinic form (PRDX3-SO2-) and this hyper 
oxidisation is reversed by SRX. 
 
The catalytic cysteine (Cys) in the mammalian 2-Cys PRDX enzymes (PRDX 1 to 4) can undergo 
hyperoxidation to cysteine sulfinic acid (Cys-SO2-), inactivating peroxidase function [205]. This 
inactive sulfinic form can be reduced back to the active form by sulfiredoxin (SRX), also seen most 
abundantly within the adrenal gland [206] (Figure 1.10). The only PRDX to be seen in sulfinic form 
within the adrenal cortex is PRDX3 and this inactivation of PRDX3 has recently been demonstrated to 
trigger a series of events within the adrenocortical environment [206]. In both the murine and 
bovine models, ACTH stimulation increases inactivated sulfinic PRDX3, an effect that is prevented by 
metyrapone treatment, a P450c11β inhibitor. This suggests that H2O2 produced in this final step of 
cortisol synthesis is in the main responsible for this hyperoxidation of PRDX3. Inactivation of PRDX3 
results in accumulation of H2O2 which can diffuse into the cytosol, activating p38 mitogen-activated 
protein (MAP) kinase signalling pathways with subsequent suppression of STAR protein synthesis 
and inhibition of steroidogenesis [206]. It is proposed that this mechanism of redox signalling exerts 
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physiological control over steroidogenesis at the level of the adrenal gland, in addition to the well 
characterised negative feedback exerted by cortisol on the HPA axis.  
1.11 Thesis Rationale 
Triple A syndrome and FGD are disorders of primary adrenal insufficiency, characterised by ACTH 
resistance. Oxidative stress has been implied in the pathogenic mechanism of several conditions of 
primary adrenal insufficiency including ALD, triple A syndrome and most recently the FGD subtype 
related to NNT mutations. 
Triple A syndrome is tissue specific and progressive, characterised by adrenal failure, alacrima, 
achalasia and neurodegenerative disease. Similarities between the neurological features of triple A 
syndrome and amyotrophic lateral sclerosis (ALS) have been recognised. The first section, aims to 
investigate ALADIN, the AAAS gene product’s role in cellular defence against oxidative stress. To 
date, models of the disease include the AAAS-/- mouse, which does not bear a similar phenotype to 
the human disease and triple A syndrome patient dermal fibroblasts. To establish an adrenal and 
neuronal model for the disease, representative of the major tissue types involved in the disease, I 
have induced shRNA lentiviral AAAS-knockdown in adrenal and neuronal cell lines. Detailed 
functional studies on these cells included investigating the effects of oxidative stress on cell growth, 
survival, and apoptosis. Using this in vitro adrenal model I interrogated specific effects of ALADIN 
deficiency on steroidogenesis. 
In the second part of the thesis I investigated several individuals, within a consanguineous Kashmiri 
family with glucocorticoid deficiency, who were demonstrated to be mutation negative for the 
known causes of FGD to date.  An autosomal recessive pattern of inheritance is suggested within this 
consanguineous kindred and I hypothesised that, in keeping with previous causes of FGD, a novel 
non-synonymous homozygous mutation would be associated with disease in this family.  Whilst 
most cases of FGD are caused by defective ACTH signaling, newly identified mechanisms of disease 
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indicate an important role for replicative and oxidative stress in the pathogenesis of FGD. It is 
possible that other candidates within these biological pathways could be associated with disease in 
this family. Whole exome sequencing was utilised together with direct sequencing of potential 
candidate genes within this extended family.  
Ultimately, I hoped to provide insights into the pathogenesis of triple A syndrome and FGD and 
identify potential therapeutic targets. This work could give insights into the understanding of disease 
mechanisms in additional cases of primary adrenal insufficiency and other neurodegenerative 
disorders.  
 
 
75 
 
Chapter 2 Materials and Methods 
2.1 Cell culture 
2.1.1 Cell culture conditions 
H295R human adrenocortical tumour cells were obtained from Ian Mason, University of Edinburgh; 
HEK293T human embryonic kidney cells from the European Collection of Cell Cultures (ECACC) at the 
Health Protection Agency (HPA; Salisbury, UK) and SH-SY5Y human neuroblastoma cells from 
European Collection of Cell Cultures (ECACC) at the Health Protection Agency (HPA; Salisbury, UK).  
H295R cells were cultured in GIBCO Dulbecco’s Modified Eagle Medium/ F12-Ham (1:1) + 
GlutaMAXTM-I (Sigma Aldrich, Poole, UK), supplemented with 5% NuSerum (BD Biosciences, Oxford, 
UK), 1% penicillin/streptomycin solution (Pen/Strep; Invitrogen, Paisley, UK) and 1% insulin-
transferrin-selenium (ITS; 6.25μg/ml Insulin, 6.25μg/ml Transferrin, and 6.25ng/ml Selenous Acid; BD 
Biosciences, Oxford, UK). SH-SY5Y neuroblastoma cells were cultured in Dulbecco’s Modified Eagle 
Medium/ F12-Ham (1:1) (Sigma Aldrich, Poole, UK), supplemented with 10% foetal calf serum (FCS; 
Invitrogen, Paisley, UK) and 1% Pen/Strep solution. HEK293T cells were maintained in DMEM (Sigma 
Aldrich, Poole, UK) with 10% FCS and 1% Pen/Strep.  All cells were incubated in a humidified 
incubator at 37°C and 5% CO2. 
Harvesting of cells was carried out as follows: cells were cultured to 90% confluency in a 75 cm2 
(T75) flask, cells were washed twice in 5 ml of Phosphate Buffered Saline (PBS) solution (Sigma 
Aldrich, Poole, UK) prior to incubation with 3 ml of Trypsin/Ethylenediaminetetraacetic acid (EDTA, 
Invitrogen, Paisley, UK) until detachment of cells was achieved. Neutralisation of TE buffer was 
achieved by addition of 7 ml of media and cells were then divided into separate flasks or spun gently 
at 1000 rpm for 5 minutes (mins) until a cell pellet was formed and the supernatant is discarded. 
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2.1.1.1 Freezing cells for future use 
Cell pellets from individual T75 flasks were obtained as described above. A solution of 2.7 ml FCS 
together with 0.3 ml Dimethylsulfoxide (DMSO; Sigma, Poole, UK) was prepared. DMSO acts as a 
cryoprotectant preventing cell death during the freezing process. The prepared solution was poured 
over the cell pellet and the pellet resuspended and the suspension divided into 2 vials for freezing. 
The vials were wrapped in bubble wrap and placed in a -80°C freezer overnight. The following day 
the vials were placed in liquid nitrogen storage. 
Following recovery from storage, cell vials were placed in a water bath at 37°C for a few minutes 
until thawed. 5 ml of media was added to the cell suspension and transferred to a 15 ml falcon tube 
for centrifugation at 1000 rpm for 5 mins. The cell pellet was subsequently resuspended in fresh 
media for plating. 
2.1.2 Lentiviral shRNA transduction 
To establish AAAS-knockdown, TXNRD2-knockdown and scrambled control cells commercially 
produced puromycin-resistant synthetic shRNA (Sigma Aldrich, Poole, UK; OpenBiosystems, 
ThermoScientific, Leicestershire, UK; for sequences and vector maps see appendices 3 and 4) were 
used together with packaging vectors PMDG.2 plasmid (packaging plasmid)  and the pCMV 8.74 
plasmid (envelope plasmid for producing viral particles).  
Introduction of small double-stranded synthetic RNA can induce sequence-specific gene silencing in 
mammalian systems and small hairpin shRNAs are used to achieve longer term gene-silencing. These 
are produced as single-stranded molecules of 50-70 nucleotides in length comprising a 5-10 
nucleotide loop connecting 2 complementary 19-29 nucleotide long RNA fragments that create a 
double stranded stem by base pairing. This forms a stem loop or ‘hairpin’ structure in vivo. The 
shRNA are subsequently ligated into a vector (plasmid, lenti- or retroviral) for transfection; the 
shRNA used in my investigations were incorporated into a lentiviral vector. Lentiviral vectors allow 
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for effective transduction of non-dividing cells and lentiviruses integrate into the host genome and 
their genomic backbone and with life-long expression of a transgene of interest.  
 
Figure 2.1. Achieving target gene knockdown using a lentiviral transduction system. Packaging of 3 
plasmids into a functional lentiviral vector, used to transduce the target cell and integrate into the 
host genome. Once transcribed shRNA can be further processed and exported into the cytoplasm for 
gene silencing. 
 
The initial transduction also requires packaging plasmids containing the viral structural genes, a 
vector plasmid containing the transgene and cis elements needed for integration and packaging and 
finally a heterologous viral (usually VZV-G) envelope encoding plasmid (Figure 2.1). This ensures that 
a replication incompetent virus is subsequently released which is then used to transduce the target 
cells for transgene expression.  In the cytoplasm the shRNA are converted, by cellular nucleases and 
the multidomain ribonuclease DICER, into small fragments (siRNAs). DICER then loads these small 
RNA products (siRNA) into a large multiprotein complex called the RNA-induced silencing complex 
(RISC) during which the passenger strand is cleaved by the enzyme Argonaute 2 (Ago2). The 
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antisense strand then guides the RISC to the corresponding mRNA as a result of sequence homology 
and the same Ago2 nuclease cleaves the target mRNA achieving sequence specific gene silencing. 
With continual expression of siRNAs toxic effects can occur. To account for these controls are 
generated using a shRNA insert that does not target human genes. Following successful transfection 
of target cells I massively expanded cell lines for freezing and I endeavored to conduct experiments 
using cells within 8 passages of the initial transfection. 
2.1.2.1 Transformation of chemically competent bacterial cells 
NEB 5-alpha Competent E. Coli (High Efficiency) (New England Biolabs, Hertfordshire, UK) were used 
for high efficiency transformation. Competent cells were stored at -80°C. For use, one tube of NEB 5-
alpha Competent E. Coli cells was thawed on ice for 5 mins. The contents of a single tube were then 
divided into five 1.5ml microcentrifuge tubes for use. 1-5 µl containing 50 ng of plasmid DNA was 
added to the cell mixture. The tube was flicked carefully 4 to 5 times to mix cells and DNA. The 
mixture was then placed on ice for 2 mins following which the mixture was heat shocked at exactly 
42°C for exactly 30 seconds. The microcentrifuge tube was then placed on ice for 2 mins following 
which 950 µl of room temperature SOC Outgrowth Medium (New England Biolabs, Hertfordshire, 
UK) was added to the mixture. The cell mixture was centrifuged at 4000g for 4 mins following which 
850 µl of supernatant was discarded.  The remaining 100 µl of the cell mixture was spread onto pre-
prepared LB agar plates containing 100 µg/ml ampicillin inverted and incubated overnight at 37°C 
for colony formation. 
2.1.2.2 Preparation of LB agar plates and LB broth 
LB broth (10g LB Broth (Sigma Aldrich, Poole, UK) and 500 ml distilled H2O) and LB Agar (10g LB 
Broth, 10g Agar (Sigma Aldrich, Poole, UK) and 500 ml distilled H2O) were both autoclaved prior to 
use. To prepare LB agar plates LB agar was simmered for 10 minutes and allowed to cool. Once cool 
to touch 50 ml LB agar was poured into a 50 ml falcon tube and 50 µl of 100 mg/ml Ampicillin (Sigma 
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Aldrich, Poole, UK) was added. 25 ml of the above was poured evenly into each plate and allowed to 
set with a lit Bunsen burner kept in close vicinity to help maintain a sterile environment. 
2.1.2.3 Midi-prep preparation 
A single colony was picked from a freshly streaked (overnight incubation) LB agar ampicillin selection 
plate and used to inoculate a starter culture of 3 ml LB broth containing 100 µg/ml ampicillin. This 
was incubated for approximately 8 hours at 37°C with vigorous shaking (300 rpm). The starter 
culture was then diluted 1/500 into 50 ml ampicillin selective LB broth. This was grown at 37°C for 16 
hours with vigorous shaking (300 rpm). Bacterial cells were harvested by centrifugation at 4000g for 
30 mins at 4°C. The supernatant was discarded and all traces of supernatant removed by inverting 
the open centrifuge tube until all medium had been drained. Midi-prep preparation was carried out 
using the Qiagen HI SPEED Plasmid Midi Kit (Qiagen, Crawley, UK). The Qiagen Tips in the kit contain 
an anion-exchange resin, allowing for an anion-exchange-based plasmid DNA preparation. During 
the procedure impurities such as RNA, protein, carbohydrates, and small metabolites are washed 
from QIAGEN resin with medium-salt buffers, while plasmid DNA remains bound until eluted with a 
high-salt buffer. For details of the composition of each of the buffers see Appendix 9.  
The bacterial pellet was resuspended in 6 ml of Buffer P1 (with LyseBlue added to achieve a 1:1000 
dilution) before adding 6 ml of Buffer P2. The suspension was mixed thoroughly by vigorously 
inverting the sealed tube 4 to 6 times and incubating at room temperature for 5 mins. Following the 
addition of Buffer P2 the suspension turns blue with mixing resulting in a homogeneously coloured 
suspension. 6 ml of chilled Buffer 3 was added to the lysate and mixed thoroughly by inverting 4 to 6 
times. The lysate was subsequently poured into the prepared QIAfilter Cartridge and incubated at 
room temperature for 10 mins. A HiSpeed Midi Tip was equilibrated by applying 4 ml of Buffer QBT 
and allowing the column to empty by gravity flow. The cap was removed from the QIAfilter outlet 
nozzle and the plunger gently inserted into the cartridge to filter the cell lysate into the equilibrated 
HiSpeed Tip. The cleared lysate was allowed to enter the resin by gravity flow. The HiSpeed Tip was 
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subsequently washed with 20 ml Buffer QC allowed through by gravity flow. The DNA was eluted 
with 5 ml Buffer QF into a 15 ml falcon tube. The DNA was precipitated by adding 3.5 ml room 
temperature isopropanol and kept overnight at -20°C. This was then spun for 30 minutes at 4000g. 
The supernatant was discarded and 3 ml 70% ethanol was added followed by a further spin for 30 
minutes. This step was repeated before resuspending the DNA pellet in 50 µl sterile water. 
2.1.2.4 Transient Transfection with Lipofectamine-2000  
Lipofectamine-2000 reagent (Invitrogen, Paisley, UK) was used for transient transfection. For a 
standard 6-well plate, 3 μg plasmid DNA was diluted in 100 μl Opti-MEM (Invitrogen, Paisley, UK), 
mixed gently by pipetting and incubated at room temperature for 5 minutes. During incubation, a 
master mix of Opti-MEM (100 μl/well) and Lipofectamine-2000 (5 μl/well) was prepared. The 
Lipofectamine-2000/ Opti-MEM solution was mixed slowly with the DNA/ Opti-MEM solution, and 
incubated for a further 20 minutes at room temperature. Media was removed from wells and 
replaced with 1.3 ml fresh cell culture media. The solutions of DNA/ Lipofectamine-2000 were added 
to wells, and cells were incubated overnight at 37°C with 5% CO2. Media was replaced the following 
morning. Depending on the size of the culture vessel, transfections were scaled up or down as 
follows: 
Culture 
Vessel 
Opti-MEM (μl) DNA (μg)  Lipofectamine-
2000 (μl) 
Opti-MEM (μl) 
6 well plate 100 3 5 100 
T25 flask 250 8 15 250 
T75 flask 1500 24 40 1500 
 
Table 2.1. Transfection with lipofectamine-2000 according to culture vessel type 
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2.1.2.5 Transfection of HEK293T cells followed by lentiviral shRNA transduction of H295R/SH-SY5Y 
cells  
HEK293T cells were used at 60% confluency on the day of transfection in 6 well plates. In each well, 
packaging vectors PMDG.2 plasmid (0.75 μg) and the pCMV 8.74 plasmid (1.0 μg), together with a 
combination of 2 commercially produced puromycin-resistant synthetic shRNA (0.625 μg each) 
(Sigma Aldrich, # TRCN0000118924 and TRCN0000118926, for AAAS-knockdown) were transfected 
using Lipofectamine-2000. A commercially available lentivirus plasmid vector containing a shRNA 
insert that does not target human and mouse genes was used to generate controls (Sigma Aldrich, 
Poole, UK). A total of 3 μg of DNA was transfected into each well of HEK293T cells in 1.5 ml of media. 
Cells were incubated for 48 hours in a humidified incubator at 37°C and 5% CO2. 48 hours post 
transfection, 1.5 ml of viral media from each well of the HEK293T cells was filtered using 0.22 µM 
Millex-GP filter units and used to transduce 1 well of H295R or SH-SY5Y cells. Viral media was left on 
the cells for 24 hours and then replaced with fresh media. Cells were left to grow for 5 days before 
application of a selection antibiotic, puromycin at a concentration of 5 μg/ml. AAAS-knockdown cell 
lines were generated in 3 biological replicates. All subsequent experiments were conducted on 
cultured cells in which AAAS-knockdown was achieved by the combination of the 2 shRNAs together 
and following a minimum of 10 days puromycin selection.  
Stable knockdown of TXNRD2 was established in H295R human adrenocortical cells again by 
lentiviral shRNA transduction. Lentiviral plasmids (V3LHS_354173; OpenBiosystems, 
ThermoScientific, Leicestershire, UK) were obtained in a p.GIPZ backbone and contained shRNA 
specific for human TXNRD2 (NM 10587) under the control of the CMV promoter, plus the puromycin 
resistance and green fluorescence protein (GFP) genes. Techniques for transduction and selection 
were as described above. Transduction efficiency was determined by fluorescence microscopy. A 
control cell line was generated using a lentiviral plasmid vector containing a shRNA insert that does 
not target human and mouse genes (Open Biosystems, ThermoScientific, Leicestershire, UK). 
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2.1.2.5 Generation of puromycin kill curve 
A puromycin kill curve was generated to identify the optimum concentration of puromycin (Sigma 
Aldrich, Poole, UK) required for selection of cells transduced with puromycin-resistant vectors. To do 
this cells were plated at 20,000 cells per well in a 24 well plate on day 0. Cells were plated in 
triplicate for 6 different concentrations of puromycin (0, 1, 2.5, 5, 7.5, 10 µg/ml). The antibiotic-
containing media was added to the wells on day 1 (cells 10% confluent at this time). Cell viability was 
examined every day and cells were cultured for 10 days. The media containing puromycin was 
replaced every 3 days. The optimum concentration of puromycin for each cell type was determined 
by the minimum concentration of puromycin that caused complete cell death after 3 to 5 days 
(Figure 2.2). For both the H295R and SH-SY5Y cells 5 µg/ml puromycin was found to be optimal. 
 
Figure 2.2. Puromycin kill curve generated for H295R cells. 5 µg/ml puromycin provides the 
minimum concentration of puromycin to cause complete cell death after 3 days. 
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2.2 Western blotting 
2.2.1 Cell lysate preparation 
Cells were lysed with RIPA buffer (50 mM Tris-HCL, pH8.0, with 150 mM sodium chloride, 1% IGEPAL 
CA-630 [NP-40], 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulphate) (Sigma Aldrich, 
Poole, UK).  150 µl of RIPA buffer was used per well of a 6 well plate, supplemented with complete, 
Mini, EDTA-free Protease Inhibitor Cocktail tablets (Roche Diagnostics Ltd, West Sussex, UK), placed 
on ice for 30 minutes and centrifuged at 15,000g for 12 minutes at 4˚C. The supernatant was 
subsequently added to an equal volume of Laemmli loading buffer (Sigma Aldrich, Poole, UK) and 
stored at -80°C for later use. To obtain lysates in non-reducing conditions, the supernatant was 
added to a non-reducing buffer (250 mM Tris HCl, pH 6.8, with 8% SDS, 40% glycerol, 0.02% 
bromophenol blue) and stored at -80°C for later use. 
2.2.2 Bradford Assay 
To determine the protein concentration of cell lysates a Bradford Assay was used prior to addition of 
Laemmli buffer to the samples. The assay is based on the maximum absorbance shift from 465nm to 
595nm of Coomassie Brilliant Blue G-250 when bound to a protein. The protein assay dye 
(Coomassie Brilliant Blue G-250(5x); Bio-Rad, Hemel Hempstead, UK) was diluted 1 in 5 with PBS 
(Sigma-Aldrich, Poole, UK) prior to the assay. For protein standards, I used serial dilutions of BSA 
(Bovine serum albumin; Sigma-Aldrich, Poole, UK) ranging from 0 to 1 mg/ml in concentration. 10 μl 
of standard or test sample were added in triplicate to each well of a 96-well plate, plus 200 μl 
protein assay dye. The samples were left to incubate at room temperature for 5 minutes, then 
absorbance was read using a standard plate reader. A standard curve was produced by plotting 
OD595 against concentration of the BSA standard, and the protein concentration of each sample 
was determined by extrapolating from the linear equation.  
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2.2.3 SDS-PAGE 
Samples were heated to 95-100˚C for 5 mins and 10 µg of protein loaded on pre-cast 4-12% 
polyacrylamide NuPage BisTris gels (Invitrogen, Paisley, UK). The gels were run in 1 x3 3-(N-
morpholino)propanesulfonic acid (MOPS) running buffer (50 mM MOPS, 50 mM Tris, 0.1% SDS, 1 
mM EDTA, pH 7.7) for 60 mins at 170 volts. Novex sharp pre-stained protein standard (Life 
Technologies, Paisley, UK) was loaded alongside the samples.  
2.2.4 Immunoblotting 
Following electrophoretic transfer, the proteins were transferred for 30 mins at 15 volts to a 
nitrocellulose membrane by semi-dry transfer using the Trans-Blot SD semi-dry transfer cell (Bio-
Rad, Hemel Hempstead, UK). The transfer buffer consisted of 20 mM Tris, 120 mM glycine and 10% 
methanol. Blots were blocked with 5 ml of 5% milk powder in PBS with 0.05% Tween (PBST). All 
incubations, unless otherwise stated, were performed for 1 hour at room temperature in blocking 
buffer. The membranes were subsequently incubated in 5 ml of 5% milk in PBST containing the 
appropriate antibody (antibody dilution and incubation period specific to each antibody). For 
antibody dilutions and incubation periods see Appendix 5. Following incubation with the primary 
antibody, membranes were washed three times in PBST, each wash lasting 20 mins. Membranes 
were subsequently incubated in appropriate species-specific infra-red secondary antibodies (Licor, 
Cambridge, UK) at a dilution of 1:5000 for 1 hour. After three 15 min washes in PBST, membranes 
were imaged using the Licor Odyssey infrared scanner.  
 
2.3 RNA extraction and reverse transcription 
2.3.1 RNA extraction from animal cells 
RNA extraction from H295R/ SH-SY5Y cells was performed using the Qiagen RNeasy mini kit (Qiagen, 
Crawley, UK). The kit relies on a specialised high-salt buffer system allowing RNA to bind to the 
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RNeasy silica-gel membrane of the RNeasy mini column. Details of the buffers can be found in 
Appendix 9.  
Cells were washed in PBS twice. For each well of a 6 well plate 350 µl of Buffer RLT was added 
together with 3.5 µl 2-β mercaptoethanol. Buffer RLT contains guanidine isothiocyanate which is 
highly denaturing and inactivates RNases, ensuring isolation of intact RNA. Cells were agitated using 
a cell scraper and the cell suspension pipetted into a 1.5 ml microcentrifuge tube. To homogenise 
the sample a syringe with a 20 gauge needle was used to withdraw and release the sample 5 times. 
One volume of 70% ethanol was added to the homogenised lysate and mixed by pipetting. The 700 
µl sample was applied to an RNeasy mini column placed in a 2 ml collection tube, this was then 
centrifuged at 13,000 rpm for 15 seconds. The flow-through was discarded and 700 µl of Buffer RWI 
was added to the RNeasy column for a wash step. Again the sample was spun for 15 seconds at 
13,000 rpm and the flow through discarded. The RNeasy column was transferred to a fresh 2 ml 
collection tube and 500 µl of Buffer RPE (supplemented with ethanol as per manufacturer’s 
protocol) was added to the column followed by a further spin at 13,000 rpm for 15 seconds. This 
step was repeated with a longer spin for 2 mins at 13,000 rpm to dry the RNeasy silica-gel 
membrane. To elute the RNeasy column was transferred to a 1.5 ml microcentrifuge tube and 30 µl 
RNAse free water added directly to the RNeasy silica-gel membrane with a final spin step for 1 min 
at 13,000 rpm. The flow through in this step contains the required RNA. Absorbance of the RNA was 
measured using the NanoDrop ND-1000 spectrophotometer; good quality RNA having an OD 
260/280 ratio of 1.8 to 2.0 or an OD 260/230 of > 1.8; indicating RNA devoid of contaminants. The 
quality of the RNA could be further assessed by electrophoresis on a denaturing agarose gel. 
Ribosomal RNA should be sharp and intense with an upper 28S rRNA band being twice as intense as 
a lower 18S rRNA band.  
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2.3.2 DNase treatment of RNA 
DNase treatment of RNA from cell lysates was carried out to cleave and remove genomic DNA. Each 
reaction mixture contained 1μg RNA, 5μl DNase Turbo buffer (Ambion, Life Technologies, Paisley, 
UK), 0.5μl RNase inhibitor (RNasin, Promega, Southampton, UK) to prevent RNA degradation and 1 
μl DNase 1 (Deoxyribonuclease 1, 10,000 units/ml, Sigma-Aldrich), made up to a volume of 50 μl 
with RNase free water (Sigma Aldrich, Poole, UK). Reactions were incubated at 37°C for 15 minutes 
and then transferred to ice. RNA was purified and precipitated as detailed in section 2.3.4. 
2.3.3 RNA extraction from whole blood 
RNA extraction from whole blood was conducted using the PAXgene Blood RNA kit, details of the 
buffers in the kit can be found in Appendix 9. 
A small amount of blood was drawn into a ‘discard’ tube prior to drawing blood into the PAXgene 
Blood RNA tube (Qiagen, Crawley, UK). The tube contains a reagent which protects RNA molecules 
from degradation by RNAses. Following blood collection the PAXgene Blood RNA tube was inverted 
8 to 10 times with subsequent storage at 4°C in an upright position for up to 5 days. Prior to the RNA 
extraction procedure the RNA tube was incubated at room temperature to achieve complete lysis of 
blood cells. The PAXgene Blood RNA tube was centrifuged for 10 mins at 3000xg using a swing out 
rotor. The supernatant was removed by pipetting. 4 ml of RNase-free water was added to the 
remaining pellet and the tube using a fresh secondary BD Hemogard closure. The pellet was 
dissolved by vortexing and then centrifuged for 10 mins at 3000xg using a swing out rotor. The 
supernatant was then discarded. 350 µl resuspension buffer (BR1) was added and again the sample 
vortexed until the pellet dissolved. The sample was pipetted into a 1.5 ml microcentrifuge tube; 300 
µl binding buffer (BR2) and 40 µl proteinase K were added and the sample mixed by vortexing for 5 
seconds. This was then incubated for 10 mins at 55 °C using a Grant OLS200 shaking waterbath 
(Cambridge, UK) at 200 rpm. After use the incubator was set at 65 °C for use in a later step of the 
protocol. The lysate was pipetted directly into a PAXgene Shredder spin column and placed in a 2 ml 
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processing tube then centrifuged for 3 mins at maximum speed to homogenise the cell lysate and 
remove any cell debris. The entire supernatant of the flow through fraction was transferred into a 
fresh 1.5 ml microcentrifuge tube without disturbing the pellet left in the processing tube. 350 µl of 
100% ethanol was added, to adjust binding conditions, and the sample mixed by vortexing and 
centrifuging briefly (1 to 2 seconds at 1000 x g). The 700 µl sample was pipetted into the PAXgene 
RNA spin column (PRC), placed in a 2 ml processing tube and centrifuged for 1 min at 10,000 x g and 
the flow-through discarded. The spin column was then placed in a new processing tube. Any 
remaining sample was pipetted into a PAXgene RNA spin column and centrifuged for 1 min at 10,000 
x g. RNA selectively binds to the Paxgene silica membrane in the spin column whilst contaminants 
pass through during centrifugation. The PRC was placed in a new 2ml processing tube.  
A series of wash steps were carried out, to remove any remaining contaminants, and include 
treatment with DNase I to remove any traces of bound DNA. Wash buffer I, BR3 (350 µl), was 
pipetted into the PRC and centrifuged for 1 minute at 10,000 x g. The flow through was discarded 
and the spin column was placed into a new 2 ml processing tube. 10 µl DNase I stock solution was 
added to 70 µl DNA digestion buffer in a 1.5 ml microcentrifuge tube. The contents of tube were 
gently fixed and centrifuged briefly to collect residual liquid from the sides of the tube. The DNase I 
incubation mix (80 µl) was pipetted directly onto the PAXgene RNA spin column (PRC) membrane 
and was left at room temperature for 15 mins. Wash buffer I, BR3 (350 µl), was pipetted into the 
PRC and centrifuged for 1 min at 10,000 x g. The flow through was discarded and the spin column 
was placed into a new 2 ml processing tube. Wash buffer 2, BR4 (500 µl), was added to the spin 
column and the centrifuge step repeated and again the flow-through discarded. A further 500 µl of 
wash buffer 2 was added to the PRC and the sample centrifuged for 3 mins at 10,000 x g. The follow 
through and processing tube were discarded and the PRC placed in a new processing tube followed 
by further centrifugation for 1 min at 10,000 x g. The flow through was discarded and the PRC placed 
in a 1.5 ml microcentrifuge tube. 40 µl of elution buffer (BR5) was pipetted directly onto the PRC 
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membrane and centrifuged for 1 min at 10,000 x g to elute the RNA. The elution step was repeated 
using a further 40 µl of elution buffer and the same microcentrifuge tube. The eluate was incubated 
for 5 mins at 65 °C in a water bath (without shaking); this step denatures the RNA. After incubation 
the sample was chilled immediately on ice. RNA samples were then stored at -80 °C if not being used 
immediately. 
2.3.4 Phenol extraction and RNA precipitation 
The organic solvent phenol was used to remove protein contaminants from nucleic acids. RNA 
samples were vortexed with an equal volume (50 µl) of pH 7.8 phenol (Sigma-Aldrich, Poole, UK). 
The samples were centrifuged at 14,000 rpm for 1.5 minutes to separate the layers. The top aqueous 
layer containing purified RNA was transferred to a fresh microcentrifuge tube and precipitated by 
ethanol precipitation. For this a mixture of 5 µl 3M sodium acetate pH 5.3 (BDH Chemicals), 4 µl 5 
mg/ml glycogen (Ambion, Life Technologies, Paisley, UK) and 125 µl absolute ethanol (Fisher-
Scientific, UK) was added to the purified RNA sample for overnight incubation at 80°C. 
Precipitated RNA was collected the next day by centrifugation at 14,000 rpm for 10 minutes at 4°C, 
with removal of supernatant. The RNA pellet was washed with 70% ethanol, spun for a further 5 
minutes at 14,000 rpm at 4°C, with removal of the supernatant. The RNA pellet was resuspended in 
RNase-free water for reverse transcription as detailed below. 
2.3.5 Reverse transcription 
For cDNA production via reverse transcription, 2 μl of 2 mg/ml RNA in 15 μl RNase-free water 
(Sigma-Aldrich, Poole, UK) was incubated with 2 μl random primers (hexadeoxynucleotides, 
500µl/ml; Promega, Southampton, UK) at 70°C for 5 mins, followed by incubation on ice for 2 mins. 
A 1 μl aliquot was taken as a pre-reverse transcription negative control which should not contain 
cDNA or genomic DNA if DNase treatment was successful. 1 μl reverse transcriptase enzyme (MMLV-
RT enzyme, Promega, Southampton, UK) was added, with 5 μl 5x reverse transcriptase buffer (50 
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mM Tris-HCl (pH8.3), 75 mM KCl, 3 mM MgCl2 and 10 mM DTT; 5x MMLV RT-buffer, Promega, 
Southampton, UK), 1.25 μl dNTPs (deoxynucleotidetriphosphates ; consisting of 10 mM dATP, 10 
mM dCTP, 10 mM dGTP, 10 mM dTTP; Promega, Southampton, UK) and 0.75 μl RNase inhibitor 
(RNasin; Promega, Southampton,UK). The entire mixture was incubated at 37°C for 60 mins. The 
resulting cDNA was used as a template for PCR amplification. 
2.4 DNA extraction from whole blood 
The illustra Nucleon Genomic DNA Extraction Kit (GE Healthcare, Buckinghamshire, UK) was used to 
extract genomic DNA from patient whole blood. The procedure involves initial cell lysis, 
deproteinisation with sodium perchlorate, extraction with chloroform treatment and nucleon resin 
and finally DNA recovery and DNA washing. Details of the buffers used in the kit can be found in 
Appendix 9. 
3-5 ml of patient blood was collected in sodium EDTA tubes. Blood stored at 4°C should ideally be 
extracted within 24 hours of collection alternatively samples can be stored at -20°C. For cell lysis, 
using an aseptic procedure 4 times the volume of provided Reagent A (10 mM Tris-HCl, 320 mM 
sucrose, 5 mM MgCl2 1% (v/v) Triton X-100, pH8.0) was added to the blood sample and placed on a 
rotary mix for 4 mins at room temperature. Samples were then centrifuged at 1300x g for 5 minutes 
and the supernatant discarded. The pellet was resuspended in 2 ml of Reagent B (detergent for 
nucleic lysis) and vortexed. The suspension was then transferred to a 15 ml falcon tube following 
which 500 µl of sodium perchlorate solution was added for deproteinisation. The suspension was 
mixed by inversion, seven times.  To extract DNA 2 ml of chloroform was added and the suspension 
was mixed again by inversion. Without remixing the phases 300 µl of Nucleon resin was added and 
the sample was centrifuged at 1300x g for 3 minutes. Two phases separated by the brown Nucleon 
resin layer were evident and the upper phase (approximately 2.5 ml) was transferred to a fresh 15 
ml falcon tube. To precipitate the DNA 2 volumes of cold absolute ethanol were added and the 
sample mixed by inversion until a precipitate was evident. This precipitated DNA was hooked out 
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using a heat-sealed Pasteur pipette and placed directly into 50 µl of sterile water. If no precipitate 
was evident the DNA was pelleted by centrifugation at 4000x g for 5 mins. For DNA washing 2 ml of 
cold 70% (v/v) ethanol was added and the sample re-centrifuged. This step was repeated and the 
supernatant discarded. The DNA pellet was then air-dried for 10 mins before adding 100 µl of sterile 
water. The sample was subsequently rotary mixed for 2 hours to dissolve the DNA.  
2.5 Polymerase chain reaction (PCR) and sequencing 
2.5.1 Oligonucleotide design 
The relevant sequence of the gene of interest was established using Ensembl (see URL). Primer 
sequences for genomic DNA correspond to sequences within the intronic regions whilst primer 
sequences for cDNA traverse intronic regions. The following guidelines were then used for PCR 
primer pair design: 
• Oligonucleotide length of between 18 to 30 nucleotides 
• GC content should be between 40-60% 
• Primer pairs should have similar Tm (melting temperature) values, where the Tm can be 
estimated as follows; Tm = 2°C x (number of A and T residues) + 4°C x (number of G and C 
residues). 
• Complementary sequences within a primer sequence and between pairs should be avoided. 
• Runs of 3 or more Gs or Cs should be avoided at the 3’ end. 
• Complementarity of 2 or 3 bases at the 3’ ends of primer pairs should be avoided to reduce 
primer-dimer formation.  
The stock primer solution was stored at -20°C. To avoid repeat freeze-thawing small working aliquots 
of 10 µM were prepared.  
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2.5.2 Polymerase Chain Reaction (PCR) 
Each exon of genes of interest including intronic boundaries was amplified by PCR using specific 
primers (primer sequences, appendix 1). The reaction mixture made up to a volume of 25 µl 
contained the following reagents: 
• 100 ng DNA template 
• 2.5 µl 10 x Standard Taq polymerase Buffer (10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, 
pH8.3) (New England Biolabs, Hertfordshire, UK) 
• 0.5 µl, 200 µM each dNTP (dATP, dTTP, dCTP, dGTP; Promega, Southampton, UK) 
• 200 nM each primer (forward and reverse, for primer sequences see Appendices 1 and 2) 
• 0.125 µl Taq polymerase (5000 u/ml) (New England Biolabs, Hertfordshire, UK) 
• Nuclease-free water (Sigma Aldrich, Poole, UK) to make up total PCR reaction volume to 25 
µl  
Cycling conditions were: 95˚C for 5 mins (1 cycle); 95˚C for 30 seconds, 55˚C for 30 seconds, and 72˚C 
for 30 seconds (30 cycles); and 72˚C for 5 mins.  
PCR products were then separated and visualized using agarose gel electrophoresis. This technique 
involves application of an electric field across an agarose gel which induces the nucleic acids loaded 
into it to migrate towards the anode due to the net negative charge of the sugar-phosphate 
backbone of the nucleic acid chain. Molecules traverse the gel at different speeds depending on 
their size, with longer molecules moving more slowly as they experience more resistance. The PCR 
products were visualized on 1-2% agarose gel made in 1x TAE buffer (40mM Tris-acetate, 2mM 
disodium ethylenediaminetetraacetate (Na2EDTA), pH 8.3; National Diagnostics, UK) with GelRed 
(Biotium, Cambridge BioScience, Cambridge, UK) staining, alongside DNA markers (GeneRulerTM DNA 
Ladder Mix, 0.5 mg DNA/ml, Fermentas). Prior to loading into the gel wells 5 μl of each reaction was 
mixed with 1 μl of loading dye solution (40% w/v sucrose, 0.25% w/v bromophenol blue or Orange 
G, 1mmol EDTA pH 8.0). Electrophoresis was carried out at approximately 120 V for 30 minutes or 
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until clear separation of products was obtained. GelRed intercalated into DNA fluoresces under UV 
light at 300 nm allowing the DNA and therefore the PCR product to be visualized. A Uvitec 
transilluminator was used to visualize the bands and capture an image of the gel. The approximate 
size of the PCR product can be determined by comparison with the DNA markers on the agarose gel. 
2.5.3 Sequencing 
PCR products were sequenced using the ABI Prism Big Dye sequencing kit and an ABI 3730 
automated DNA sequencer (Applied Biosystems, Foster City, CA), carried out by the Genome Centre 
in Bart’s and the London, QMUL. This is based on the Sanger dideoxy-mediated chain termination 
method [207], which requires a DNA template, a DNA primer, DNA polymerase, conventional dNTPs 
and modified nucleotides that terminate DNA strand elongation (ddNTPs). The double stranded DNA 
fragment is denatured into single DNA strands and a primer complementary to the known DNA 
sequence binds to the single stranded DNA template. DNA polymerase then binds to the primer and 
a new strand of DNA incorporating free nucleotides, complementary to the target DNA sequence, is 
synthesised. The terminating nucleotides of the ddNTPs are fluorescently labelled and modified to 
lack the 3’OH group required for the formation of the phosphodiester bond between two 
nucleotides thus terminating each DNA strand at the point of inclusion. This process is repeated 
many times thus generating many fragments of different lengths that all terminate in fluorescently 
labelled bases, corresponding to A, T, G and C. The reaction is then transferred into thin glass 
capillaries where application of an electrical charge moves negatively charged particles through a gel 
matrix and DNA fragments are then separated according to size. Finally a laser is used to excite the 
chain terminating fluorescent base, which is subsequently recorded as a coloured band or peak by 
the automated sequencer. 
2.5.4 Sequencing analysis 
Analysis of sequence chromatograms was carried out using BioEdit (see URL). BioEdit is a freeware 
biological sequence alignment editor and analysis program for Windows 95/98 NT. The program 
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enables the user to compare the DNA sequence to a reference sequence, enabling identification of 
differences between 2 or more sequences by eye. This program can therefore be used to detect 
potential mutations in the chromatograms generated from patient samples. 
2.6 Whole exome sequencing 
2.6.1 Sample preparation 
Genomic DNA was extracted from human blood as described in section 2.4. High quality DNA was 
required with a concentration of 20 ng/µl to 500 ng/µl and an OD260/280 ratio of greater than 1.8 
and OD260/230 ratio of greater than 1.9. Absorbance of the samples was measured using a 
NanoDrop ND-1000 spectrophotometer at λ= 260 nm/280 nm and 260nm/230nm respectively. 
2.6.2 Sequence capture array and sequencing 
Whole exome sequencing (WES) using the Illumina HiSeq 2000 Sequencer was conducted on 3 
affected individuals (samples processed by Otogenetics Corporation, USA). WES samples were 
prepared as an Illumina sequencing library, and in the second step, the sequencing libraries were 
enriched using the Agilent V4 (51 Mbp) exome enrichment microarray. Briefly, DNA was fragmented 
and a library was created using standard techniques including end repair, A-tailing and paired 
adaptor ligation. DNA was hybridised to the array, washed to remove un-tethered strands, and then 
enriched, eluted and amplified. The enriched DNA was subjected to massively parallel sequencing on 
the Illumina HiSeq 2000. The captured libraries were sequenced and downstream analysis conducted 
via DNAnexus Classic (see URLs).  Single Nucleotide Polymorphisms, with a threshold coverage of at 
least 20 reads on the respective nucleotide, were assessed. A filtration strategy was adopted to 
minimize the number of variants for analysis, discussed in Chapter 4.5. 
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2.7 Quantitative RT-PCR 
2.7.1 Gel extraction 
For gel extraction, PCR bands were cut out of the gel and purified using the Qiagen QIAquick Gel 
extraction kit (Qiagen, Crawley, UK). The procedure involves silica-membrane-based purification of 
DNA fragments from gels and details of the buffers used in this kit can be found in Appendix 9. 
The excised gel bands were incubated in a solubilisation buffer (3x volume of the gel band, Buffer 
QG) at 50°C until the agarose had melted, before the resolubilised DNA was applied to a silica DNA-
binding membrane. The membrane was washed once in 500 µl solubilisation buffer (Buffer QG) to 
remove any agarose and once in 750 µl ethanol-containing buffer (Buffer PE) to remove salts. DNA 
was eluted in nuclease-free water before 1 μl of sample was re-run on 1% agarose gel to confirm 
efficient purification. Alternatively, DNA concentration in ng/ml was determined using a Nanodrop 
ND-1000 spectrophotometer, with the purity of the DNA determined by calculating the ratio of 
absorbance at 260 nm and 280 nm. A ratio of ~1.8 was considered to be pure DNA. DNA samples 
were stored at 20°C. 
2.7.2 Standards for quantitative RT-PCR 
Samples of known concentration (standards) of the gene of interest were needed to generate a 
standard curve, from which quantities of ‘targets’ could be extrapolated. All genes of interest were 
normalised to GAPDH. Gel extracts of the genes of interest and GAPDH were used to generate 
standards. 2 µl of a known concentration of DNA from the gel extract was added to 98 µl of sterile 
water to generate a ‘10-2’ standard. 10 µl of this was added to 90 µl of sterile water to generate the 
‘10-3’ standard. Further dilutions were established in the same way. The lower the anticipated 
expression of the gene of interest the more dilutions were required, for instance up to a ‘10-10’ 
standard. 
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2.7.3 Quantitative RT-PCR (qPCR) 
A quantitation assay is a real-time PCR assay which measures the amount of nucleic acid during each 
amplification cycle of the PCR. For this purpose fluorescent SYBR Green I dye chemistry was used. 
This uses the SYBR Green I dye which binds to double stranded DNA formed during PCR. During the 
PCR, DNA polymerase amplifies the target sequence, which creates the PCR products (amplicons). 
The SYBR Green I dye then binds to each new copy of double stranded DNA. As the PCR progresses 
more amplicons are created resulting in an increase in fluorescence intensity proportionate to the 
amount of PCR produced. 
RNA samples were quantified with a spectrophotometer and 1.0 μg of RNA from each sample was 
reverse transcribed following DNAse treatment. Quantitative RT-PCR was set up in triplicate (per 
sample and standard) on a Stratagene Mx3000P thermocycler using KAPA SYBR Fast qPCR master 
mix with 200 nM forward and reverse primers targeted to AAAS, TXNRD2 or GAPDH (primer 
sequences, Appendix 1); giving a total volume of 10 µL. KAPA SYBR Fast qPCR master mix is a ready 
to use cocktail containing all components, except primers and template, for the amplification and 
detection of DNA in qPCR. This includes a DNA polymerase and SYBR Green I fluorescent dye. ROX 
reference dye is also utilised to provide an internal fluorescence reference to which the reporter dye 
signal can be normalised during data analysis. Normalisation is required to correct for fluorescence 
fluctuations caused by changes in concentration, volume or sample effects. For PCR conditions, after 
an initial denaturation step of 3 mins at 95°C, PCR cycling was performed for 40 cycles of 95°C for 3 
seconds, 55°C for 20 seconds and 72°C for 1 seconds, followed by 1 cycle of 1 min at 95°C, 55°C for 
30 seconds and 95°C for 30 seconds. 
In the initial cycles of PCR, there is little change in fluorescence signal and an increase in 
fluorescence above baseline indicates the detection of an accumulated target. Amplification plots 
are the plots of fluorescence signal versus cycle number (Figure 2.3A). A fixed fluorescence threshold 
is set in the region associated with exponential growth of the PCR product. The threshold cycle (Ct) is 
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defined as the fractional cycle number at which fluorescence passes the fixed threshold. The higher 
the starting copy number of the nucleic target the sooner a significant increase in fluorescence is 
observed. The no template control (NTC) is a sample that does not contain template and is used to 
verify amplification quality. The Ct of the NTC should be more than 5 cycles away from that of the 
target. Dissociation curve analysis is used to determine the melting temperature (Tm) of the PCR 
product. The Tm is characteristic of the GC content, length and sequence of a DNA product and can 
be used to establish that the correct DNA product has been amplified.  
 
 
Figure 2.3. Representative images for standards generated during quantitative RT-PCR. (A) 
Amplification plots of the standards of the gene of interest. The threshold cycle (Ct) is the point at 
which the amplification plot for each standard crosses the threshold line. (B) Dissociation curve of 
the standards, with the non-template control (NTC) having a lower melting temperature. (C) 
Standard curve generated from the Ct of the standards, from which the quantity of a target can then 
be extrapolated. 
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In Figure 2.3B the standards of the gene of interest have the same Tm, with the NTC melting at a 
lower temperature. The standard curve is generated from the Cts of the standards. Adequate PCR 
efficiency has to be achieved with a minimum of 3 replicates and a minimum of 5 logs of standard 
template concentration. A slope of -3.3 +/- 10% reflects an efficiency of 100% +/- 10% (Figure 2.3C). 
A PCR reaction of lower efficiency will have lower sensitivity. If the standard curve is of appropriate 
efficiency it can then be used to extrapolate the quantity of the target.    
2.8 Cell viability 
2.8.1  Cell counting using haemocytometer 
Cells were plated at a seeding density of 2 x 104 cells per well in a 12 well plate. Prior to trypsinising, 
cells were washed with Dulbecco’s Phosphate Buffered Saline allowing removal of any dead cells. 
Following trypsinisation on day 5, a 50 μl sample of cells was removed and injected into the Neuberg 
haemocytometer channel. Cells were counted in all 4 corners (each corresponding to an area of 1.0 
mm2 and a volume of 100 nl) of one of the grids (see Figure 2.4) using the Leica DMIL light 
microscope with 10x objective. If more than 500 cells were counted, the cell stock was diluted and 
another sample taken. If there were fewer than 200 cells, all 4 corners of both grids were counted. 
The total number of cells in the cell suspension corresponded to the number of cells/ml (number of 
cells/100 nl x 104) multiplied by the ml of media in which the cells were diluted. Results for cell 
numbers are comprised of 5 representative experiments and statistical analysis undertaken was the 
t test. 
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Figure 2.4. Haemocytometer grid 
2.8.2  Cell viability assay 
The CellTiter96 Aqueous non–radioactive cell proliferation assay (MTS (3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay) (Promega, Southampton, UK) 
was used to assess cell viability. The assay consists of a novel tetrazolium compound (MTS) and an 
electron coupling reagent (phenazine methosulphate; PMS). Details of the reagents can be found in 
Appendix 9. MTS is bioreduced by dehydrogenase enzymes found in metabolically active cells into a 
formazan product that is soluble in tissue culture medium. The absorbance of the formazan at 490 
nm can then be directly measured, the amount of 490 nm absorbance being proportional to the 
number of metabolically active cells in culture.  
Cells were plated at a density of 5000 cells per well in a 96 well plate on Day 0. Six wells were plated 
for each experimental condition required. Cells were incubated for 48 hours in normal media or 
media treated with 100 μM H202 (Sigma Aldrich, Poole, UK). Media was then removed and replaced 
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with 100 μl fresh normal media. In each 96 well plate standards were established by plating H295R 
cells at densities between 1000 to 35000 cells per well, in triplicate. Cells were then incubated for 2 
hours in a humidified incubator at 37°C. The CellTiter96 kit was used according to the 
manufacturer’s protocol. 100 µl of PMS solution was added to 2 ml of MTS solution. 20 µl of the 
combined MTS/PMS solution was added to each well and cells were re-incubated in a humidified 
incubator at 37°C, in darkness. The absorbance of the wells at 490 nm was read at 2.5 hours using an 
ELISA plate reader (Wallac spectrophotometer). The mean absorbance for each set of cells was 
representative of the 6 readings. Results are comprised of representatives from 3 to 4 separate 
experiments with statistical analysis using the Student’s t test (GraphPad Prism 5 software). 
2.8.3 PARP (Poly-ADP-ribose polymerase) cleavage 
Cells (80% confluency in 6 well plates) were incubated in serum-free medium containing 1 mM H202 
for 30 min before the medium was replaced with fresh serum-containing medium in all cells as 
previously described. After overnight recovery at 37°C, cells were lysed and analysed via Western 
analysis, using PARP rabbit polyclonal antibody at 1:1000 (Cell Signalling Technology; New England 
Biolabs, Hertfordshire, UK) and mouse monoclonal GAPDH antibody at 1:5000 (Abcam, Cambridge, 
UK). Cleaved PARP was quantified using densitometric analysis from 3 representative experiments 
relative to total PARP. Student’s t test was used for statistical analysis (GraphPad Prism 5 software).  
2.9 Analysis of cell GSH/GSSG ratio  
Glutathione (GSH) is a potent antioxidant which reduces ROS. It functions as an electron donor, 
which on reducing disulphide bonds between proteins, becomes oxidised itself (GSSG). One can 
therefore use the ratio of GSH: GSSG as an indicator of cell toxicity; in normal conditions a high GSH: 
GSSG ratio is maintained. 
The GSH/GSSG-Glo assay (Promega, Southampton, UK) is a luciferase based assay with an output 
measure of luminescence. The assay principle is that the conversion of Luciferin-NT to Luciferin by 
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glutathione-s-transferase, is dependent on GSH. This reaction is coupled to a firefly luciferase 
reaction producing light, hence GSH is proportional to luminescence. Details of all reagents can be 
found in Appendix 9. 
AAAS (or TXNRD2)-knockdown and control cells were plated at a seeding density of 1x 105 in 
duplicate in a luminometer compatible 96 well plate. At 48 hours GSH/GSSG Glo Assay was used 
according to the manufacturer’s guidelines, using a Total Glutathione Lysis Reagent or Oxidised 
Glutathione Lysis Reagent for each set of cells for the desired endpoint. As a positive control, control 
cells were treated with 40 μM menadione for 1 hour prior to the assay. Menadione is a synthetic 
agent which has been demonstrated to increase levels of GSSG. 
Cell medium was removed from wells and 50 µl of either Total Glutathione Lysis Reagent or Oxidised 
Glutathione Lysis Reagent was added to each well. The plates were shaken for 5 mins.  50 µl of 
Luciferin Generation Reagent was added to each well and the plate incubated for 30 mins. Following 
application of 100 µl Luciferin Detection Reagent to each well and equilibration for 15 mins, 
luminescence was read. The total glutathione measurement and the oxidised glutathione 
measurement (GSSG) were used to calculate the GSH/GSSG ratio, with a 2-fold adjustment made for 
GSSG as each mole of oxidised GSSG upon reduction in the assay produces 2 moles of reduced 
glutathione (GSH): 
(Net total glutathione RLU- Net GSSG RLU)/ (Net GSSG/2) 
Results are comprised of representatives from 3 separate experiments with statistical analysis using 
the Student’s t test (GraphPad Prism software).  
2.10 Cortisol analysis 
AAAS (or TXNRD2)-knockdown and control cells were cultured in serum-free media. Media was 
extracted when cells were at 90% confluency following 24-hour stimulation with 10 µM forskolin. 
Cortisol levels were analysed on a Roche Modular E170 automated immunoassay analyser using 
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electrochemiluminescent detection; the assay imprecision has been described as less than 6%.  
Levels were subsequently normalised to 1 mg of protein following Bradford assays of the 
corresponding cell lysates. For N-acetylcysteine treatment, media was supplemented with 1mM N-
acetylcysteine (Sigma Aldrich, Poole, UK) for the 24 hour period. 
2.11 Thioredoxin Reductase Assay 
A thioredoxin reductase (TXNRD) assay kit (Abcam, Cambridge, UK), a colorimetric assay, was used 
to assess total TXNRD activity in cell lysates from TXNRD2-knockdown and control cells. In the assay 
TXNRDs catalyse the reduction of 5, 5’-dithiobis (2-nitrobenzoic) acid (DTNB) with NADPH to 5-thio-
2-nitrobenzoic acid (TNB2-), generating a strong yellow colour (λmax=412 nm). To determine TXNRD-
specific activity (as compared to other enzymes such as glutathione reductase and glutathione 
peroxidase) a thioredoxin reductase specific inhibitor is used. Of note, the kit does not allow for the 
differentiation of activity of each of the individual TXNRDs. Details of the reagents in the kit can be 
found in Appendix 9. 
Two assays are performed, the first measuring total DTNB reduction by the sample and the second 
DTNB reduction by the sample in the presence of the inhibitor. The difference between the 2 results 
is the DTNB reduction by the TXNRDs. 
Cells, grown to 90% confluency in T25 flasks, were homogenised in 300 µl cold Assay Buffer, 
supplemented with complete, Mini, EDTA-free Protease Inhibitor Cocktail tablets (Roche Diagnostics 
Ltd, West Sussex, UK),  on ice. The samples were centrifuged at 10,000 x g for 15 mins at 4°C. The 
supernatant was collected for assay and stored on ice. The protein concentration of the supernatant 
was determined by Bradford assay. 
Two sets of samples, in duplicate, were tested with or without the TXNRD inhibitor. 50 µl of sample 
was added into each well, in duplicate, in clear 96 well plates. For a positive control 10 µl of the 
provided TXNRD control was added to 40 µl Assay Buffer. To one set of samples 10 µl of the TXNRD 
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inhibitor was added for testing background enzyme activity. To the second set, 10 µl of Assay Buffer 
was added, for testing total DTNB reduction. TNB standards for the assay were established in 
duplicate. 0, 2, 4, 6, 8, 10 µl of the provided TNB standard, were brought to a final volume of 100 µl 
with Assay Buffer, generating 0, 10, 20, 30, 40, 50 nmol/well standards.  
The reaction mix was comprised of 30 µl assay buffer, 8 µl DTNB solution, 2 µl NADPH.  40 µl of this 
reaction mix was added to each sample well and mixed bringing the final volume to 100 µl. A412nm 
was measured using a thermostatic spectrophotometer. A412nm was measured for 30 minutes at 
25°C with readings taken at 30 second intervals. The total change in A412nm within the linear range 
was calculated for each sample:  
Δ A412nm = (A2t-A1t)- (A2I-A1I) 
Where the A412nm was measured at T1 (time of the first reading) to establish the A1t and A412nm was 
measured again at T2 to get At2, in the sample set without the TXNRD inhibitor. The A1I and A2I were 
derived from the sample set with the TXNRD inhibitor. The Δ A412nm was applied to the TNB 
standard curve to get ΔB nmol of TNB; the TNB amount from the standard curve. TXNRD activity was 
then calculated as follows: 
TXNRD activity = ΔB/ ((T2-T1) x V)   x  Sample dilution factor= nmol/min/,l = mU/ml  
Where T1 is the time of the first reading (A1t and A1I) (in mins); T2 is the time of the second reading 
(A2t and A2I) and V is the pretreated sample volume (ml) added to each reaction well. One unit of 
TXNRD is the amount of enzyme that generates 1 µmol of TNB per minute at 25°C. The oxidation of 1 
mole of NADPH to NADP will generate 2 mole TNB, therefore 1 TNB unit equals 0.5 NADP unit. 
2.12 Leukocyte separation 
Fresh whole blood was collected in EDTA- containing tubes. Mononuclear cells were extracted using 
a gradient density centrifugation method with Histopaque-1077 according to the manufacturer’s 
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protocol (Sigma Aldrich, Poole, UK). When blood is layered onto the Histopaque solution 1077, 
which has a density of 1.077 g/ml, and subjected to centrifugal forces, mononuclear cells are held at 
the plasma–histopaque interphase while erythrocytes gravitate to the bottom (Figure 2.5). 6 ml 
histopaque-1077 was added to a 15 ml centrifuge tube and 6 ml blood carefully layered onto it. This 
was centrifuged at 700g for 30 mins at room temperature (18-26°C). The plasma was carefully 
aspirated and discarded to within 0.5 cm of the mononuclear layer. The mononuclear layer was then 
removed into a clean tube. This was washed with 10ml isotonic PBS and centrifuged for 10 mins at 
200g. The supernatant was aspirated and discarded and the cells resuspended and washed again as 
above. Cells were subsequently lysed using 50 µl RIPA buffer, supplemented with complete, Mini, 
EDTA-free Protease Inhibitor Cocktail tablets (Roche Diagnostics Ltd, West Sussex, UK), placed on ice 
for 30 mins and centrifuged at 15,000g for 12 minutes at 4˚C. The supernatant was subsequently 
added to an equal volume of Laemmli loading buffer (Sigma Aldrich, Poole, UK) and stored at -80°C 
for later use. 
 
 
Figure 2.5. Leucocyte separation using Histopaque solution 1077. The mononuclear cells are 
subsequently used to derive cell lysates. 
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2.13 Flow cytometry 
2.13.1 Cell cycle analysis by flow cytometry 
Cell cycle analysis of AAAS-knockdown cells compared with controls was conducted using flow 
cytometry following propidium iodide treatment of the cells at 50% confluency, on the FACSCalibur 
cytometer (Becton Dickinson, New Jersey). Briefly, for cell fixation cells were suspended in 0.5 ml of 
PBS and the cell suspension was added to 5 ml of 1% (w/v) paraformaldehyde in PBS and placed on 
ice for 15 mins. Cells were centrifuged for 5 mins at 300g and the supernatant discarded. Cells were 
washed with PBS twice and then resuspended in 0.5 ml of PBS, which was added to 5 ml of ice cold 
70% (v/v) ethanol and left to stand for 30 mins on ice. Cells were subsequently spun, the pellet 
washed with PBS and then resuspended with 0.5 ml of propidium iodide/ RNase A staining buffer 
(Invitrogen, Paisley, UK). Samples were incubated for 30 mins at room temperature prior to FACS 
analysis. The CellQuestPro version 6.0 software programme (Becton Dickinson) was used to 
deconvolute the cellular DNA content frequency histograms to obtain the percentage of cells in the 
3 major phases of the cell cycle (G0/1, S, and G2/Mitosis). For representative images of the DNA 
content frequency histograms for control and AAAS-knockdown H295R cells see Figure 2.6. 
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Figure 2.6. Cell cycle arrest in AAAS-knockdown H295R cells. DNA content frequency histograms of 
(A) control and (B) AAAS-knockdown H295R cells showing blunting of the G2/Mitotic peak in the 
ALADIN deficient cells. 
 
2.13.2 Mitochondrial superoxide production (MitoSox Red) 
MitoSOX Red reagent (Invitrogen, Paisley, UK) is a fluorogenic dye specifically targeted to 
mitochondria in live cells. Oxidation of MitoSOX Red reagent by mitochondrial superoxide produces 
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red fluorescence. The reagent is rapidly oxidized by mitochondrial superoxide but not by other ROS 
and reactive nitrogen species (RNS).  
Cells were grown to 50–70% confluence and fresh media added before each experiment. MitoSOX 
Red was added to a final concentration of 5 μM according to the manufacturer’s 
recommendation. After 20 mins loading of MitoSOX, TXNRD2-knockdown and control cells were 
trypsinized for 4 mins and neutralized with media. Cells were washed with PBS (with Ca/Mg) (Sigma 
Aldrich, Poole, UK) and resuspended in fresh media in a sterile FACS tube.  
For the determination of mitochondrial superoxide by flow cytometry, measurements were carried 
out using an LSR Fortessa (BD Bioscience, San Jose, CA), data obtained were recorded and 
subsequently analysed using DIVA version6.2 (BD Bioscience, San Jose, CA). 10,000 gated events 
were recorded. The following steps were carried out for gating: cell debris as represented by distinct 
low forward and side scatter were gated out for analysis (P1), only singlet events were gated (P2), 
GFP-positive cells (cells incorporating either scrambled control or TXNRD2-knockdown shRNA) were 
selected (excited by 488 nm blue laser, band pass filter 530/30 nm) (P3), and finally MitoSOX Red 
was excited by 561 nm yellow/green laser with a band pass filter of 670/30 nm (P4) (Figure 2.7).  For 
quantitative analysis the frequency of events in P4 was multiplied by the median fluorescence 
intensity (MFI) within P4 to give an integrated MFI (iMFI) [208] reflecting the total functional 
response of this population of cells to MitoSOX (Figure 5.5B). Student’s t test was used for statistical 
analysis (GraphPad Prism 5 software). 
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Figure 2.7. Determination of mitochondrial superoxide production, steps used in gating: (A) Low 
forward and side scatter were gated out for analysis (P1); (B) Singlet events were gated (P2); (C) GFP-
positive cells were selected (excited by 488 nm blue laser, band pass filter 530/30 nm) (P3), and (D) 
finally MitoSOX Red was excited by 561 nm yellow/green laser with a band pass filter of 670/30 nm 
(P4). 
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Chapter 3  
Deficiency of ALADIN impairs redox homeostasis in human adrenal cells and inhibits 
steroidogenesis 
3.1 Triple A syndrome and oxidative stress 
The phenotype in triple A syndrome is complex and all the clinical features are progressive 
suggesting a degenerative process. The alacrima, achalasia and neurological symptoms are all 
assumed to be secondary to progressive neurodegeneration. Adrenal insufficiency commonly occurs 
within the first decade of life though can present later in life. Both neurons and adrenal cells have 
higher metabolic requirements and are therefore more susceptible to perturbations in redox 
homeostasis. 
Oxidative stress may play a role in the pathogenesis of this disease. Triple A patient dermal 
fibroblasts have both an overall higher basal intracellular ROS, as measured using the fluorogenic 
probe dihydrorhodamine (DHR), and higher mitochondrial superoxide species production, as 
measured by MitoSOX red and FACS analysis [129]. Following induction of oxidative stress with 10 
mM of paraquat (1-1′-diethyl-4,4′-bipyridylium dichloride) a further significant increase in ROS 
production is observed in patient fibroblasts  [129]. The authors also investigated the expression of 
four key ROS-detoxifying enzymes in patient fibroblasts, describing a significant increase in 
superoxide dismutase 1 (SOD1). Finally, patient cells showed a 1.4 fold increase in doubling time. 
Taken together, these studies provide supporting evidence that an underlying defect in triple A 
syndrome is oxidative stress. Long-term stress can induce an irreversible senescent phenotype or 
stress-induced premature senescence (SIPS) and the authors proposed that the higher basal level of 
ROS results in SIPS in the patient dermal fibroblasts [129] . ROS play an important role in normal cell 
cycle regulation but in excess can lead to DNA insult. DNA damage responses during the cell cycle 
induce an irreversible senescence as a means of maintaining genomic stability [209].  Extrapolating 
this to what may be seen in adrenal disease, a failure of appropriate proliferation could have impact 
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on growth and remodelling capabilities of the adrenal gland, certainly histology suggests atrophy of 
the adrenal cortical zona fasciculata and zona reticularis [11]. ALADIN is ubiquitously expressed yet a 
tissue-specific phenotype is observed in the condition. The high metabolic demand of the adrenal 
gland and neurons, may explain the susceptibility of these particular tissues to oxidative stress, and 
ultimately to disease in triple A syndrome.  
3.2 Failure of nuclear import of specific cargo-(es) leads to increased oxidative stress in triple A 
syndrome patient dermal fibroblasts 
In the triple A patient dermal fibroblast model, failure of nuclear import of two DNA repair proteins 
is described [127, 128]. Patient fibroblasts harbouring the I428Sf mutation, leading to mislocalisation 
of ALADIN to the cytoplasm, are hypersensitive to the induction of oxidative stress [127]. Treatment 
with 1 mM of the GSH-depleting agent, BSO leads to reduced cell viability of the patient fibroblasts 
in comparison to controls, with evidence of DNA fragmentation, characteristic of apoptotic cell 
death. This effect was partially reversed by the antioxidants decylubiquinone and all-transretinol. 
Defects in repair of DNA damage have been linked to neurodegenerative disease and the nuclear 
import of several DNA repair proteins were investigated in this model. Reduced nuclear import of 
two DNA repair proteins was described; these being aprataxin, mutations of which have been 
associated with autosomal recessive cerebellar ataxia, and DNA ligase I [127]. Importantly, 
successful nuclear import of both of these DNA repair proteins, using a modified nuclear localisation 
signal, did not fully restore the survival of the patient fibroblasts to the level of the controls [128]. 
This suggested the presence of other proteins that may be imported ALADIN-dependently.  
To that effect, full-length human ferritin heavy chain protein (FTH1), which has a DNA-protective 
role in the nucleus, has been identified as an interacting protein partner for ALADIN in vitro [107]. 
Unlike control cells, no nuclear FTH1 is apparent in triple A patient fibroblasts or lymphocytes 
implicating ALADIN in the nuclear localisation of FTH1. Apoptosis of SK-N-SH neuroblastoma cells 
induced by 1 mM H2O2 was significantly reduced by transfection of AAAS or FTH1 and maximally by 
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both genes together. These findings provide compelling evidence that oxidative stress is involved in 
disease progression and that nuclear import of specific cargo-(es) may be defective [107, 127-129]. 
How these nuclear import defects lead to an increase in intracellular ROS remains unclear.  
3.3 Aims of the study 
Current models of the disease, that is, dermal fibroblasts derived from triple A patients and the 
Aaas-/- mouse [67], which does not lead to a triple A syndrome-like phenotype, have significant 
limitations. Therefore to further understand the functional role of ALADIN in the pathogenesis of 
triple A syndrome a better model of this complex disease is necessary. 
In the present study, I aimed to establish for the first time novel in vitro models of the disease by 
inducing AAAS-knockdown in H295R human adrenocortical tumour cells and SH-SY5Y human 
neuroblastoma cells, chosen as representative of the predominant cell types affected by the disease. 
The H295R cell line has been shown to express all key enzymes of steroidogenesis [210-212]. They 
have the physiological characteristics of zonally undifferentiated human foetal adrenal cells whilst 
having the ability to produce steroid hormones found in the adult adrenal cortex. They have been 
used extensively as an in vitro model to study the steroidogenic pathway [213-215].  The SH-SY5Y 
cell line has been widely used in experimental neurological studies including function related to 
neurodegeneration and neuronal adaptation to toxicity. They are a subline of SK-N-SH cells originally 
derived from a patient neuroblastoma in the 1970s [216]. This cell line has been used by our group 
for previous triple A syndrome studies [107]. 
Using these 2 cell line models, I investigated the potential role of oxidative stress in the pathogenesis 
of triple A syndrome and anti-oxidant treatment in recovery. These studies provide a better 
understanding of the pathogenic mechanisms of triple A syndrome looking specifically at affected 
tissue types.   
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Results 
3.4 AAAS-knockdown in H295R adrenocortical tumour cells and SH-SY5Y neuroblastoma cells 
A combination of 2 commercially-available lentiviral shRNA, targeting overlapping regions of exon 5 
in the AAAS gene (for specific sequences see Appendix 3), was used to achieve AAAS-knockdown 
(see Methods Section 2.1). Greater than 70% AAAS-knockdown was established in both cell lines, 
quantified by real-time qPCR (Figure 3.1A and B). AAAS mRNA expression in AAAS-knockdown 
(AAAS-KD) H295R cells was significantly reduced to 12.6% + 1.6 compared with controls (p<0.001, 
n=3) and to 21.1% + 7.4 in SH-SY5Y AAAS-KD cells (p<0.01, n=3). In both cell lines, a reduction in 
ALADIN protein expression is also observed by immunoblotting (Figure 3.1C and D). 
 
 
Figure 3.1. Lentiviral shRNA knockdown of the AAAS gene in (A) H295R and (B) SH-SY5Y cells. AAAS 
mRNA expression was quantified using real-time qPCR and normalised to GAPDH (n=3). Control 
represents transfection with scrambled shRNA. (C) Reduced expression of the protein ALADIN is seen 
in AAAS-knockdown (AAAS-KD) H295R and (D) SH-SY5Y cells. Data represents mean + SD. p < 0.01**, 
p<0.001***. 
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3.5 AAAS-knockdown results in a reduction in cell viability in H295R cells 
Cell number assessed by cell counting, was significantly reduced on day 5 after plating AAAS-KD 
H295R cells (10.73 x 104 + 1.59 x 104 (mean + SD)), compared with controls (41.45 x 104 + 4.97 x 104 
(p<0.0001, n=4)) (Figure 3.2A). MTS assays were used to assess cell viability where absorbance 
readings are proportional to cellular metabolic activity (Methods 2.8.2). In AAAS-KD H295R cells 
there was a significant reduction in measured absorbance compared with controls; 0.43 + 0.01 
versus 0.53 + 0.04 on day 2 after plating (p< 0.05, n=3) and 0.64 + 0.05 versus 0.83 + 0.03 on day 5 
(p< 0.01, n=3) respectively (Figure 3.2B). However, there was no reduction in measured absorbance 
in AAAS-KD SH-SY5Y cells compared with controls. 
 
Figure 3.2. A reduction in cell viability of AAAS-KD cells. (A) There was a significant difference in the 
total number of cells (by cell counting) on day 5 in the AAAS-KD H295R cells (n=4) compared with 
controls following seeding at 2 x 104 cells per well. (B) MTS assays on Day 2 and Day 5 with initial 
seeding density of 5 x 103 cells per well on day 0. There was a significant reduction in absorbance 
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readings of AAAS-KD H295R cells in comparison with controls on day 2 (n=3); and day 5 (n=3). (C) 
Following treatment with 100 μM H2O2, a significant reduction in absorbance readings is seen in 
AAAS-KD H295R cells (n=3) and (D) AAAS-KD SH-SY5Y cells (n=4) using MTS assays. There was no 
reduction in absorbance in untreated AAAS-knockdown SH-SY5Y cells compared with controls. Data 
represents mean + SD. p< 0.05*, p< 0.01**, p< 0.001*** 
 
3.6 AAAS-knockdown cells are hypersensitive to oxidative stress 
Several inducers of oxidative stress have been used in the previous triple A syndrome studies. These 
include paraquat, BSO (L-buthionine-(S,R)- sulfoximine) and H2O2. Paraquat is a herbicide which 
inhibits the reduction of NADP to NADPH thereby generating superoxide anions, while BSO is a 
highly selective inhibitor of ƴ-glutamylcysteine synthetase and its addition to culture medium arrests 
GSH synthesis. H2O2 was chosen to induce oxidative stress in this in vitro model, in line with previous 
work from our group [107]. In addition, H2O2 can be found endogenously, produced by reduction of 
superoxide anions and can contribute to oxidative stress. It readily traverses membranes and is able 
to access several subcellular compartments.   In contrast to the 1 mM concentration used to induce 
apoptosis in the SK-N-SH neuroblastoma cell model [107], a concentration of 100 μM H2O2 was used 
for these assays as higher concentrations proved toxic to the cells for this duration of treatment.  
In addition to the reduction in cell viability seen at baseline, application of oxidative stress in the 
form of 100 μM H2O2 for 48 hours resulted in a further significant decrease in cell viability during the 
MTS assay in AAAS-KD H295R cells (absorbance readings 0.38 + 0.01; mean + SD) compared with 
untreated knockdown cells (0.43 + 0.01) (p<0.01 n=3) (Figure 3.2C). No significant difference in 
absorbance was seen between the untreated and treated control H295R cells (Figure 3.2C). There 
was no reduction in measured absorbance in AAAS-KD SH-SY5Y cells compared with controls, day 2 
after plating (Figure 3.2D). However, treatment of AAAS-KD SH-SY5Y cells with 100 μM hydrogen 
peroxide resulted in a significant reduction in absorbance readings, 0.26 + 0.01, compared with 
treated controls 0.48 + 0.05 (p<0.01, n=4) (Figure 3.2D).  
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3.7 AAAS-knockdown in H295R cells results in cell cycle arrest and an increase in cell death by 
apoptosis 
To further investigate the finding of reduced cell viability of the AAAS-KD H295R cells at baseline, cell 
cycle analysis of AAAS-KD cells compared with controls was carried out using flow cytometry 
following propidium iodide treatment (Methods 2.13.1). In flow cytometry, propidium iodide is used 
as a DNA stain to allow the evaluation of DNA content during cell cycle analysis, thereby delineating 
the various phases of the cell cycle.  
The cell cycle comprises of several phases leading to the division of a single cell into 2 daughter cells; 
G0 phase, the resting phase where cells have left the cell cycle; G1 phase, during which the cell 
increases in size and checkpoints are in place to ensure the cell is prepared for DNA synthesis; S 
phase, when DNA replication occurs; G2 phase, in which checkpoints exist to ensure that the cell is 
ready to divide and finally; the Mitotic phase, during which orderly division into 2 daughter cells 
occurs.  There was a significant reduction in the proportion of cells in the G2/Mitotic phase of the 
cell cycle in the AAAS-KD H295R cell population, 9.2% + 2.7, compared with controls, 21.0% + 3.0   
(p< 0.05, n=3). This suggests that ALADIN deficiency causes a reduction in cellular proliferation 
secondary to cell cycle arrest prior to the G2/mitotic phase (Figure 3.3A, Methods Figure 2.6). 
Apoptosis was assessed by immunoblot analysis of cleaved PARP (Poly ADP ribose polymerase) 
(Methods 2.8.3). PARP detects single-strand DNA breaks, binds to DNA and signals to DNA-repair 
enzymes. PARP is inactivated by caspase cleavage in situations where DNA damage is extensive. The 
cleavage of full length PARP (116kDa) to 85kDa and 27kDa fragments is a well-documented effect of 
cell death by apoptosis [217, 218]. An increase in the ratio of cleaved PARP relative to total PARP 
was observed in AAAS-KD H295R cells treated with 1 mM H2O2 compared with controls, 20.2 + 3.9% 
versus 12.2 + 0.8%, respectively (p<0.05, n=3) (Figure 3.3B).  
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Figure 3.3. Cell cycle arrest and increased apoptosis is observed in AAAS-KD H295R adrenal cells 
(A) A significant reduction in the % cell population in the G2/ Mitotic phase of the cell cycle is seen in 
AAAS-KD H295R cells compared to controls suggesting cell cycle arrest (n=3). (B) An increase in 
cleaved relative to total PARP, measured by densitometric analysis following immunoblotting, is 
observed in H2O2 treated AAAS-KD cells compared with controls (n=3). Data represents mean + SD. 
p< 0.05* 
 
3.8 AAAS-knockdown in H295R cells results in an imbalance of redox homeostasis 
Glutathione, a three amino acid peptide (gamma glutamyl-cysteinylglycine), is an abundant 
antioxidant found in eukaryotic cells, existing in reduced (GSH) and oxidised (GSSG) states. GSH is 
the predominant form and maintains strong reducing conditions in several subcellular 
compartments. However with increased ROS formation increased levels of the GSSG are seen (Figure 
3.4A). The ratio of oxidised to reduced glutathione is used as a measure of redox thiol status and 
therefore the intensity of oxidative stress. The luciferase-based GSH/GSSG-Glo assay (Promega, 
Southampton, UK) was used to assess this ratio in the AAAS-KD H295R cells compared with controls 
(Methods 2.9). 
A significant reduction in the GSH/GSSG ratio is seen in AAAS-KD H295R cells (19.3 + 2.7 relative light 
units) compared with controls (26.2 + 1.9) (p<0.05, n=3) suggesting a baseline increase in oxidative 
stress in the knockdown cells (Figure 3.4B). As a positive control, a significant reduction in the 
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GSH/GSSG ratio (0.7 + 0.2 relative light units) was demonstrated by treatment of the control cells 
with 40 µM menadione, a potent inducer of oxidative stress. 
 
Figure 3.4. An imbalance in redox homeostasis is observed in AAAS-KD H295R adrenal cells. (A) 
Increased reactive oxygen species leads to an increase in cellular oxidised glutathione (GSSG) and a 
decrease in the GSH/GSSG ratio. (B) The GSH/GSSG ratio was lower in AAAS-KD cells relative to 
controls (n=3). Oxidative stress induced by treatment with 40 µM menadione to control cells further 
reduces the ratio. RLU, relative light units. Data represents mean + SD. p< 0.05* 
 
3.9 Treatment with the anti-oxidant N-acetylcysteine, improves cell viability in AAAS-
knockdown cells 
N-acetylcysteine (NAC) is a thiol compound, which by providing sulfhydryl groups can act as a 
precursor to GSH and a direct ROS scavenger. The antioxidant properties of NAC are well 
documented both in vivo and in vitro. Application of NAC for 48 hours at a dose of 1 mM, 
significantly increased absorbance readings in the AAAS-KD H295R cells (0.47 + 0.06; mean + SD), 
compared with untreated knockdown cells (0.28 + 0.03) (p<0.01, n=4). Higher doses of NAC were 
found to be toxic to all the cell lines. Absorbance readings were also increased in NAC treated 
control cells (0.60 + 0.07) compared with untreated controls (0.47 + 0.08) (p<0.01, n=4) (Figure 
117 
 
3.5A). However the percentage increase in absorbance readings following NAC application was 
greater in the AAAS-KD cells (68.8% + 14.9) compared with controls (28.5% + 10.1) (p<0.05, n=4) 
(Figure 3.5B). A dose of 10 mM NAC for 48 hours significantly increased absorbance readings in 
AAAS-KD SH-SY5Y cells (0.70 + 0.08, mean + SD) compared to untreated knockdown cells (0.64 + 
0.07) (p<0.05, n=4). However, no significant difference in cell viability was seen in the control SH-
SY5Y cells with the same NAC treatment (Figure 3.5C). 
 
 
Figure 3.5. Treatment with the anti-oxidant N-acetylcysteine (NAC) improves AAAS-KD cell 
viability. (A) Treatment with 1mM NAC for 48 hours significantly increases absorbance in both AAAS-
KD and control H295R cells (n=4). (B) There is a significantly greater % increase in absorbance 
following treatment in the knockdown cells in comparison with controls (n=4). (C) Treatment with 10 
mM NAC significantly increases absorbance in AAAS-KD SH-SY5Y cells but not controls (n=4). Data 
represents mean + SD. p< 0.05*, p< 0.01** 
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3.10 AAAS-knockdown affects key components of the steroidogenic pathway including a 
reduction of steroidogenic acute regulatory protein (STAR) and P450c11β protein 
expression 
I investigated the expression of three steroidogenic enzymes in the AAAS-knockdown model 
involved in the production of cortisol: STAR, P450scc (encoded by CYP11A1) and P450c11β (encoded 
by CYP11B1) (Figure 3.6). Depletion of these key enzymes has been associated with oxidative stress 
[219, 220] (further described in the discussion 3.12).  
 
Figure 3.6. The expression of three key enzymes in cortisol production was studied. These are 
denoted in red and include STAR involved in transport of cholesterol from the OMM to the IMM; 
P450scc responsible for conversion of cholesterol to pregnenolone and P450c11β involved in the 
final step of cortisol production. 
 
 
Following immunoblot and densitometric analysis, I observed a significant reduction in the 
expression of 30kDa STAR relative to GAPDH in AAAS-KD H295R cells compared with controls 
(p<0.01, n=4) (Figure 3.7A and 3.7B). Furthermore we demonstrate a significant reduction in protein 
expression of P450c11β, responsible for the final step in cortisol production (p<0.05, n=3) (Figure 
3.7A and 3.7C). There was no significant difference in the expression of the other steroidogenic 
enzyme investigated, P450scc (encoded by CYP11A1) (n=4) (Figure 3.7A and 3.7D). 
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The effect on STAR is seen at transcriptional level, with a significant reduction in STAR mRNA levels 
in AAAS-KD cells (0.47 + 0.01 (mRNA levels relative to GAPDH)) compared with controls (0.62 + 0.04) 
(p<0.01, n=3). 100 µM H2O2 treatment reduces STAR mRNA levels (0.38 + 0.07) in control cells to 
levels similar to the untreated AAAS-KD cells. In contrast, 100 µM H2O2 treatment does not reduce 
STAR mRNA expression further in the AAAS-KD cells (Figure 3.7E). 
 
Figure 3.7. STAR and P450c11β (CYP11B1) expression are reduced in AAAS-KD H295R cells with a 
subsequent reduction in cortisol production. (A) Immunoblot analysis and (B) Densitometric 
analysis showing a reduction in STAR (n=4) and (C) P450c11β protein expression in AAAS-KD H295R 
cells compared with controls (n=3) with (D) no effect on P450scc levels (n=4). (E) There is a 
significant reduction in STAR mRNA levels in AAAS-KD cells compared with controls and H2O2 
treatment of controls reduces levels to that seen with ALADIN deficiency (n=3). (F) There is a 
significant reduction in cortisol production by the untreated AAAS-KD H295R cells compared with 
controls (n=9), with partial improvement following N-acetylcysteine (NAC) treatment (n=3). Data 
represents mean + SD. p<0.05*, p< 0.01**, p< 0.001*** 
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3.11 AAAS-knockdown in H295R cells results in a significant reduction in cortisol production, 
which is partially rescued by N-acetylcysteine treatment 
Cortisol production was investigated in the AAAS-KD and control H295R cells following 24 hour 
stimulation with 10µM forskolin; cortisol levels were analysed on a Roche Modular E170 automated 
immunoassay analyser using electrochemiluminescent detection (Methods 2.10). Whilst H295R cells 
show little response to ACTH stimulation, the organic compound, forskolin, is extensively used to 
induce steroidogenesis in this cell line, via the activation of the cAMP pathways [221]. This particular 
concentration of forskolin has been demonstrated to be effective in inducing steroidogenesis. 
A significant decrease in cortisol production is observed after stimulation with forskolin in the 
untreated AAAS-KD H295R cells (344.0 nmol/L/mg of lysate protein + 44.4) compared with controls 
(1404.4 + 663.5) (p<0.001, n=9) (Figure 3.7F). Treatment for 24 hours with 1 mM NAC during 
forskolin stimulation (n=3) significantly increases cortisol production in the AAAS-KD cells (1037.4 
nmol/L/mg of lysate protein + 154.7) (p<0.001) (Figure 3.7F). 
3.12 Discussion 
The clinical manifestations of triple A syndrome are progressive and the pathogenic mechanisms 
involved in the disease process are unclear. Interestingly, despite ubiquitous expression of AAAS 
mRNA [25], tissue specificity is observed in this condition. In particular, the clinical features of 
adrenal insufficiency and neurodegeneration affecting the central, peripheral and autonomic 
nervous systems are not present at birth but develop over time implicating a degenerative process in 
the pathogenesis of this disorder [12, 13, 15, 22].   
Whilst the Aaas-/- mouse does not bear a significant phenotype, possibly suggesting some functional 
redundancy for ALADIN in the mouse model [67], in vitro studies on triple A syndrome patient 
dermal fibroblasts demonstrate an increased susceptibility to oxidative stress [127-129]. 
Additionally, a reduction in patient fibroblast cell survival and an increase in DNA fragmentation is 
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reported following exposure to the glutathione-depleting agent, BS0 [127]. Triple A syndrome 
patient dermal fibroblasts are also observed to have higher basal levels of reactive oxygen species 
and more extensive mitochondrial networks [129]. The precise mechanism(s) for these alterations 
remain unclear and it is uncertain how reliably observations in dermal fibroblasts can be 
extrapolated to the tissues affected by triple A syndrome. Disease-causing mutations of the AAAS  
lead to either ALADIN deficiency or ALADIN mislocalisation suggesting correct targeting of ALADIN to 
the NPC is required [94]. The failure of nuclear accumulation of DNA repair proteins together with 
the antioxidant protein FTH1 in triple A syndrome patient dermal fibroblasts may render these cells 
more susceptible to oxidative stress [107, 127, 128]. 
This work, revealed a reduction in cell viability following AAAS-knockdown in the adrenocortical 
H295R cell line, which is further exacerbated by exposure to artificial oxidative stress. Stress induced 
premature senescence (SIPS) has been described in triple A syndrome patient fibroblasts [129]. The 
cell cycle analysis of ALADIN deficient adrenal cells suggests that a similar situation exists in adrenal 
cells probably secondary to cell cycle arrest, with a reduction of the proportion of cells progressing 
to the G2/Mitotic phase. Control of DNA repair is closely linked to regulation of the cell cycle. Several 
checkpoints are in place to ensure that DNA is intact before DNA replication and cell division is 
permitted. The S phase precedes G2/M and replicating DNA is particularly sensitive to DNA-
damaging insult during this phase.  The DNA-damage response is activated in response to DNA 
injury, and depending on the extent of damage involved, directs the cell into senescence or 
apoptosis, or alternatively permits cell survival with activation of DNA repair or damage tolerance 
mechanisms [222].  Failure of nuclear import of 2 DNA repair proteins, aprataxin and DNA ligase I, 
reported in triple A syndrome patient dermal fibroblasts [127, 128], may contribute to the cell cycle 
arrest, forcing the cells into senescence/apoptosis rather than cell survival mechanisms. Additionally, 
nuclear FTH1 protects against DNA fragmentation and failure of FTH1 nuclear localisation in ALADIN 
deficient cells may render these cells acutely vulnerable to oxidative stress [107, 119]. Chromosomal 
122 
 
fragility is described in triple A syndrome patients and interestingly, this is also a feature of FGD 
secondary to a mutation in MCM4 [173, 223]. MCM4 is a DNA replicase and a component of the 
minichromosome maintenance complex, required for the initiation and elongation phases of 
eukaryotic DNA replication. Thus DNA fragmentation, defective DNA repair and replication appear to 
be associated with disorders of adrenal insufficiency. ALADIN may also play an important role during 
the cell cycle, as a member of the NPC. Several Nups localise to kinetochores during mitosis, 
including members of the Nup 107-160 subcomplex and Nup358/RanBP2 [224, 225]. These 
processes are thought to be integral for the cell to enter into mitosis. Nup358/RanBP2, like ALADIN, 
is located on the cytoplasmic face of the NPC ring. RNA-interference knockdown of this Nup induces 
G2/M arrest with subsequent mitotic cell death [226]. A missense mutation of human 
Nup358/RANBP2 was identified in familial cases of infection triggered acute necrotizing 
encephalopathy [102]. Depletion of certain Nups also leads to aberrant spindle formation [86]. 
Therefore it is possible that defective ALADIN may impact adversely on cell cycle regulation and cell 
proliferation at multiple levels.  
This impact on cellular proliferation could adversely affect normal adrenal tissue growth and 
remodelling in response to an insult either as a result of, or independent of ALADIN deficiency. 
Under normal conditions adrenal cell proliferation follows the circadian rhythm of ACTH, with a peak 
occurring at 0400h, predominantly in the outer zona fasciculata [227]. Chronic ACTH stimulation 
expands the zona fasciculata with an increase in P450c11β expression and glucocorticoid secretion 
[228]. Conversely, suppression of the HPA axis by dexamethasone can cause contraction of the zona 
fasciculata [228]. The adult adrenal gland is capable of remodelling, as demonstrated by the 
regeneration of the adrenal cortex following enucleation of the rat adrenal gland and by 
compensatory adrenal growth in the contralateral adrenal gland following unilateral adrenalectomy 
[229]. Regeneration can also occur in the human adrenal as evidenced by recovery of adrenal 
123 
 
function following traumatic bilateral haemorrhages [230]. Remodelling may involve differentiation 
of a stem cell/ progenitor population, de-differentiation of mature cells or cell proliferation. 
I also observed an increase in apoptosis in AAAS-knockdown adrenal cells following exposure to 
artificial oxidative stress. Increased apoptosis combined with impaired cellular proliferation would 
be in keeping with histopathological findings in post-mortem triple A syndrome adrenal glands. 
These reveal atrophy of the zona fasciculata, which would be in keeping with a progressive 
degenerative process [11]. It is also possible that ALADIN deficiency affects cellular proliferation and 
apoptosis indirectly by impacting on the baseline levels of oxidative stress particularly in the adrenal 
gland. This may be a result of intracellular ROS interacting with critical cell signalling molecules, thus, 
regulating several key signalling pathways critical in cellular proliferation and survival [187, 225]. A 
neurodegenerative process is present in a significant proportion of patients and the other cardinal 
features of the disease, alacrima and achalasia, are also postulated to manifest secondary to 
neurological impairment. Autonomic dysfunction at the level of the lacrimal glands has been 
suggested as the cause of the failure of tear production and a marked reduction of the number of 
myenteric ganglia and myenteric neurons suggests a lack of intrinsic innervation leads to achalasia 
[16, 19]. Whilst I do not see a difference in cell viability in untreated AAAS-knockdown neuronal 
cells, they appear hypersensitive to oxidative stress. The effects of reduction of AAAS expression are 
less remarkable in the SH-SY5Y cells and this could be a feature of the lower efficacy of the 
knockdown in this cell line. Alternatively, ALADIN may have adrenal cell specific roles or 
compensatory mechanisms may exist in other cell types and this warrants further investigation. 
Nevertheless this preliminary data supports previous suggestions that oxidative stress is also 
involved in the neurodegenerative process. 
Intracellular redox homeostasis is maintained by several mechanisms involving both enzymatic and 
non-enzymatic anti-oxidant defences. Oxidative stress refers to the imbalance of ROS and oxidants 
over the capability of the cell to mount an effective anti-oxidant response. A disruption in redox 
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homeostasis is suggested in the ALADIN deficient adrenal cells with a depletion of GSH. 
Furthermore, I also demonstrate an improvement in the viability of AAAS-knockdown adrenal and 
neuronal cell lines following treatment with the anti-oxidant N-acetylcysteine, which replenishes 
stores of GSH and acts as a direct scavenger of free radicals. There are currently several ongoing 
clinical trials using N-acetylcysteine, both alone and in combination with other anti-oxidants in the 
treatment of other neurodegenerative conditions such as Parkinson’s disease, Alzheimer’s disease 
and Adrenomyeloneuropathy (AMN) (http://www.clinicaltrials.gov). My studies suggest the 
importance of the glutathione antioxidant pathway in the pathogenesis of triple A syndrome hence 
anti-oxidant treatments may prove to be a viable therapeutic strategy to slow or even prevent triple 
A syndrome disease progression.  
I demonstrate that AAAS gene deficiency impacts on adrenocortical cell function with a significant 
reduction in cortisol production in the AAAS-knockdown H295R cells. STAR is fundamental for the 
transport of cholesterol across the mitochondrial membrane and is the rate-limiting step for 
steroidogenesis. There is evidence that STAR is particularly sensitive to ROS. In Leydig cells, oxidative 
stress inhibits the mitochondrial import and processing of STAR with a reduction in the 30-kDa 
intramitochondrial form of STAR, resulting in a reduction in steroidogenesis. Whilst several studies in 
Leydig cells demonstrate a clear reduction in 30 kDa STAR expression in response to reactive oxygen 
species, it is unclear whether there is also an effect of ROS at the transcriptional level as current data 
are inconsistent [219, 220] Consistent with the findings of Shi and colleagues who demonstrate an 
effect on STAR promoter activity in Leydig cells, for the first time I demonstrate that an imbalance of 
redox homeostasis in AAAS-knockdown cells reduces both STAR mRNA and the expression of 30 kDa 
STAR protein in adrenocortical cells with no effect on P450scc expression [220]. Interestingly, I also 
see a significant reduction of P450c11β protein expression in the AAAS-knockdown cells. P450c11β 
catalyses the final step in cortisol production and is cited as one of the most ROS-producing steps of 
steroidogenesis [178]. This is in contrast to the P450scc system where much smaller amounts of ROS 
125 
 
are produced. More recently a new model for H2O2-mediated physiological control of 
steroidogenesis in the adrenal has been described. H2O2 is produced as a by-product of 
steroidogenesis [206]. Specific mitochondrial antioxidant mechanisms exist in the adrenal cortex and 
when the antioxidant capacity is exceeded, there is an accumulation of H2O2 in the mitochondria 
with overflow into the cytosol that triggers a reduction in STAR protein expression [206]. It is 
possible that a similar mechanism causes a reduction in P450c11β expression, protecting the adrenal 
from further oxidative damage. This may explain the particular susceptibility of the zona fasciculata 
to disease, with predominance of glucocorticoid deficiency. Recently, Korytowski et al also described 
an additional mechanism by which steroidogenesis may be compromised by oxidative stress in 
Leydig cells. In this model, STAR-mediated trafficking of redox active cholesterol hydroperoxides 
results in mitochondrial toxicity rendering these steroidogenic cells susceptible to further oxidative 
insult [231]. 
Whilst it is accepted that STAR plays a critical role in adrenal and gonadal steroidogenesis, STAR 
mutations can present with a spectrum of phenotypes ranging from LCAH to milder atypical or 
nonclassic forms of LCAH [168, 171]. Nonclassic LCAH is caused by STAR mutations that retain partial 
activity and may present with a phenotype analogous to FGD. I hypothesise that ALADIN deficiency 
leads to an imbalance in cellular redox homeostasis resulting in a reduction in STAR and consequent 
impairment of cortisol and less frequently, mineralocorticoid production. Preservation of 
mineralocorticoid synthesis may reflect not only the relative preservation of zona glomerulosa but 
also the lower production rate of aldosterone compared to cortisol. Interestingly, gonadal 
dysfunction is not reported in triple A syndrome. This suggests that the impairment of STAR is mild 
similar to patients with the p.R188C/R192C STAR mutations in which the protein retains 25-30% 
functionality or that other mechanisms also contribute to the adrenal phenotype [168].   
Oxidative stress has been implicated in the pathogenesis of numerous other neurodegenerative 
diseases and in several adrenal conditions. One such disorder is X-linked ALD where mutations in 
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ABCD1 (encoding the peroxisomal ABCD transporter) result in tissue and plasma accumulation of 
VLCFAs. Similar to triple A syndrome, this disorder is also characterised by graded damage to the 
nervous system together with adrenal insufficiency. The toxic effects of the excessive VLCFAs are 
thought to result from an increase in steady-state ROS production, depletion of GSH and, therefore, 
dysregulation of the cell redox homeostasis [232, 233]. More recently, mutations in the anti-oxidant 
gene NNT, encoding nicotinamide nucleotide transhydrogenase, which supplies high concentrations 
of NADPH necessary for the regeneration of GSH from GSSG, have been reported to cause FGD with 
ACTH-resistant adrenal failure [173]. Thus, there is an emerging picture of defects in antioxidant 
defence impacting specifically on the adrenal gland. It is possible that functional compensation by 
overlapping antioxidant defence mechanisms protects other cell types or tissues unaffected in these 
disorders. In FGD secondary to NNT mutations, an isolated adrenal defect has so far been described, 
in comparison to ALD and triple A syndrome where a more severe phenotype is seen with additional 
neurological disease. It is likely that there is more robust compensation for defective NNT, and 
certainly mitochondrial NADPH can also be generated by NADP-linked malic enzyme and NADP-
linked isocitrate dehydrogenase [234]. 
The precise mechanisms by which antioxidant defences are impaired in triple A syndrome need to be 
further characterised. However, using AAAS-knockdown adrenal and neuronal cells I provide further 
compelling evidence that oxidative stress is involved in the progression of triple A syndrome. As the 
adrenal cortex and neural tissue are highly oxidative environments this may explain the susceptibility 
of these tissues in the absence of functional ALADIN. 
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Chapter 4 
A stop gain mutation in the mitochondrial antioxidant, Thioredoxin reductase 2 (TXNRD2) is 
associated with familial glucocorticoid deficiency (FGD). 
4.1 Aetiology and molecular genetics of FGD 
Familial glucocorticoid deficiency (FGD; OMIM #202200) is characterised by ACTH resistance and 
glucocorticoid deficiency, with typical biochemical findings of low serum cortisol levels and high 
plasma ACTH. Classical ACTH resistance is primarily caused by mutations in the ACTH receptor 
(melanocortin 2 receptor; MC2R) and the melanocortin 2 receptor accessory protein (MRAP), 
required for trafficking MC2R to the cell surface and subsequent signalling [138, 159].  Mutations in 
MC2R and MRAP thus disrupt ACTH signalling in the zona fasciculata and reticularis resulting in 
glucocorticoid and adrenal androgen deficiencies respectively. 
Direct sequencing of MC2R in 1993 led to the first description of a disease-causing mutation in FGD; 
the identification of the p.S74I mutation in MC2R in 2 siblings with FGD [138]. The next gene 
discovery in the FGD cohort was the identification of the adrenal specific gene, MRAP (melanocortin 
receptor 2 accessory protein) in 2005 [159]. For this a whole genome scan was undertaken by single 
nucleotide polymorphism (SNP) array in one family followed by homozygosity mapping, RT-PCR of 
candidate genes within the region together with screening for adrenal expression. This discovery has 
provided invaluable information about the mechanism of ACTH signalling in the adrenal cortex. 
Mutations in MC2R and MRAP have since accounted for 25% and 20% of disease pathogenesis 
within the patient cohort, respectively [131] (Figure 4.1).  
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Figure 4.1. Aetiology of disease within the FGD cohort, comprising more than 250 patients. The 
majority of cases are caused by defective ACTH signaling and mutations in MC2R and MRAP. 39% of 
cases remain of unknown aetiology. 
 
It is however with the use of targeted sequencing that we have seen rapid identification of disease-
causing genes within our FGD cohort. Autozygosity mapping in 8 affected children from 3 kindreds 
from the Irish traveller community localised the disease locus to the pericentric region on 
chromosome 8 and targeted exome capture and high throughput sequencing identified the causal 
variant, c.71-1insG, in minichromosome maintenance 4 protein (MCM4; OMIM #609981) in 2012. 
This mutation is responsible for FGD in the Irish traveller population, incorporating a phenotype of 
short stature, natural killer cell deficiency and chromosomal fragility.  Closely following this 
discovery, linkage to a further locus on chromosome 5 was identified in 3 consanguineous families 
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by SNP genotyping with identification of a mutation in nicotinamide nucleotide transhydogenase 
(NNT, OMIM #614736) in 2012 [177]. Mutations in NNT, spread throughout the gene, have 
accounted for disease within 10% of the cohort (Figure 4.1). NNT, located in the inner mitochondrial 
membrane, plays an important role in NADPH generation in the mitochondria. The 
transhydrogenase activity of NNT catalyses the interconversion of NADH and NADPH with the 
generation of NADPH as the predominant direction. High concentrations of reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) are required by the thioredoxin and glutathione systems 
to detoxify mitochondrial H2O2. Without NNT, the production of NADPH is compromised, causing the 
mitochondria to become more sensitive to oxidative stress.  
Thus, within a short space of time, targeted sequencing has allowed for the identification of 
causative genes in differing biological pathways. These discoveries have provided invaluable 
information about pathways, other than defective ACTH signalling, leading to primary adrenal 
insufficiency.  
4.2 Aims of the study 
Thirty-nine percent of cases within the FGD cohort have unknown aetiology and the novel 
pathogenic mechanisms described above have highlighted alternative biological pathways for 
further investigation (Figure 4.1).  In this study, I describe the investigation of several affected 
individuals within an extended consanguineous Kashmiri family (for pedigree see Figure 4.2), in 
whom sequencing of coding exon/intron boundaries of MC2R, MRAP, STAR, MCM4 and NNT genes 
had been undertaken and no mutations found. I aimed to identify the disease-associated mutation 
in this kindred and carry out functional validation of any putative candidate(s). 
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Figure 4.2. Pedigree of the affected kindred. Black-filled symbols indicate affected individuals. Grey-
filled symbols indicate unaffected individuals. The individual shaded in blue, patient 2.4, is 
undergoing annual screening for FGD. The asterisks denote the three affected individuals who were 
subjected to whole exome sequencing. 
   
4.3 Study approval 
This study was approved by the Outer North East London Research Ethics Committee, reference 
number 09/H0701/12. 
4.4 Clinical Case Reports 
Affected individuals within the kindred exhibited a wide spectrum of severity in symptoms at 
diagnosis with late onset in several family members (Table 4.1). The index case (patient 1.1), whose 
parents were first cousins, was diagnosed with isolated glucocorticoid deficiency at the age of 10.8 
years following hyperpigmentation during febrile illnesses. Biochemical results revealed ACTH 
resistance: raised 0900h plasma ACTH (160 ng/L, normal <50) and low 0900h serum cortisol levels 
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(<10 nmol/L, normal range 200-600).  Her sister (patient 1.2) was subsequently diagnosed, aged 4.5 
years, with a two-year preceding history of hyperpigmentation.  
The children of the index case (patients 2.1 to 2.3) were screened from birth and diagnosed with 
glucocorticoid deficiency between the ages of 0.1 and 6.9 years. Patient 2.5 presented at 0.1 years 
with cardiac failure secondary to congenital truncus arteriosus and a ventricular septal defect. 
During his admission he was diagnosed with isolated glucocorticoid deficiency. He is the only 
affected member of the kindred known to have comorbidity. Echocardiograms and ECGs were 
normal in all individuals homozygous for the mutation except patient 1.2, who has trivial tricuspid 
and mitral valve regurgitation. All clinically affected individuals demonstrated a poor cortisol 
response to ACTH stimulation (125 µg tetracosactide (synacthen) intramuscularly) requiring standard 
glucocorticoid replacement therapy. All have normal mineralocorticoid production. The post-
pubertal patients, patients 1.2 and 1.2, both have reduced androstenedione and DHEAS levels. 
Patient 2.4 is currently clinically well aged 7.4 years with normal biochemistry and is under close 
clinical surveillance. Interestingly, she had raised ACTH levels in early infancy (0900h ACTH of 124 
ng/L at 0.02 years of age; corresponding cortisol of 305 nmol/L), which subsequently normalised. 
Her older sister, individual 2.2, similarly had raised ACTH levels in infancy (0900h ACTH 171 ng/L at 
0.98 years of age; corresponding cortisol of 448 nmol/L) which normalised, but she was later 
diagnosed with isolated glucocorticoid deficiency at 6.9 years of age.
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Table 4.1. Clinical details of the members of the kindred. 0900h cortisol normal range 200-600 nmol/L, 0900h adrenocorticotropic hormone 
(ACTH) normal range <50 ng/L. Maximum cortisol with ACTH stimulation normal >550 nmol/L. VSD, ventricular septal defect; TR, tricuspid 
regurgitation; MR, mitral regurgitation. Biochemical data at time of diagnosis. *Most recent levels 
 
Pt Sex 
Age 
(yr) 
Age at 
diagnosis 
(yr) 
Mode of 
presentation 
Relevant 
clinical 
history 
Degree of 
pigmentation at 
presentation 
0900h 
Cortisol 
(nmol/L) 
0900h 
ACTH 
(ng/L) 
Max. cortisol with ACTH 
stimulation (nmol/L) 
ECHO 
1.1 F 33.8 10.8 
Hyper- 
Pigmentation 
Asymptomatic until 
diagnosis 
Moderate <10 160 Not done Normal 
1.2 F 27.1 4.5 
Hyper- 
Pigmentation 
Asymptomatic until 
diagnosis 
Severe <25 500 <25 Trivial TR and  MR 
2.1 M 13.9 2.9 Screening Mild neonatal jaundice None 65 8130 61 Normal 
2.2 F 9.5 6.9 Screening Asymptomatic Mild 158 514 33 Normal 
2.3  F 8.6 0.1 Screening Asymptomatic Severe 28 3249 147 Normal 
2.4 F 7.4 - Currently well Asymptomatic None 262* 23.2* 1052* Normal 
2.5 M 2.1 0.1 Poor feeding 
Heart failure secondary 
to cardiac defect 
Mild 46 >1240 190 
Truncus arteriosus 
and VSD 
133 
 
4.5 A stop gain mutation in TXNRD2 is associated with disease in the kindred 
Whole exome sequencing (WES) has been used as a powerful tool in gene discovery since the 
description of the first application of the technique to identify the gene for a rare monogenic 
condition of unknown cause; the discovery of DHODH mutations causing Miller syndrome (OMIM 
#263750) [220]. It has been a particularly useful tool in the study of diseases of autosomal recessive 
inheritance, where more extensive filtering of candidates is possible. In the case of the family I have 
been studying, an autosomal recessive pattern of inheritance was suggested by the pedigree (Figure 
4.2). Affected individuals were mutation negative for the known genetic causes of FGD. In keeping 
with the other known causes of FGD, I hypothesised that a rare non-synonymous homozygous 
mutation would be associated with disease in this extensive kindred. To identify the causative 
genetic variant in this family I adopted a WES approach followed by Sanger sequencing to assess 
segregation within the kindred.  
WES of 3 affected individuals (denoted by the asterisks in the pedigree, Figure 4.2) was conducted 
using the Illumina HiSeq 2000 Sequencer (samples processed by Otogenetics Corporation, USA) 
(Methods 2.6). The number of variants was reduced by the following strategy; (i) identifying variants 
that were common to all 3 individuals (ii) excluding variants that were heterozygous (iii) removing 
variants, annotated in SNP databases (Ensembl SNP database, release 54, see URL), with a minor 
allele frequency of >0.01 and (iv) evaluating non-synonymous coding variants, splice variants and 
indels only (Figure 4.3). Variant calling in the 3 individuals identified over 300,000 variants, 
approximately 20,000 of which were homozygous variants common to all 3 individuals. Rarity 
filtering identified 35 possible candidates with a MAF of <0.01 in dbSNP (Appendix 6). The final step 
of the filtering process reduced this further to 4 candidates (Appendix 7). Sanger sequencing of 
candidate variants was then carried out in the whole family to analyse segregation of the disease. 
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Figure 4.3. Whole exome sequencing filtering strategy. The number of variants was reduced at each 
stage after initial variant calling. 
 
Four rare homozygous variants within coding sequences, common to all 3 individuals, were 
identified following application of our filtration strategy (Figure 4.3; Appendix 7). Three variants in 
two candidate genes did not segregate with the disease. All three variants are in dbSNP; the OR2T35 
variant (rs370874670) and the two MUC4 variants (rs374495657 and rs202060675), but there is no 
frequency or population data. The variants were discounted on the basis that disease affected 
patient 2.2 was wildtype for rs370874670 in OR2T35 and the unaffected husband of patient 1.1 
(individual 1.3) was homozygous for both changes in MUC4.  
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Figure 4.4. Segregation of the p.Y447* TXNRD2 mutation in the pedigree. Black-filled symbols 
indicate individuals homozygous and half-filled indicate individuals heterozygous for the p.Y447* 
TXNRD2 mutation. White-filled symbols indicate wild-type individuals. Grey-filled symbols indicate 
individuals not tested. The asterisks denote the three affected individuals who were subjected to 
WES. 
 
Only one variant, a stop gain mutation (c.1341T>G; p.Y447*) within exon 15 of TXNRD2 (RefSeq 
accession number NM_006440.3), encoding mitochondrial thioredoxin reductase 2 (TXNRD2), 
segregated with the disease in this kindred (Figure 4.4 and 4.5). Individuals heterozygous for the 
change were clinically unaffected.  Two SNPs at this position are annotated in dbSNP (ID 
rs202059967) an A>G change and the A>C change reported here. The A>G change is silent and seen 
in only 1/12686 alleles in NHLBI GO Exome Sequencing Project, ESP6500 (See URLs), the A>C change 
is not recorded in this database but is listed in dbSNP EXOME_CHIP data (submitter SNP ID 
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ss491568437), with no frequency data. Sequencing of >1000 healthy adult British Pakistanis revealed 
a minor allele frequency of 1.04% for this variant, genotypes were A/A=1080; A/C=23; C/C=0. 
Importantly, in this control population, the variant was never seen in homozygosity. One other stop 
gain mutation (p.R441*; rs200162480) is listed for TXNRD2 but is only present in heterozygosity in 
one individual (1/12730 alleles).  The coding exons of TXNRD2 were sequenced in 50 patients with a 
clinical diagnosis of FGD by a combination of whole exome and Sanger sequencing. WES data was 
analysed in each individual and for any exonic region with a coverage of <20 reads PCR amplification 
and Sanger sequencing was carried out. Sequencing within this cohort revealed variants at 
rs5748469 (p.A66S), rs5992495 (p.S299R) and rs1139793 (p.I370T) with MAF of 30%, 17.5% and 25% 
respectively, in keeping with their frequencies in the European American cohort from GO-ESP (see 
URL). This would fit with the fact that most of our FGD patients are of European extraction. No other 
variants were discovered in 100 FGD alleles making this TXNRD2 mutation a rare cause of FGD.   
 
Figure 4.5. Identification of p.Y447* TXNRD2 mutation. (A) Partial sequence chromatograms of 
genomic DNA from wild-type, heterozygote carrier and a patient, showing the base change from T to 
G in exon 15, resulting in a premature stop codon. (B) Gene structure of TXNRD2; p.Y447* mutation 
prior to the selenocysteine active site (SEC). 
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4.6 Expression of TXNRD2 in affected individuals  
The mutation was predicted to cause a protein truncation prior to the selenocysteine active site 
(SEC), with a predicted truncated protein size of approximately 52 kDa (Figure 4.5), the full length 
protein being 56kDa.  To investigate the effect of the mutation, RT-PCR of patient cDNA was carried 
out (primer sequences, Appendix 2) and protein expression in patient leukocytes was determined by 
western blot analysis of TXNRD2 (rabbit polyclonal anti-TXNRD2 antibody; immunogen incorporating 
amino acid sequence 203 to 353 of TXNRD2). Leukocytes were extracted using a gradient density 
centrifugation method with Histopaque-1077 (Sigma Aldrich, Poole, UK) (Methods 2.12). Western 
blotting of patient lysates revealed absence of the protein in homozygous patients in comparison to 
a heterozygote carrier and an age and sex-matched control (Figure 4.6).  In contrast, western 
blotting for the cytoplasmic thioredoxin reductase 1 revealed patients express TXNRD1 at similar 
levels to controls (Figure 4.6) GAPDH was used as a loading control. 
 
Figure 4.6. p.Y447* TXNRD2 mutation leads to loss of TXNRD2 protein. Lysates from a homozygous 
patient, heterozygote carrier (Het) and control human lymphocytes were immunoblotted with an 
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anti-TXNRD2 antibody. While control and the heterozygote carriers expressed the 56 kDa protein, 
this is absent in the homozygote patient with no evidence of a truncated protein. All individuals 
express cytoplasmic TXNRD1 at similar levels.  
 
To determine whether mRNA of the mutant allele was present, RNA was extracted from patient 
blood using the PAXgene Blood RNA kit (Qiagen, Crawley, UK) (Methods 2.3.3). Reverse transcription 
of the samples and RT-PCR were then carried out.The absence of a TXNRD2 fragment on 
amplification from cDNA of the homozygote patient coupled with the finding that direct sequencing 
of amplicons from the heterozygote carrier revealed amplification of the wild-type sequence alone 
was consistent with nonsense-mediated decay (Figure 4.7) of mRNA. 
 
Figure 4.7. RT-PCR of TXNRD2. Amplification of a fragment of TXNRD2 from cDNA of patient, 
heterozygote carrier and control suggested nonsense mediated decay of mRNA.  
 
4.7 Discussion 
In 2009 in a proof of concept study, Ng and colleagues demonstrated that candidate genes for 
monogenic disorders, in this case a  rare dominantly inherited disorder, Freeman-Sheldon syndrome 
(OMIM #193700), could be identified by WES a small number of unrelated individuals [235]. 
Subsequently the same group demonstrated mutations in DHODH caused Miller syndrome (OMIM 
#263750) in 4 affected individuals in 3 independent kindreds, in the first successful application of 
exome sequencing to identify the gene for a rare monogenic condition of unknown cause [220]. 
Since these first studies there has been a rapid expansion in the use of WES in gene discovery.  
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In this study, I describe the use of WES to identify the first homozygous mutation in the 
mitochondrial selenoprotein, thioredoxin reductase 2 (TXNRD2) associated with FGD in a 
consanguineous Kashmiri kindred. Absence of the 56 kDa TXNRD2 is associated with adrenal 
insufficiency in this kindred, with all affected members being homozygous for the identified genetic 
defect. TXNRD2 is one of 25 human selenoproteins, which require insertion of a highly reactive 
selenocysteine residue for enzymatic activity. Selenium (Se) is an essential trace element which can 
be incorporated into proteins and some modified tRNAs, as selenomethionine, competing with 
sulphur in the biosynthesis of methionine, a process which involves little regulation. On the other 
hand the biosynthesis of selenocysteine (Sec), the 21st amino acid, and its cotranslational 
incorporation into specific proteins (selenoproteins) is highly regulated.  The UGA codon acts as an 
opal stop codon during translation. However it can also encode the translational incorporation of Sec 
into target proteins when their mRNA contains a distinct hairpin mRNA sequence downstream of the 
UGA codon in the 3’-untranslated region (UTR) [236]. This sequence termed the Sec insertion 
sequence (SECIS) competes for release factors that would otherwise cause disassembly of the 
mRNA-ribosomal complex and termination of translation. The SECIS structure recruits SBP2 
(selenocysteine binding protein 2) and binds Sec-specific elongation factor (EFSec) loaded with its 
tRNASec , allowing for cotranslational incorporation of Sec at the UGA [237-239] (Figure 4.8). SBP2 
stably associates with the ribosome and mutagenic analysis has demonstrated that this association is 
necessary for Sec insertion and a conformational change occurs in the ribosomes [240].  Further 
components of the complex network of proteins required for this process continue to be identified. 
Failure of the above process can result in recoding the UGA codon as a stop codon with subsequent 
nonsense-mediated decay of the resulting protein. 
Selenoproteins have diverse functions including metabolism of thyroid hormones (deiodinases), 
transporting selenium to peripheral tissues (selenoprotein P), and protein folding and ER stress (Sep-
15, SELM, and SELS). Several selenoproteins, including the thioredoxin reductases (TXNRD 1-3) and 
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glutathione peroxidases (GPX 1-4, 6) contribute significantly to redox regulation. The selenocysteine 
residue confers high redox activity [241]. TXNRD2 is predominantly mitochondrial and one of three 
thioredoxin reductases. It is responsible for reducing thioredoxin 2 (TXN2) and other substrates. 
Within the mitochondria the thioredoxin and glutathione systems, reliant on the provision of 
NADPH/H+ by NNT, contribute to the maintenance of redox homeostasis, discussed further in 
Chapter 5.  
 
Figure 4.8. Selenoprotein biosynthesis with incorporation of Sec at UGA codons. Co-translational 
incorporation of Sec into proteins occurs at the UGA codon, which recruits Sec-loaded tRNA Ser (Sec) to 
the ribosome. This occurs via an interaction of Sec-specific translation factor EFSec with the SECIS 
binding protein 2 (SBP2). SBP2 recognises the 3’-UTR hairpin loop SECIS mRNA structure in all 
mRNAs encoding Sec-containing proteins.  
 
  
Two inherited human diseases have been associated, thus far, with mutations in selenoproteins and 
associated proteins; these include mutations in SECISBP2 and SEPN1. SEPN1 mutations encoding 
selenoprotein N1 lead to rigid spine syndrome (OMIM #602771), a rare form of congenital muscle 
dystrophy [242]. Selenoprotein N is an integral membrane glycoprotein in the endoplasmic 
reticulum with a postulated role in myogenesis. Mutations in SECISBP2, encoding SBP2, lead to 
reduced Sec insertion in several selenoproteins including the deiodinases, GPX, TXNRD, SEPN1, and a 
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reduction in these have been linked to clinical features of thyroid dysfunction, gastrointestinal 
disturbance, infertility and myopathy [243]. Se supplementation appears to have no effect on clinical 
phenotype. Interestingly no SBP2 patient has thus far been identified to have adrenal insufficiency 
(personal communication, Chatterjee 2013). In SBP2 deficiency there is still some low level of 
expression of all selenoproteins affected. In this instance, whilst there is a reduction in the 
thioredoxin reductases, there is still scope for some functional activity of TXNRD2 in comparison to 
our adrenal insufficient patients with absence of TXNRD2. This low level of functional activity may be 
sufficient to protect the SBP2 patients from adrenal insufficiency. It is also possible that a hierarchy 
of selenoproteins exists with preferential preservation of Sec insertion in those selenoproteins that 
are biologically most important in SBP2 deficiency. Certainly mouse knockout models suggest 
TXNRD2 may feature highly within such a hierarchy. Whilst individual disruption of certain 
selenoproteins including several Gpxs (Gpx1 to 3), selenoprotein P and type 2 iodothyronine 
deiodinase induce mild phenotypes in mice [244-249], mice lacking Txnrd2, Txnrd1 (thioredoxin 
reductase 1), Txn1 (thioredoxin 1) and Txn2 (thioredoxin 2) die in early embryogenesis [250-253]. 
Furthermore, interestingly, in transgenic mice that expressed a variant of the tRNA species 
mediating Sec insertion,  that lacked a modified base corresponding to the wild type tRNA species, 
synthesis of selenoproteins was differentially affected, with Txnrd1, Txnrd2 and Gpx4 least affected 
[254, 255].   Amongst the thioredoxin reductases themselves, there is a prioritisation of Txnrd2 over 
Txnrd1 during Se deficiency such that Txnrd1 expression is more sensitive to Se supply than Txnrd2 
[256].  
The wide variability in age at presentation within this family and the comorbidity in patient 2.5 is 
interesting and suggests the presence of modifiers of disease, either genetic or environmental. 
Phenotypic heterogeneity amongst affected members of the same kindred has been demonstrated 
in several disorders including other disorders of primary adrenal insufficiency such as triple A 
syndrome [13]. Given the complex network of proteins involved in antioxidant defence it is possible 
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that other variants within this network contribute to phenotypic differences. As TXNRD2 is 
ubiquitously expressed in humans, individuals with this genetic defect are potentially at risk of 
developing extra-adrenal manifestations. Txnrd2 deletion in mice is embryonically lethal at day 13 as 
a consequence of a combination of cardiac and haematopoietic defects [250]. Knockout mice are 
severely anaemic with reduced colonies of all types of haematopoietic cell types, though 
differentiation is not affected. The full blood counts in all affected individuals within this family were 
normal with no evidence of haematopoietic problems. The knockout mice are described to have 
thinner ventricular walls and trabeculae. Cardiac specific ablation of Txnrd2 results in a fatal dilated 
cardiomyopathy (DCM) with mitochondrial dysfunction of cardiomyocytes [250]. Thus in mice the 
TXNRD2 system is clearly indispensable for normal cardiac development and function. Hemizygous 
mouse models for Txnrd2 (Txnrd2+/-) show no apparent phenotype even in combination with 
selenium deficiency [257]. In humans, two novel heterozygous mutations affecting the FAD (flavin 
adenine dinucleotide) region of TXNRD2 were identified in 3 of 227 patients with a diagnosis of DCM 
screened [258]. The role of selenium in cardiomyopathy has also been described in Keshan’s disease, 
originally described in North East China where selenium deficiency induced heart failure is well 
documented [259]. Interestingly, in our affected homozygote individuals, with complete absence of 
TXNRD2, we observed no evidence of cardiomyopathy or conduction disease. One affected family 
member presented with truncus arteriosus and ventricular septal defect, an extremely rare 
congenital cardiac anomaly. In light of the high consanguinity within this kindred the cardiac defect 
in this patient is likely to be caused by another gene defect. Approximately 40% of truncus arteriosus 
cases are associated with Di George syndrome , secondary to haploinsufficiency of a region of 
varying length on chromosome 22q11.2 [260]. Several genes within this commonly deleted region 
have been linked to defects in cardiac development including TBX1 and Crkl, essential for survival, 
proliferation and migration of neural crest cells [261, 262].  Interestingly, TXNRD2 falls within this 
region on chromosome 22, raising the possibility that TXNRD2 contributes to the cardiac phenotype 
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of Di George syndrome. As heterozygote carriers of the p.Y447* TXNRD2 mutation have normal 
adrenal function, we would predict that haploinsufficiency of TXNRD2 would not lead to an 
abnormal adrenal phenotype, and consistent with this, I have been unable to identify any published 
reports of adrenal insufficiency in Di George syndrome. 
A role for the thioredoxin system has been postulated in several human conditions. It is proposed 
that thioredoxin-related antioxidant defence may be important in protecting against age-related 
oxidative stress. To that effect transgenic mice overexpressing Txn1 are reported to have a longer 
life span and are more resistant to oxidative-induced stress [263]. In age-related cataract 
development, the thioredoxin system has been shown to revive the inactivated enzyme glutathione 
reductase, protecting against oxidative stress [264].  TXNRD upregulation is seen in conditions such 
as Alzheimer’s disease where oxidative stress is implied and the system is suggested as a potential 
therapeutic target [265]. Intronic SNPs in TXNRD1, rs6539137 and rs4630362, were significantly 
associated with another neurodegenerative disease, familial amyotrophic lateral sclerosis, and the 
authors suggest that TXNRD1 may act as an important genetic modifier of disease [263]. The 
upregulation of TXNRD, mainly cytosolic TXNRD1, has been reported in several cancer cell lines and 
human cancers. The role of selenoproteins has been investigated in the carcinogenic process. 
Indeed, the thioredoxin system has been proposed as a therapeutic target for cancer related 
disease. Several groups have proposed associations of selenoprotein genotypes, including SNPs in 
TXNRD1 and TXNRD2 affecting cancer risk in conjunction with lifestyle factors. Intronic SNPS in 
TXNRD1 and TXNRD2 are postulated to significantly alter risk of high-grade or advanced stage 
prostate cancer in a population with suboptimal Se intake [266]. SNPS in TXNRD2 have also been 
discussed in association with rectal and colon cancer risk [267]. The functional significance of the 
SNPs in the conditions described above has not been fully explored and characterisation will be 
challenging given their intronic nature. There is no history of early onset cancer reported in our 
family. 
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This is the first report of a homozygous mutation in any component of the thioredoxin system 
associated with inherited disease and the first mutation in TXNRD2 associated with an adrenal 
phenotype in humans, signifying the importance of the thioredoxin system in maintaining redox 
homeostasis in the adrenocortical environment. Clinical surveillance, including regular cardiac 
review, and careful phenotyping of the affected individuals in this family will be necessary, together 
with functional interrogation of the candidate identified to better understand the role of TXNRD2 in 
primary adrenal insufficiency. It will be important to assess whether other organ systems will be 
affected over time and furthermore whether this mutation poses a cancer risk. Characterisation of 
the effect of TXNRD2 deficiency specifically in the adrenocortical environment is discussed further in 
Chapter 5. 
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Chapter 5  
TXNRD2-knockdown in human adrenocortical cells causes an imbalance in redox homeostasis 
5.1 Mitochondrial TXNRD2 
The thioredoxin family of proteins, to which TXNRD2 belongs, plays a crucial role in regulating 
cellular redox homeostasis. This protein family comprises the thioredoxins, glutaredoxins and 
peroxiredoxins, all of which share a thioredoxin fold and an active site motif containing one or more 
cysteine (Cys) residues [268]. Cys residues may be involved in inter or intra-molecular disulphide 
bond(s), or they may exist as unbound thiols and it is the free Cys that forms an integral part of 
enzyme catalytic activity [269]. Surface-exposed Cys residues in a variety of proteins are potential 
targets for redox based modifications, and thiols can be reversibly oxidized to disulphides. The 
presence of disulphide bonds in peptides or proteins confers a relatively rigid structure and can 
affect protein function or activity [269]. Other reversible modifications include thiols being modified 
to sulfenic acid and glutathionylation, the process by which Cys side chains form disulphide bonds 
with GSH.  These redox-based modifications can regulate protein activity and hence redox signalling 
can regulate several cellular processes in a fast and specific manner. The thioredoxin system itself 
comprises thioredoxin (TXN), the selenoprotein thioredoxin reductase (TXNRD) and the electron 
donor NADPH (Figure 5.1). The protein disulphide in the active site of TXN is reduced by TXNRD, 
receiving electrons from NADPH [270]. Reduced TXN in turn binds to the target protein disulphide, 
thereby reducing the target protein.  
Mammalian genomes encode two main thioredoxin systems; the cytosolic and mitochondrial 
systems. TXNRD2, one of three thioredoxin reductases, is predominantly mitochondrial, whilst 
TXNRD1 is cytosolic and the recently discovered TXNRD3 is localised to the microsome [271-273]. 
The mitochondrial localisation signal of TXNRD2 is present in the N-terminus, though some 
transcripts have been described without this localisation signal [274]. The functional significance of 
these latter transcripts has yet to be determined. TXNRD2 exists as an anti-parallel homodimer 
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[275]. The N and C-terminal redox active centres of the two subunits functionally interact and 
transfer electrons from NADPH/H+ to TXN2 and other substrates [275]. NNT provides the high 
concentrations of NADPH/H+ required by the thioredoxin and glutathione systems to maintain redox 
homeostasis (Figure 5.1). The glutathione and thioredoxin systems act in parallel in mitochondria to 
maintain Peroxiredoxin 3 (PRDX3), an important mitochondrial antioxidant, in reduced form.  
 
 
 
Figure 5.1. The thioredoxin and glutathione systems maintain mitochondrial redox homeostasis. 
TXNRD2 reduces thioredoxin 2 (TXN2) and glutaredoxin 2 (GLRX2), both of which can reduce PRDX3, 
which in turn detoxifies H2O2 in mitochondria. Glutathione reductase (GSR) and glutathione (GSH) 
contribute to the process through reduction of GLRX2.  Nicotinamide nucleotide transhydrogenase 
(NNT) provides the high concentrations of NADPH required by both the thioredoxin and glutathione 
systems.   
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5.2 Aims of the study 
Absence of TXNRD2 is associated with adrenal insufficiency in the consanguineous kindred described 
in detail in chapter 4, with all affected members being homozygous for the identified genetic defect. 
To further investigate the effect of TXNRD2 deficiency in the adrenocortical environment, TXNRD2-
knockdown was established in the H295R human adrenocortical cell line. I investigated the effect of 
TXNRD2 deficiency on redox homeostasis in the adrenocortical environment and the potential 
impact on steroidogenesis. 
5.3 TXNRD2 is highly expressed in the human adrenal cortex 
The expression of TXNRD2 and GAPDH mRNA was investigated using a panel of cDNAs derived from 
11 adult tissues (adrenal cortex, heart, liver, testes, thyroid, lung, kidney, spleen, ovary, brain, 
skeletal muscle).   Quantitative real-time PCR was performed for each tissue. Whilst TXNRD2 mRNA 
is ubiquitously expressed in all the human tissues tested, highest levels were observed in the adrenal 
cortex (Figure 5.2), consistent with mouse expression profiles [276].  
 
Figure 5.2. TXNRD2 is expressed in all human tissues investigated, with highest TXNRD2 mRNA 
levels in the adrenal cortex. 
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5.4  TXNRD2-knockdown in H295R adrenocortical cells 
Stable knockdown of TXNRD2 was established in H295R human adrenocortical cells by lentiviral 
shRNA transduction (Methods Section 2.1.2). Lentiviral plasmids (V3LHS_354173) were obtained 
from OpenBiosystems in a p.GIPZ backbone and contained shRNA specific for human TXNRD2 (NM 
10587) under the control of a CMV promoter, plus genes for puromycin resistance and green 
fluorescence protein (GFP) (for sequences and vector maps see Appendices 3 and 4). A control cell 
line was generated using a lentiviral plasmid vector containing a shRNA insert that does not target 
human and mouse genes (Open Biosystems). A significant reduction in TXNRD2 mRNA is observed 
following knockdown in comparison to controls (n=4) (Figure 5.3A). This is confirmed by western blot 
analysis demonstrating approximately 95% knockdown in protein levels (n=4) (Figure 5.3B).  
Cell viability was assessed using the MTS assay (CellTiter96 Aqueous non–radioactive cell 
proliferation assay, Promega, Southampton, UK) where absorbance readings are proportional to 
cellular metabolic activity (Methods 2.8.2). TXNRD2-knockdown in the H295R human adrenocortical 
cell line by shRNA had no effect on cell viability (Figure 5.3C). A colorimetric, thioredoxin reductase 
(TXNRD) assay kit (Abcam, Cambridge, UK) was used to assess total TXNRD activity in cell lysates 
from TXNRD2-knockdown and control cells (Methods 2.11). In the assay TXNRDs catalyse the 
reduction of 5, 5’-dithiobis (2-nitrobenzoic) acid (DTNB) with NADPH to 5-thio-2-nitrobenzoic acid 
(TNB2-), generating a strong yellow colour (λmax=412 nm). Of note, the kit does not allow for the 
differentiation of activity of the mitochondrial and cytosolic forms of TXNRD. Interestingly, TXNRD2-
knockdown did not have any significant impact on total TXNRD activity (p=0.7, n=4), suggesting 
possible compensatory upregulation of the activity of the other TXNRDs (Figure 5D). Cytosolic 
TXNRD1 protein expression itself is not significantly different in the TXNRD2-KD cells in comparison 
to controls (p=0.5, n=4) (Figure 5E).  
149 
 
 
Figure 5.3. Lentiviral shRNA knockdown of the TXNRD2 gene in H295R cells. (A) TXNRD2 mRNA 
expression was quantified using real-time qPCR and normalised to GAPDH (n=4). Control represents 
transfection with scrambled shRNA. (B) Reduced expression of the protein TXNRD2 is seen in 
TXNRD2-knockdown (TXNRD2-KD) H295R cells; western blot with densitometric analysis. (C) No 
difference in cell viability is seen at baseline between TXNRD2-KD and control cells using the MTS 
assays. (D) There is no difference between total TXNRD activity in TXNRD2-KD H295R cell lysates in 
comparison to controls using the TXNRD assay (n=4). (E) No difference in TXNRD1 protein expression 
is seen in TXNRD2-KD H295R cells; western blot with densitometric analysis. RU, relative units. Data 
represents mean + SD. p < 0.05*, p<0.001***. 
 
5.5 TXNRD2-knockdown in H295R adrenocortical cells results in an imbalance of redox 
homeostasis 
The glutathione and thioredoxin systems maintain reduced peroxiredoxin 3 (PRDX3) (Figure 5.1), 
which is integral for redox regulation within the adrenal [206]. In the absence of TXNRD2, increased 
pressure on the glutathione system was hypothesised. The luciferase-based GSH/GSSG-Glo assay 
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(Promega, Southampton, UK) was used to assess the GSH/GSSG (Reduced: oxidised glutathione) 
ratio in the TXNRD2-KD H295R cells compared to controls (Methods 2.9). 
A clear impact on redox homeostasis was demonstrated, with increased pressure on the glutathione 
system observed as a decrease in the GSH/GSSG ratio (10.3±1.3 vs 7.7±0.4 in control vs knockdown 
cells respectively; p=0.02, n=4) (Figure 5.4A-B). As a positive control, a significant reduction in the 
GSH/GSSG ratio (0.4 + 0.1 RLU) was demonstrated by treatment of the control cells with 25 µM 
menadione, a potent inducer of oxidative stress. 
 
 
Figure 5.4. TXNRD2 deficiency in H295R cells leads to increased pressure on the glutathione 
system. (A) Increased reactive oxygen species leads to an increase in cellular oxidised glutathione 
(GSSG) and a decrease in the GSH/GSSG ratio. (B) Increased pressure on the glutathione system is 
observed in TXNRD2 deficiency with a significant decrease in the reduced: oxidised glutathione (GSH: 
GSSG) ratio. Oxidative stress induced by 25 µM menadione in the control cells reduced this ratio to 
0.4+0.1 (n=4). RLU, relative light units. Error bars represent standard deviation. * p< 0.05. 
 
During H2O2 elimination, two reduced PRDX3 subunits are converted to an oxidised disulphide-linked 
dimer that is reduced again by the TXNRD2/TXN2 system [203]. Cell lysates from TXNRD2-KD and 
control cells were western blotted in non-reducing conditions to compare the ratio of the
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Figure 5.5. TXNRD2-KD in H295R cells leads to impaired mitochondrial redox homeostasis. (A) 
TXNRD2-KD leads to a decrease in the reduced to oxidised PRDX3 ratio, western blot with 
densitometric analysis (n=3). (B) Quantitative analysis of superoxide production by MitoSOX, shows 
a significant increase in superoxide production in KD cells relative to controls; (n=3) following 
fluorescence-activated cell sorting (FACS): (C) Control and (D) TXNRD2-KD H295R cells before 
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application of MitoSOX reagent. Following application of MitoSOX reagent for assessment of 
mitochondrial superoxide production a greater frequency of events is observed in area P4 (See 
Methods 2.13.2) for both (E) control H295R cells and (F) TXNRD2-KD cells with an approximately 3-
fold increase observed in the TXNRD2-KD cells in comparison to control cells, reflective of increased 
mitochondrial superoxide production. RU, relative units. Error bars represent standard deviation. * 
p< 0.05. 
 
monomeric (reduced) to dimeric (oxidised) form of PRDX3 (Methods 2.2.1). The ability to maintain 
mitochondrial PRDX3 in its reduced form is impaired, with a significant decrease in the ratio of the 
reduced to oxidised form in the TXNRD2-deficient cells compared to controls 0.19+0.06 vs 0.48+0.09 
respectively; p=0.02, n=3 (Figure 5.5A).   
Finally, the MitoSox Red fluorogenic probe was used to investigate mitochondrial superoxide 
production by flow cytometry (Methods 2.13.2). As a consequence of TXNRD2-knockdown in the 
adrenocortical cells, an approximately 3-fold increase in levels of mitochondrial reactive oxygen 
species (ROS) are seen, further demonstrating an impairment of redox regulation (Figure 5.5B-F, 
Methods Figure 2.7). 
5.6 Steroidogenesis in TXNRD2-deficient H295R cells 
In the AAAS-KD H295R model, a clear impact on protein expression is seen in STAR and 
mitochondrial P450c11β (CYP11B1) with a subsequent reduction in cortisol expression. To ascertain 
if the same were true in the TXNRD2-deficient H295R model investigated the protein expression of 
STAR, P450scc and P450c11β followed by measurement of cortisol production. 
Western blotting of lysates from TXNRD2-KD and control H295R cells revealed no significant 
difference in STAR (p=0.8, n=4), P450c11β (p=0.9, n=3), or P450scc protein expression (p=0.3, n=3) 
(Figure 5.6A-D). Cortisol production was analysed on a Roche Modular E170 automated 
immunoassay analyser, following 24 hour stimulation of the cells with 10 µM forskolin (Methods 
2.10). There was no significant difference in cortisol production in TXNRD2-deficient H295R cells 
(1520.4 nmol/L/mg of lysate protein + 284.3) in comparison with controls (1729.7 nmol/L/mg of 
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lysate protein + 276.4), (p=0.3, n=5) (Figure 5.6E). These findings are somewhat surprising given the 
proposed role that TXNRD2 has in mitochondrial antioxidant defence. Potential reasons for this 
discrepancy in findings between the AAAS-KD and TXNRD2-KD are discussed further in Section 5.7. 
 
 
Figure 5.6. There is no significant impact on steroidogenesis in TXNRD2-deficient H295R cells 
compared with controls. (A) Immunoblot analysis and (B) Densitometric analysis reveals no effect 
on STAR (n=4), (C) P450c11β (n=3) or (D) P450scc (n=3) protein expression in TXNRD2-KD H295R 
cells. (E) Furthermore, there is no significant difference in cortisol production in forskolin-treated 
TXNRD2-KD H295R cells compared with controls (n=5). Data represents mean + SD. 
 
5.7  Discussion 
Under conditions of selenium deficiency, some selenoproteins and some tissues are protected at the 
expense of others. Selenium is preferentially distributed to organs such as the brain, endocrine and 
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reproductive organs [277]. The testes and adrenals in particular have greatest retention of selenium 
in conditions of selenium deficiency [199]. Indeed selenium deficiency results in a marked decrease 
in selenoprotein glutathione peroxidase activity and subsequent cortisol production in an adrenal 
cell line [200]. In this section of work I investigated the role of the selenoprotein, TXNRD2 in the 
human adrenocortical environment. Particularly high TXNRD2 mRNA levels were noted in the 
adrenal cortex compared to the other human tissues investigated, suggesting a critical role in this 
tissue. This reflects expression data in the mouse and high TXNRD2 levels are also reported in the 
bovine adrenal cortex [197, 276].  
There are 3 distinct thioredoxin reductases: cytosolic thioredoxin reductase 1 (TXNRD1) [272], 
mitochondrial thioredoxin reductase 2 (TXNRD2) [278], and the most recently identified thioredoxin 
reductase 3 (TXNRD3), isolated from the microsomal fraction of mouse testes [273].This final TXNRD, 
which has combined thioredoxin and glutathione reductase activities and can thus reduce several 
components of the glutathione system, is mainly expressed in the testes and has been implicated in 
sperm maturation [258, 273]. Each TXNRD is expressed from a different gene and each reduces 
substrates in different subcellular compartments. TXNRD1 and 2 are flavoproteins containing a FAD-
binding domain within the N-terminus, an NADPH binding domain and an interface domain for 
dimerization. It is the redox active site of the C-terminal domain that contains the selenocysteine 
(Sec) moiety critical for thioredoxin reductase activity as both an acceptor and donor of electrons 
[279, 280]. The thioredoxin reductases function within an anti-parallel homodimer allowing 
interaction between the two N- and C-terminal-located redox active centres (Figure 5.7). Electrons 
provided by NADPH/H+ are delivered to the redox centre of the N-terminal FAD-binding domain and 
are transferred to the C-terminal redox active site of the adjacent monomer with final delivery to the 
substrate [275].  
The major substrate for TXNRD2 is mitochondrial thioredoxin 2 (TXN2) (Figure 5.1). However, the 
readily accessible and reactive C-terminal catalytic centre and Sec element allows for high versatility  
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Figure 5.7. Ribbon representation of the overall structure of the mouse Txnrd2 homodimer. 
Subunit A is shown in dark colours, and subunit B is shown in light colours. The protein is comprised 
of three domains: a FAD-binding domain (yellow), an NADP(H)-binding domain (green), and an 
interface domain (blue). Bound FAD molecules are represented as space-filling models with carbon 
atoms coloured in grey, nitrogen atoms in blue, oxygen atoms in red, and phosphorous atoms in 
cyan. Images reproduced with author’s permission [275]. 
 
and the thioredoxin reductases are also involved in reduction of various other substrates including 
H2O2, lipid peroxides, vitamin A, C and K amongst others [281-283]. Mammalian cells have 2 main 
TXN systems; the cytosolic thioredoxin 1 (TXN1) and mitochondrial TXN2, reduced by TXNRD1 and 
TXNRD2 respectively. Mitochondrial TXN2 is a small redox active protein with two redox active 
cysteinyl residues, whilst cytosolic TXN1 has 3 additional cysteine residues at its active site. TXN1 
and TXN2 share 35% sequence homology and similar catalytic properties in vitro [284].The TXNs 
have roles in cell to cell communication, signal transduction, DNA metabolism and repair, 
transcription regulation and protein folding and degradation [282, 285]. TXN1 is involved in redox 
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signalling and can regulate the activities of many oxidative-sensitive transcription factors including 
Nrf-2, NF-ƘB and P53 [286, 287]. TXN1 and TXN2 can both reduce methionine sulfoxide reductases 
and are thus involved in the repair of oxidized free methionine and protein methionine [288]. Both 
forms also importantly provide defence against oxidative stress by acting as electron donors for  
peroxiredoxins, which are rapid scavengers of H2O2 [289].   
Peroxiredoxin 3 (PRDX3) is one of six PRDX isoforms and is restricted to the matrix of the 
mitochondria. It is reported to be the most important H2O2 eliminating enzyme in the mitochondria 
of the adrenal cortex with hyperoxidation of PRDX3 resulting in diminished steroidogenesis [206] . 
During H2O2 elimination, two reduced PRDX3 subunits are converted to an oxidised disulphide-linked 
dimer that is reduced again by TXN2 [203]. Thus PRDX3, together with mitochondrial-specific TXN2 
and TXNRD2, provide a primary line of defence against H2O2 produced by the mitochondrial 
respiratory chain in the adrenal gland. Additionally, Glutaredoxin 2 (GLRX2) has recently been 
identified as another electron donor for PRDX3 [204]. GLRX2 also has high affinity for the GSH 
moiety and catalyses the reduction of mixed disulphides, including glutathionylated proteins [290]. 
GLRX2 itself is reduced by TXNRD2 as well as GSH and the mitochondrial thioredoxin and GSH 
systems function in parallel to protect against oxidative stress [204] (Figure 5.1). Overlap between 
the thioredoxin and GSH systems is further indicated by findings in ex vivo cultures of Txnrd2-/- 
mouse embryonic fibroblasts, where proliferation and survival is compromised by addition of the 
GSH-depleting agent, BSO [250]. In my in vitro knockdown adrenocortical model I demonstrated that 
the glutathione system is unable to fully compensate for the TXNRD2 deficiency leading to an 
increase in the oxidised PRDX3 dimer and increased mitochondrial superoxide production. 
157 
 
 
Figure 5.8. Maintenance of reduced peroxiredoxin 3 (PRDX3-SH) by thioredoxin 2 (TXN2) and 
sulfiredoxin (SRX). PRDX3, in its reduced form, detoxifies H2O2 in the mitochondria. This process 
induces the formation of disulphide PRDX3 which in turn is reduced back to PRDX3-SH by TXN2. With 
excessive H2O2 PRDX3 is hyper oxidised to an inactive sulfinic form (PRDX3-SO2-) and this hyper 
oxidisation is reversed by SRX. 
 
During catalysis PRDX can also be hyperoxidised to an inactive sulfinic form [205] (Figure 5.8). Only 
Prdx3 is found in sulfinic form in the adrenal cortex, accounting for approximately 10 to 20% of all 
Prdx3 in the mouse adrenal cortex [206]. The enzyme sulfiredoxin (SRX) reverses this hyperoxidation 
in a slow process which requires ATP hydrolysis and reducing elements including TXN2 and GSH 
[291]. SRX is a cytosolic protein that translocates into mitochondria when cells are under oxidative 
stress [292]. Treatment of adrenocortical cells with ACTH lends to further translocation of Srx into 
the mitochondria [206]. Thus SRX together with the TXN2 system, plays a crucial role in maintaining 
active PRDX3. With increasing H2O2 production the capacity for Srx to carry out this reversal is 
exceeded and levels of inactive sulfinic Prdx3 increase with subsequent H2O2 build up [206]. This in 
turn leaks into the cytosol leading to the phosphorylation (activation) of p38 mitogen-activated 
protein (MAP) kinase with consequent inhibition of STAR synthesis, the precise mechanism of which 
is currently unclear. Interestingly, levels of inactivated Prdx3, Srx, and activated p38 demonstrate 
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diurnal variation and conditional ablation of Srx in steroidogenic tissues in mice leads to build up of 
sulfinic Prdx3 and suppression of the diurnal production of corticosterone [206]. The authors 
propose that this build-up of inactive sulfinic Prdx3 plays a physiological role in signifying that 
sufficient cortisol has been synthesized, thus exerting a level of negative feedback independent of 
the HPA axis. It is also therefore possible that this mechanism comes into play in pathophysiology, in 
conditions where mitochondrial redox homeostasis is impaired. One could postulate that defects in 
the TXNRD2/TXN2 and SRX system may have the most impact in this regard. 
Oxidative stress impedes steroidogenesis and steroidogenesis itself induces oxidative stress as a 
result of electron leak throughout the steroidogenic pathway. Within the mitochondria this leak can 
occur at various points in the pathway, through components such as ferredoxin, ferredoxin 
reductase and the cytochrome P450 enzymes [178]. The final step of cortisol production, catalysed 
by P450c11β1 within the mitochondria, accounts for a significant proportion of electron leak during 
steroidogenesis [178]. This, together with the higher production of cortisol in comparison to 
aldosterone, may explain the particular susceptibility of the zona fasciculata to oxidative stress and 
hence individuals with TXNRD2 and NNT mutations develop primarily glucocorticoid deficiency.  
Oxidative stress is also demonstrated to have an effect on the expression of key players in 
steroidogenesis including STAR and P450c11β [219, 220]. Indeed this is seen in the triple A syndrome 
in vitro model, described in Chapter 3. One would therefore expect in conditions where 
mitochondrial redox homeostasis is specifically impaired, as in TXNRD2 deficiency, expression of 
these enzymes with mitochondrial localisation, would be similarly reduced. Instead in our TXNRD2-
KD H295R model there are no observable differences. Indeed we do not see a difference in cortisol 
production in this in vitro model. There are several possible explanations for this. One needs to 
consider the role of potential compensatory systems in the maintenance of redox homeostasis for 
steroidogenesis. Certainly the glutathione and glutathione reductase system have a part to play and 
we see increased pressure on this system within our model. A potential role for the other forms of 
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TXNRD also needs to be considered, in particular TXNRD1. The embryonic phenotypes of Txnrd1 and 
Txnrd2 knockout mice are less severe than the knockouts for Txn1 and Txn2, implying that there may 
be some functional overlap between Txnrd1 and Txnrd2 during embryogenesis [250-253]. 
Interestingly, TXNRD1-silencing in HeLa cells, resulting in approximately 90% knockdown, 
demonstrates no increase in the TXN1 redox state, suggesting that even 10% residual TXNRD1 
activity is sufficient for activity and/or there are other enzymes aside from TXNRD1 that can reduce 
TXN1 [293]. This may also therefore be the case for mitochondrial thioredoxin system. Furthermore 
in vitro studies suggest that Txnrd1 and Txnrd2 appear to lack preferences towards Txn1 and Txn2 
and both thioredoxins appear to be equally good substrates for both Txnrd1 and Txnrd2 [274]. 
TXNRD1 is demonstrated to have cytoplasmic location [272]. However, the transcription of human 
TXNRD1 is a complex process and alternative splicing in the 5’ region lends to different isoforms, one 
of which is noted to encode a mitochondrial localisation system [294]. Certainly in my knockdown 
model the total thioredoxin reductase activity was not significantly diminished indicating potential 
TXNRD1 activity upregulation. Thus more compensation than originally anticipated may exist. It is 
possible that genetic variability in these complex compensatory mechanisms could influence the age 
of presentation of adrenal insufficiency in the kindred studied and indeed in some of the patients, 
the rather late presentation in comparison to other inherited forms of FGD. 
In considering the lack of impact on steroidogenesis seen in my in vitro model, one needs to also 
consider the model system itself. The H295R cell line is a human adrenocortical tumour cell line. This 
clonal cell line has been used extensively as an in vitro model for steroidogenesis. Since conducting 
my experiments further data has been published relating to the use of this model system for 
investigating steroidogenesis, specifically in the context of the peroxiredoxin and sulfiredoxin 
systems [295]. Cultured H295R cells, which produce cortisol upon stimulation with forskolin, express 
SRX at a high level in order to survive in ambient conditions. Furthermore the total levels of PRDX3 
are greatly reduced in the cell line in comparison to the adrenal gland [295]. Taken together this is 
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likely to lead to very little in the way of PRDX3 hyperoxidation, and indeed the authors demonstrate 
that forskolin stimulation does not to lead to PRDX3 hyperoxidation in this cell line [295]. Thus in my 
model, whilst the levels of the PRDX3 oxidised dimer are increased in the TXNRD2-knockdown cells, 
with some impact on mitochondrial superoxide production, it is possible that high levels of SRX 
present in this in vitro model prevent PRDX3 hyperoxidation and therefore ameliorate any impact on 
steroidogenesis.  
There is compelling evidence that the TXNRD2 mutation identified is associated with disease in this 
family. TXNRD2 is abundantly expressed in the adrenal cortex and is downstream of NNT (mutations 
of which are associated with FGD in a significant proportion of our cohort). Absence of the 56 kDa 
TXNRD2 protein is seen in patient lysates and there is a clear impact on redox homeostasis in the 
TXNRD2-deficient H295R cells. However whilst I see an increase in mitochondrial ROS production in 
TXNRD2-deficient H295R cells I do not observe a difference in steroidogenesis in this in vitro model. 
This potentially relates to challenges in disease modelling; therefore to further interrogate the 
potential impact of TXNRD2 deficiency on steroidogenesis other models of disease need to be 
considered in any future investigations, discussed further in Chapter 6.  
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Chapter 6 
General discussion and future work 
6.1 Oxidative stress and adrenocortical insufficiency 
Reactive Oxygen Species (ROS) play an important physiological role in steroidogenesis however in 
excess they can have deleterious effects on adrenal function. Steroidogenesis itself increases the 
generation of ROS rendering the adrenal gland susceptible to oxidative damage.  
In redox terms, mitochondria are the most reducing compartment in mammalian cells and have the 
highest rates of electron transfer (accounting for greater than 90% of electrons to O2 as the terminal 
electron acceptor); they are therefore highly sensitive to oxidation. Mitochondria are also 
responsible for the majority of cellular ROS production secondary to electron leak as a consequence 
of respiration. Further electron leak by the cytochrome P450 enzymes during steroidogenesis 
renders adrenal mitochondria acutely vulnerable to redox imbalance [178]. Inherited mutations in 
NNT disrupt mitochondrial redox homeostasis leading to FGD [177]. NNT uses energy from the 
mitochondrial proton gradient to regenerate NADPH from NADP+, using NADH produced in the 
tricarboxylic acid (TCA) cycle. NADPH in turn is required as a reducing agent for the two major 
mitochondrial thiol antioxidant systems, dependent upon GSH and thioredoxin. I have described a 
mutation in TXNRD2, which acts downstream of NNT, associated with FGD. TXNRD2 encodes a 
selenoprotein with important functions in preventing oxidative damage in the mitochondria. As 
mitochondria function as the ‘power house’ of the cells and there is  high lipid turnover here during 
steroidogenesis, it is unsurprising that that the adrenal is particularly sensitive to defects in 
mitochondrial antioxidant defence. It remains to be seen whether other manifestations of TXNRD2 
dysfunction will develop and patients in both cohorts remain under close follow-up. Careful 
phenotyping during follow-up will help further elucidate the role of NNT and TXNRD2 in human 
biology. 
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Peroxisomes also play an important role in lipid metabolism and are in close communication with 
mitochondria. Peroxisomal dysfunction too has been associated with adrenal insufficiency. X-linked 
adrenoleukodystrophy (ALD) is an inherited neurometabolic disorder incorporating 
neurodegenerative disease and adrenal insufficiency [9]. The disease is caused by mutations in the 
ABCD1 gene on Xq28, encoding the adrenoleukodystrophy protein (ALDP), a member of the 
peroxisomal ATP-binding cassette (ABC) transporters. ALDP imports VLCFA-CoA esters into the 
peroxisome for degradation by β-oxidation [296], with particularly high expression in cells 
characterised by steroid hormone production (the adrenal gland and testis) [297].  
Histology from both ALD mouse models and human specimens suggests involvement of oxidative 
stress in the pathogenesis of the disease, with evidence of increased MnSOD and lipid peroxidation 
[298]. Increased ROS production, depletion of GSH and decreased mitochondrial membrane 
potential are described in patient dermal fibroblasts [299]. VLCFAs are substrates of β-oxidation 
within the peroxisomes, a process that aids acyl-CoA availability and subsequent synthesis of 
plasmalogens, phospholipids with reported antioxidant properties [300-302]. As both organelles are 
in communication, generation of ROS within peroxisomes can disturb the mitochondrial redox 
balance [303]. VLCFAs may also have direct effects on mitochondrial function and structural 
abnormalities including lipid accumulation are seen within the mitochondria in Abcd1 -/- mice [304]. 
It is also proposed that VLCFAs may be involved in signalling within the immune system exacerbating 
inflammation which in turn can have further effects on ROS and RNS generation [305]. Whilst mouse 
models for X-linked ALD are able to recapitulate some of the neurodegenerative aspects of the 
human disease; with regards to adrenal function, similar to the Aaas-/- model, no effect is seen on 
corticosterone production at either basally or upon stress [304, 307, 308]. 
Nuclei, like mitochondria, also have reduced redox potentials, however they are relatively resistant 
to oxidation [309]. This is of significance as sequestration of DNA within the nuclei protects the 
genome from reactive chemicals that can build up in other subcellular compartments. Despite this, 
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H2O2, nitric oxide and organic hydroperoxides can diffuse into nuclei. The GSH and thioredoxin 
systems (through TXN1) also play a role in the nucleus. The GSH system has been demonstrated to 
play a role in protecting DNA and DNA binding proteins from oxidative stress [310, 311]. 
Furthermore it regulates nuclear matrix organisation, chromosome consolidation, DNA synthesis and 
DNA repair [312-314]. GSH is postulated to act as a ‘redox sensor’ at the onset of DNA synthesis by 
providing the appropriate redox environment for DNA replication thereby safeguarding DNA 
integrity [315].  Both the GSH and TXN1 systems may also play a role in providing a more reducing 
environment for binding of transcription factors to DNA [316, 317]. The antioxidant TXN1 also 
translocates from the cytoplasm into the nucleus during conditions of oxidative stress [318]. Nuclear 
GSH and TXN1 function distinctly from the respective cytoplasmic systems. Whilst TXN1 appears to 
shuttle freely into the nucleus the mechanism of GSH transport into the nucleus is unknown [315]. 
The NPC is the sole site of transport between the nucleus and cytoplasm. The NPC has been 
implicated in adrenocortical insufficiency, with mutations in AAAS, encoding ALADIN an NPC protein, 
causing triple A syndrome [24, 25]. Failure of nuclear import of DNA repair proteins and FTH1, with 
antioxidant properties, is reported in triple A syndrome patient dermal fibroblasts [107, 127, 128]. 
How these nuclear import defects lead to an increase in intracellular ROS remains unclear. DNA 
fragmentation and increased apoptosis are reported as a consequence of these defects. 
Furthermore, increased chromosomal fragility is also reported [223], a finding that has also recently 
been described in cases of FGD within the Irish traveller community, caused by mutations in the DNA 
replicase mini chromosome maintenance protein 4 (MCM4) [173]. In this study I have demonstrated 
that ALADIN-deficient adrenal cells are more susceptible to oxidative stress, with a decrease in the 
reduced to oxidised glutathione (GSH/GSSG) ratio. These cells are more prone to cell cycle arrest and 
apoptosis. I have demonstrated that AAAS-knockdown in H295R cells also affects key components of 
the steroidogenic pathway, STAR and P450c11β expression, with an impact on cortisol production, 
164 
 
an effect that is partially reversed with antioxidant N-acetylcysteine treatment, which replenishes 
GSH.  
In triple A syndrome and ALD, the zona fasciculata and zona reticularis are most impacted, affecting 
glucocorticoid and adrenal androgen production [10, 150]. Deficiency of adrenal androgens which is 
reported in both conditions, can be a sensitive marker of adrenal insufficiency and occurs prior to 
glucocorticoid deficiency [10]. In our kindred with the TXNRD2 mutation, the post-pubertal patients 
are also noted to have low adrenal androgens. This has not been previously reported in the cohort of 
patients with FGD and NNT mutations. Steroid production is itself associated with ROS production. 
Therefore, in these disorders involving defects in antioxidant defence, it stands to reason that the 
layers of the adrenal cortex are affected in order of relative steroid production, with the zona 
glomerulosa and mineralocorticoid production least affected and in some cases, not affected at all.  
Further interrogation of the pathogenic mechanisms in triple A syndrome and FGD secondary to 
TXNRD2 mutations is required. It is very likely that excessive oxidative stress impacts negatively on 
steroidogenic cells at a number of different levels. Grossly, oxidative stress may adversely affect cell 
proliferation leading to increased apoptosis. Further interrogation of DNA damage including DNA 
fragmentation would be useful in both the AAAS- and TXNRD2-knockdown H295R models. More 
subtle effects on cell signalling are also likely; including the steroidogenic machinery itself such as 
the PRDX3-SRX systems as described by Kil and colleagues [206]. It would be interesting to 
investigate the impact that increased oxidative stress may have on ACTH signalling including the 
interaction of MRAP with MC2R at the ER and the correct folding or trafficking of the receptor to the 
plasma membrane.  
In each of the adrenal insufficiency conditions, exploring compensatory mechanisms would be of 
particular interest since these could potentially be manipulated as future therapeutic targets. In the 
TXNRD2-deficient model further exploring the compensatory role of the glutathione system and 
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other TXNRDs is warranted. Specific interrogation of the mitochondrial subcellular compartment is 
indicated. In the first instance, repeating the thioredoxin reductase assay with mitochondrial 
fractions of lysates from the TXNRD2-knockdown and control cells would be useful to ascertain the 
effect of knockdown within this subcellular compartment. An ability to sustain thioredoxin reductase 
activity in this compartment would suggest either that the low level of TXNRD2 remaining in the 
knockdown is sufficient for activity or alternatively that other TXNRDs are present in the 
compartment and able to compensate. In depth investigation of mitochondrial function in these 
TXNRD2 deficient cells could be achieved by isolation of mitochondria allowing measurement of 
several parameters including mitochondrial respiration, ROS production and scavenging and 
susceptibility to apoptotic events. However disadvantages of this approach include the substantial 
cell number required to provide enough mitochondrial isolate for the experiments needed and the 
transient rupture of mitochondrial membranes can occur during the procedure. Furthermore, it is 
becoming evident that mitochondrial morphology is integral to its activity and disruption of 
mitochondrial architecture can occur during the isolation procedure resulting in impairment of 
function [319, 320]. Newer techniques involving extracellular flux analysis in intact and 
permeabilised cells allow investigation of mitochondrial activity without significantly disrupting 
mitochondrial architecture [321]. Techniques such as this could provide detailed information 
regarding mitochondrial activity, allowing for further interrogation of the mitochondrial antioxidants 
implicated in FGD, including TXNRD2. 
Whilst the NNT and TXNRD2 pathways are relatively well studied, delineating the function of ALADIN 
is more challenging. Very little is known about this NPC protein and various strategies may be 
considered to identify the cellular systems in which ALADIN may play a role.  Strategies to consider 
include identifying further interacting protein partners for ALADIN. FTH1 was identified as an 
interacting protein partner of ALADIN using a bacterial two-hybrid screen [107]. Yeast two-hybrid 
screens are advantageous in that interactions at low affinity can be detected though this can also 
166 
 
generate false positives. Protein-protein interactions can be investigated in a species-specific 
manner using high throughput mammalian 2 hybrid techniques [322, 323]. All of these techniques 
allow for mass screening and further focused studies on individual candidates would then be 
required to understand the interaction in context.   
Techniques such as RNA-seq could also prove to be useful in delineating differences in the 
transcriptome between control and AAAS-knockdown cells, thereby identifying biological pathways 
which are disrupted in triple A syndrome. This technique could also be applied comparing adrenal 
tissue from AAAS-/- and wild-type mouse models. Defective nuclear import is described in triple A 
syndrome and given ALADIN’s position at the NPC, it is highly likely that transport of other proteins 
across the NPC is also impaired.  Identifying the subcellular distribution of proteins and more 
importantly the changes in their localisation depending on experimental conditions is challenging. 
Techniques of ‘spatial proteomics’ may be useful in this regard, involving high throughput mass-
spectrometry based proteomics [324]. This would, for instance, allow for comparison of the nuclear 
and cytoplasmic fractions of ALADIN-deficient and control cells, at baseline and in conditions of 
oxidative stress, thereby identifying subtle changes in transport across the NPC.  
There remain a population of triple A syndrome patients with adrenal insufficiency who are AAAS-
mutation negative. Adopting a genomic approach by exploring genetic variants in this cohort of 
patients could provide further useful information of the role that ALADIN may play in human 
biology. WES in the cohort of triple A syndrome patients without AAAS mutations and those patients 
who are mutation negative for known causes of FGD may provide further candidates within 
antioxidant defence associated with adrenal disease.  In both triple A syndrome and FGD related to 
the TXNRD2 variant, variability in disease presentation is described. This indicates potential genetic 
or environmental modifiers of these autosomal recessive diseases. It would be of interest to look for 
variants in genes encoding other antioxidant proteins, in addition to AAAS or TXNRD2 mutations, 
which may contribute to the phenotype seen in each of the conditions. This could involve targeted 
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sequencing of a designated panel of antioxidant genes or alternatively WES with filtering for the 
‘targeted’ genes. Validation of genetic modifiers is likely to be difficult, particularly when considering 
that on average each person carries approximately 300 loss of function variants and 50 to 100 
variants implicated in inherited disease as demonstrated by data generated from the 1000 genomes 
project [325]. Furthermore, particularly in the case of TXNRD2, with limited numbers of patients, this 
type of experiment would be difficult to power.  Despite the challenges involved, this could provide 
further information about critical antioxidant pathways in steroidogenesis.  
6.2 Models of disease 
6.2.1 In vitro models of disease 
In this thesis I have used lentiviral shRNA knockdown techniques to study the silencing of particular 
target genes in the in vitro environment. However as demonstrated, particularly in the TXNRD2-
knockdown H295R model, there are several limitations to using a tumour cell line for the purposes 
of this work, particularly with regards to interrogating anti-oxidant systems, as discussed in Chapter 
5. Kil and colleagues describe hyperoxidised PRDX3 impacting steroidogenesis [206]. Despite 
observing increased levels of the PRDX3 oxidised dimer in my TXNRD2-knockdown cells, there was 
no effect of knockdown on cortisol production. The high levels of SRX present in this in vitro model 
potentially prevent PRDX3 hyperoxidation and therefore may ameliorate any impact on 
steroidogenesis in this particular model [295].  
A novel and potentially exciting and productive alternative would be to use iPS cells. Human 
embryonic stem cells and human induced pluripotent stems (iPS) cells are being used increasingly in 
the fields of developmental biology and regenerative medicine. Mouse and human mesenchymal 
stem cells can be induced to differentiate into steroid-producing cells, though these have not been 
well characterised. Sonoyama and colleagues have recently demonstrated that human iPS cells 
(generated from human dermal fibroblasts) can be differentiated into adrenocortical lineage cells 
[326]. This was achieved in a multistep process, involving differentiation into the mesodermal 
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lineage in the first instance with subsequent introduction of the orphan nuclear receptor 
steroidogenic factor-1 (SF-1). SF1 performs an essential role in the formation of steroidogenic tissues 
[327]. These iPS cells demonstrated mRNA expression of genes encoding adrenocortical or gonad-
specific steroidogenic enzymes such as CYP17A1, CYP21A2 and CYP11B1 [326]. Additionally, these 
cells produced steroid hormones including progesterone, corticosterone and cortisol. The iPS cell 
model has the advantage of using patient cells, dermal fibroblasts; allowing for investigation of 
disease in patient-derived differentiated steroidogenic cells. This would provide a more faithful 
model of the disease and would also allow comparison of the effects of different types of disease-
causing mutations. Of course, models like these need to be carefully characterised prior to use. 
Difficulties with this type of model include the relatively poor proliferation of differentiated cells in 
comparison to undifferentiated cells, limiting mass expansion of cells for experimental use. 
Furthermore, as with the clonal tumour cell lines, antioxidant mechanisms are likely to be altered in 
order for cells to survive in culture in ambient conditions. As the PRDX3-SRX system potentially plays 
an important role in signalling during steroidogenesis, establishing a model system that does not 
distort antioxidant defence at baseline is ideal. Kil and colleagues have recently demonstrated the 
use of organ culture systems, in this case isolated whole adrenal organs from mice, as suitable for 
the study of this mechanism ex vivo [295]. 
6.2.2 In vivo models of disease 
In all the adrenal insufficiency conditions discussed above, mouse models of the disease do not 
faithfully recapitulate the human phenotype. With regards to ALD, FGD related to NNT, and triple A 
syndrome it is possible that additional mechanisms of antioxidant defence exist within the 
adrenocortical environment of the mouse, conferring relative protection. The Txnrd2-knockout 
mouse model is interesting in that it leads to embryonic lethality [250]. In mouse models certainly, 
the thioredoxin system appears to be of greater significance than the glutathione system, with 
knockout of various components of the thioredoxin system having far greater phenotypic impact 
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[250-253]. It is possible that in humans the glutathione system has greater weight in the adrenal. 
Establishing a mouse model with adrenal-specific knockout of Txnrd2 may provide further insight 
into the role of TXNRD2 in steroidogenesis. The adrenal cortex is dynamic and is able to remodel to 
maintain homeostasis. It is proposed that during this process of remodelling, stem cells/progenitor 
cells are recruited into the zona glomerulosa and fasciculata. The thioredoxins are required for 
proliferation and protection from apoptosis and are clearly important during embryogenesis as 
demonstrated by the embryonic lethality of the various thioredoxin knockout models [250-253]. An 
adrenal-specific Txnrd2-knockout model would allow for the investigation of a possible role for 
TXNRD2 in adrenal development during embryogenesis and remodelling thereafter. 
Given the potential limitations of mouse models to study the adrenal aspects of these diseases 
consideration should be given to other available in vivo models for further investigation of precise 
pathogenic mechanisms. Non-human primate models such as Papio hamadryas (baboons) and 
Macaca mulatta (rhesus monkeys) have been used to study age-related changes in endocrine 
function [328]. These have an advantage over rodents in that they produce DHEA/ DHEAS, with a 
steroidogenic profile therefore more reflective of that in man. Similar to man, DHEA/ DHEAS 
production decreases significantly whilst glucocorticoid production varies little with age [328, 329]. 
However older monkeys demonstrate reduced HPA axis sensitivity to glucocorticoid regulation, with 
a delay in normalisation of the axis after stimulation. This suggests impairment of negative feedback 
mechanisms, a phenomenon also observed in man. These non-human primate models have been 
used to study the effect of corticosteroids on antioxidant defence, in the context of aging [330-332]. 
Circadian rhythmicity of SOD in erythrocytes correlates well with the characterised rhythmicity of 
DHEAS and cortisol [332]. Additionally a similar age-related flattening of these SOD circadian 
rhythms is observed, suggesting a possible regulatory effect of corticosteroids on antioxidant 
defence. Age-related changes in stress responsiveness of SOD (increasing with age) and glutathione 
reductase (decreasing with age) are also described in non-human primate models [330]. This in turn 
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can lead to peroxide oxidation of lipids, haemolysis of erythrocytes and a diminished reliability of 
oxygen transport. The primate model is not however a practical model for further adrenal studies, 
particularly given efforts being made to refine, reduce, and indeed replace animal models.  
Zebrafish, however, are increasingly being used in steroid hormone research, particularly in relation 
to the effects of endocrine disruptors, such as oestrogenic compounds, gestagens and 
selenomethionine, which have negative impacts on steroidogenesis [333]. Zebrafish are amenable to 
genetic manipulation and furthermore the zebrafish genome has been completely sequenced 
(http://www.sanger.ac.uk/Projects/D_rerio/), providing a useful model for the study of candidate 
genes. Zebrafish express both aaas and tnxrd2, as yet there is no published data in relation to these 
genes in the zebrafish model. Importantly, in comparison to many other fish species the majority of 
endocrine-related genes are present in single copies simplifying knockdown approaches [334]. 
Additionally with multiple progeny following single mating and rapid embryonic development, 
zebrafish pose an attractive in vivo model system. Steroid synthesis in zebrafish occurs in several 
peripheral tissues including the gonads, brain and the interrenal. The interrenal comprises 
specialised cells within the head kidney that are homologous to the mammalian adrenal gland [335]. 
Steroidogenesis here is under the control of the hypothalamus-pituitary-interrenal axis, and similar 
to the mammalian system the first and rate limiting step involves mitochondrial transport of 
cholesterol by STAR [336]. Most of the steroidogenic enzymes apart from Cyp11B and CYP21a1 have 
been identified within zebrafish (Busby et al. 2010). The biosynthetic pathways, given the homology 
of the identified enzymes with mammalian counterparts, are postulated to be similar though the 
precise pathways need to be further functionally characterised [333, 337]. The receptors of these 
steroid hormones and subsequent signalling cascades are highly similar to those in mammals and 
relatively well characterised in adult zebrafish. Cortisol is the main stress hormone in zebrafish with 
demonstrated impact on metabolic processes, immune regulation and influence on circadian cell 
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cycle rhythmicity [338-340]. Additionally, cortisol from whole zebrafish and in zebrafish-holding 
water can be measured in high throughput assays enabling large scale sampling [341-343]. 
Oxidation-sensitive transcription factors and key components of antioxidant defence are also well 
conserved in zebrafish. Enzymes involved in de novo glutathione biosynthesis, glutathione 
peroxidase 1 (gpx1), Mn- and CuZn dependent superoxide dismutases and catalase are well 
documented in zebrafish [344-348]. The expression levels of these antioxidant enzymes are 
significantly increased in response to pollutants and drugs [349, 350]. Zebrafish larvae are optically 
transparent enabling the use of fluorescent probes, such as the fluorogenic dye 2’,7’-
dihydrodichlorofluoresceindiacetate (H2DCFDA), to study cellular shifts in oxidation  in vivo [351, 
352]. Furthermore, genetically encoded (GFP) - derivatives (Hyper or RoGFP) with highly selective 
probes for peroxides, have also been developed to investigate spatiotemporal gradients of ROS, 
which could be of particular use to study the compartment specific effects of various defects in 
antioxidant defence [353, 354]. The use of these genetically encoded sensors have been 
demonstrated in zebrafish [355]. Given the similarities in key components of the steroidogenic and 
antioxidant pathways, the zebrafish model may prove to be highly useful to elucidate the roles of 
antioxidant candidates in steroidogenesis, allowing for high throughput studies. 
6.3 Conclusion 
Disruption of normal function within several sub-cellular organelles has been associated with 
inherited primary adrenal disease, with evidence of oxidative damage.  Interestingly, in all cases, the 
proteins involved are ubiquitously expressed, albeit enriched in the adrenal cortex. Antioxidant 
defence within eukaryotic cells is complex and several overlapping systems exist which may confer 
relative protection in other organ systems. Defining the precise pathological mechanisms involved in 
these conditions will be invaluable in providing information on prognosis and directing patient 
surveillance. Furthermore, it may be possible to identify and manipulate compensatory mechanisms 
to delay onset or prevent progression of disease. 
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APPENDIX 1 
cDNA Primer Sequences 
Name 
 
Sequence (5’ to 3’) Amplicon (bp) 
AAAS1 for 
 
GCCAGCAGCACCATAGTC 190 bp 
AAAS1 rev 
 
CAGGGTGAGACAGCACTTG 
AAAS2 for 
 
GAGCCACTGATTTACTCCCTG 167 bp 
AAAS2 rev 
 
CCAGACCATGGAGTGAGC 
GAPDH for 
 
GAAGGTGAAGGTCGGAGTC 206 bp 
GAPDH rev 
 
GAAGATGGTGATGGGATTTC 
StAR 1 for 
 
GACATTCAAGCTGTGCGCTG 191 bp 
StAR 1 rev 
 
TGTAGAGAGTCTCTTCTAGCCGA 
TXNRD2 cDNA for 
 
TTGAGGTCTATCACGCCC  
TXNRD2 cDNA rev 
 
CTTGAGTAACTTCGCCTGC 
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APPENDIX 2 
Genomic DNA Primer Sequences 
Name 
 
Sequence (5’ to 3’) 
TXNRD2 EX1 for 
 
AGTGTTCCACCCTAGGTCTGA 
TXNRD2 EX1 rev 
 
GGTATGTGGACACCCCC 
TXNRD2 EX2 for AATGGAGTGTCCAATCCTG 
 
TXNRD2 EX2 rev GCTCATGGACGTTTTCTG 
 
TXNRD2 EX3 for TCACAAGCCCTGAGGAG 
 
TXNRD2 EX3 rev CTGAAGGACTTTGGTGTCAG 
 
TXNRD2 EX4 for TGTCAGCTGGTCTGTGTTAG 
 
TXNRD2 EX4 rev GCTGAGAAACCCATCCTAC 
 
TXNRD2 EX5 for CCATTTGAATCTAATAGTCCATC 
 
TXNRD2 EX5 rev CATGCTCTGCACAGTAAGTAAG 
 
208 
 
TXNRD2 EX6 for TCCCTTTTACCAGTGTTCC 
 
TXNRD2 EX6 rev TTACTAAGAACAGCACCCAG 
 
TXNRD2 EX7 for GGTCTGTGGTGCTCAGG 
 
TXNRD2 EX7 rev AAAGGGTGTGCAAGCTG 
 
TXNRD2 EX8 for GGAAAGCTCTGCTTGATTC 
 
TXNRD2 EX8 rev CACCAGCACAGGCTCTAAG 
 
TXNRD2 EX9 for TTGAACAGTAACCTTGGAGC 
 
TXNRD2 EX9 rev AGTAAGTGCCGATCTGAGG 
 
TXNRD2 EX10 for GTCTTGAGTTGGGAGCC 
 
TXNRD2 EX10 rev CATCCAATTCAAGGGTTATC 
 
TXNRD2 EX11 for CTTCATTGAGGCCTTCG 
 
TXNRD2 EX11 rev GAGGTGACAGGAAGTGGG 
 
TXNRD2 EX12 for CGGTCTCTAAGTGGACATTC 
209 
 
 
TXNRD2 EX12 rev CTCCTACAGGACGGCAG 
 
TXNRD2 EX13&14 for 
 
GAGGGCAAAGGGTGATG 
TXNRD2 EX13&14 rev 
 
CTGGAAAGGAGAGACCTTG 
TXNRD2 EX15&16 for 
 
GCAGCACTGATCCAGGGTT 
TXNRD2 EX15&16 rev 
 
CGCATCGCAGCCTGCATTCC 
TXNRD2 EX17 for 
 
CTGAGGCCCTCCTCTTC 
TXNRD2 EX17 rev 
 
GTAGCCTTGCTGTACACCTG 
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APPENDIX 3 
 
AAAS shRNA sequences (Sigma- Aldrich) 
 
Name Sequence (5’ to 3’) Product code 
shRNA 22 CCGGCCAAGGGTACAGGATGGTAAACTCGAGTTTACCATCC
TGTACCCTTGGTTTTTG 
TRCN0000118922 
shRNA 23 CCGGCCGACTGCTGTTCACTGTATTCTCGAGAATACAGTGAA
CAGCAGTCGGTTTTTG 
TRCN0000118923 
shRNA 24 CCGGGCGAAGATCTGATCGCTGAATCTCGAGATTCAGCGAT
CAGATCTTCGCTTTTTG 
TRCN0000118924 
shRNA 25 CCGGTGCATCAACATTTGGCGTGATCTCGAGATCACGCCAAA
TGTTGATGCATTTTTG 
TRCN0000118925 
shRNA 26 CCGGCGAAGATCTGATCGCTGAATTCTCGAGAATTCAGCGA
TCAGATCTTCGTTTTTG 
TRCN0000118926 
 
A combination of shRNA 24 and 26 (TRCN0000118924, TRCN0000118926) was used in the study as it 
achieved best AAAS-knockdown in the H295R cells and SH-SY5Y cells. 
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TXNRD2 shRNA sequences (Openbiosystems) 
Name Sequence (5’ to 3’) Product code 
shRNA 171 ACATTGTCGTAGTCCATCA (Exon 13) V3LHS_354171 
shRNA 173 
TACATAACACTGGGATGCA (Exon 15) 
V3LHS_354173 
 
shRNA 174 TTTTGAACAGCTTCTGCCA (Exon 5) V3LHS_354174 
 
shRNA 603 TTTGCATTGCAGAAATGCC (Exon 18) V2LHS_63603 
 
shRNA 607 TTACATAACACTGGGATGC (Exon 15) V2LHS_63607 
 
 
shRNA 173 (V3LHS_354173) was used in the study as it achieved best TXNRD2-knockdown in the 
H295R cells. 
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APPENDIX 4 
Vector Maps 
Sigma pLKO.1 puro lentiviral shRNA vector used for AAAS-knockdown and scrambled control 
Vector element Utility 
Cppt Central polypurine tract 
hPGK Human phosphoglycerate kinase eukaryotic 
promoter 
puroR Puromycin resistance gene for mammalian 
selection 
SIN/LTR 3' self-inactivating long terminal repeat 
f1 ori f1 origin of replication 
ampR Ampicillin resistance gene for bacterial selection 
pUC ori pUC origin of replication 
5' LTR 
 
5' long terminal repeat 
Psi 
 
RNA packaging signal 
RRE 
 
Rev response element 
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Sigma pLKO.1 puro lentiviral shRNA vector used for AAAS-knockdown and scrambled control 
(cont) 
 
 
 
 
 
 
 
214 
 
Openbiosystems GIPZ Lentiviral shRNA vector used for TXNRD2-knockdown and scrambled control 
 
 
 
 
 
 
215 
 
APPENDIX 5 
Details of antibodies used in western blotting 
Name of antibody Peptide/ Protein Target Manufacturer, 
catalogue # 
Species raised in; 
monoclonal or polyclonal 
Dilution used 
Anti-Adracalin antibody Recombinant fragment, corresponding to 
amino acids 1-101 of Human Adracalin 
Abcam, #ab56384 Mouse; monoclonal 1 in 500 
Anti-GAPDH antibody Rabbit muscle GAPDH Abcam, #ab8245 Mouse; monoclonal 1 in 5000 
Anti-GAPDH antibody Full length native protein from human 
erythrocytes 
Abcam,  #ab9485 
 
Rabbit; polyclonal 1 in 5000 
Anti- STAR antibody Recombinant fragment,  corresponding to 
amino acids 81-180 of Human StAR 
Abcam, #ab58013 Mouse; monoclonal 1 in 1000 
PARP antibody Synthetic peptide corresponding to the caspase Cell Signalling, #9542 Rabbit; polyclonal 1 in 1000 
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cleavage site in PARP 
Polyclonal Anti-CYP11B1 CYP11B1 full length human protein Sigma, #SAB1401106 Rabbit; polyclonal 1 in 200 
Anti-CYP11A1 Cytochrome P450 11A1, mitochondrial 
precursor recombinant protein epitope 
signature tag (PrEST) 
Sigma, #HPA016436 Rabbit; polyclonal 1 in 500 
Anti-TXNRD2 antibody Immunogen incorporating amino acid 
sequence 203 to 353 of TXNRD2 
Sigma, #HPA003323 Rabbit; polyclonal 1:500 
Anti-TXNRD1 antibody Human recombinant full length protein Abcam, #ab16840 Rabbit; polyclonal 1:500 
Anti-Peroxiredoxin III 
antibody 
Human peptide Proteintech, #55087-1-AP Rabbit polyclonal 1:400 
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APPENDIX 6 
Details of the candidate variants remaining following the penultimate filtration step applied to my WES data; i.e homozygous variants common to all 3 
individuals, with a MAF <0.01 in dbSNP 
  
Where #Chrom (Chromosome), left (refers to position on the left of the variant), right (refers to position on the right of the variant), ref Seq (the base in 
the reference sequence), var Seq (the variant base seen in our 3 individuals in homozygosity), CDS (coding sequence). The final column indicates the 
anticipated disruptive change.
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Details of the candidate variants remaining following the penultimate filtration step applied to my WES data (cont) 
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Appendix 7 
Details of candidate variants following the final filtration step applied to WES data 
Variants in the 3 affected members of the kindred, filtering for non-synonymous coding variants, splice variants and indels only; variants with a MAF 
>0.01 in GO-ESP were also excluded.  
 
Where Chrom (Chromosome), left (refers to position on the left of the variant), right (refers to position on the right of the variant), ref Seq (the base in the 
reference sequence), Var type (type of variation), INS (insertion), SNP (single nucleotide polymorphism), Hom (variant seen in homozygosity), var Seq 1 (the 
variant base in allele 1), var Seq 2 (the variant base in allele 2), coverage (refers to the read coverage in the WES data), CDS (coding sequence). The final 
column refers to the anticipated disruptive change.  
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APPENDIX 8 
GENERAL BUFFERS AND SOLUTIONS 
The following buffers/ solutions were prepared for general laboratory use: 
Buffer/ Solution  Formulation 
BS3 conjugation buffer For 5mM solution 2mg Bis(sulfosuccinimidyl)suberate (BS3)(#21580, 
Thermo Fisher Scientific) was dissolved in 700 µl dH2O 
dNTPs Sequencing grade dNTPs [100mM] (Promega)  were combined in a 
1:1:1:1 ratio (dATP:dCTP:dGTP:dTTP) in dH2O to produce a 10mM 
stock solution dNTP mix which was stored at -20C 
 
LB Agar 10g Agar (#A1296, Sigma), 10g LB Broth (# L3022, Sigma) in 500ml 
dH2O 
LB Broth 10g LB Broth in 500ml dH2O 
MOPS running buffer [1x] 50 ml MOPS SDS Running buffer [20x] (#NP0001-02, Invitrogen) in 
1L dH2O 
PBS 5 tab Phosphate Buffer Saline (#P4417, Sigma) in 1L dH2O 
PBS Tween 5 tab Phosphate Buffer Saline (#P4417, Sigma) in 1L dH2O, 0.01% 
Tween (Sigma) 
Transfer buffer [1x] 2.42g Tris, 9g glycine, 800 ml dH2O, 200ml methanol 
3M Sodium Acetate Dissolve 40.8g sodium acetate in 80 ml H2O. Adjust pH to 5.2 with 
glacial acetic acid; make final volume up to 100ml and autoclave 
221 
 
APPENDIX 9 
COMMERCIAL ASSAYS USED AND COMPOSITION of REAGENTS 
CellTiter96 Aqueous non–radioactive cell proliferation assay (MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay) (Promega, Southampton, UK): 
DPBS (MTS reagent): 0.2 g KCl; 8.0 g NaCl; 0.2 g KH2PO4; 1.15 g Na2HPO4; 100 mg 
MgCl2*6H2O; 133 mg CaCl2*2H2O (room temperature dH2O is added to KCl, NaCl, KH2PO4 
and Na2HPO4 to a 1L final volume. pH is adjusted to 7.5 by addition of 1N HCl; MgCl2*6H2O 
and CaCl2*2H2O are then added) 
Phenazine methosulfate (PMS): 0.92 mg/ml PMS in DPBS 
illustra Nucleon Genomic DNA Extraction Kit (GE Healthcare, Buckinghamshire, UK): 
Reagent A (lysis agent): 10 mM Tris-HC1; 320 M sucrose; 5 mM MgCl2; 1%(v/v) Triton X-100; 
pH 8.0 (pH adjusted using 40%(w/v) NaOH) 
Reagent B: (precise composition is not disclosed by the company) 
5 M Sodium percholate 
Nucleon resin: includes potassium hydroxide (precise composition is not disclosed by the 
company) 
GSH/GSSG-Glo assay (Promega, Southampton, UK): 
GSH-Glo Reagent: Luciferin-NT substrate (100 µl) and Glutathione S-Transferase Solution 
(100 µl) diluted 1:00 in 10 ml GSH-Glo Reaction Buffer (50mM Tricine (pH 7.9)) (sufficient for 
a complete 96 well plate) 
Luciferin Detection Reagent: Reconstitution Buffer with esterase added to lyophilized 
Luciferin Detection Reagent 
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Glutathione 5mM: for standard curve (serial dilutions in water to generate standards ranging 
from 0 µM to 5 µM) 
   
PAXgene Blood RNA kit (Qiagen, Crawley, UK): 
Buffer BR1 (Resuspension Buffer): (precise composition is not disclosed by the company) 
Buffer BR2 (Binding Buffer): contains a guanidine salt (precise composition is not disclosed by 
the company) 
Buffer BR3 (Wash Buffer): contains a guanidine salt, as well as ethanol (precise composition 
is not disclosed by the company) 
Buffer BR4 (Wash Buffer): ethanol containing (precise composition is not disclosed by the 
company) 
Buffer BR5 (Elution Buffer): (precise composition is not disclosed by the company) 
RNase-Free Water   
Proteinase K  
DNase I, RNase-Free (lyophilized) 
Buffer RDD: allows digestion of DNA also ensures RNA remains bound to the column. 
(precise composition is not disclosed by the company) 
Other components of the kit: PAXgene Blood RNA Tube (contains propriety reagent, 
composition of which protects RNA molecules from degradation by RNases); PAXgene RNA 
Spin Columns; Processing Tubes (2 ml); Microcentrifuge Tubes (1.5 ml); PAXgene Shredder 
Spin Columns 
  
Qiagen HI SPEED Plasmid Midi Kit (Qiagen, Crawley, UK): 
Buffer P1 (resuspension buffer): 50 mM Tris·Cl; 10 mM EDTA; 100 µg/ml RNase A 
Buffer P2 (lysis buffer): 200 mM NaOH; 1% SDS (w/v) 
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Buffer P3 (neutralisation buffer): 3.0 M potassium acetate, pH 5.5 
Buffer QBT (equilibration buffer): 750 mM NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol 
(v/v); 0.15% Triton® X-100 (v/v) 
Buffer QC (wash buffer): 1.0 M NaCl; 50 mM MOPS, pH 7.0; 15% isopropanol (v/v) 
Buffer QF (elution buffer): 1.25 M NaCl; 50 mM Tris·Cl, pH 8.5; 15% isopropanol (v/v) 
Other components of the kit: QIAfilter Cartridge; QIAGEN-tip 
 
Qiagen RNeasy mini kit (Qiagen, Crawley, UK): 
Buffer RLT (lysis buffer): contains a guanidine salt (precise composition is not disclosed by the 
company) 
Buffer RW1 (stringent wash buffer): contains a guanidine salt, as well as ethanol (precise 
composition is not disclosed by the company) 
Buffer RPE (mild wash buffer): Ethanol containing (precise composition is not disclosed by the 
company) 
Other components of the kit: RNeasy mini spin columns (with silica membrane for RNA 
binding); Collection tubes (1.5; 2 ml); RNase-free water 
 
Qiagen QIAquick Gel extraction kit (Qiagen, Crawley, UK): 
Buffer QG (solubilization and binding buffer, with pH indicator): 5.5 M guanidine 
thiocyanate, 20 M Tris Hcl pH 6.6 
Buffer PE (wash buffer): 10 mM Tris-HCl pH 7.5; 80% ethanol 
Other components of the kit: QIAquick spin column; Collection tube (2 ml) 
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Thioredoxin reductase (TXNRD) assay kit (Abcam, Cambridge, UK):  
TrxR Assay Buffer: 500 mM potassium phosphate, pH 7.0, containing 500 mM potassium 
chloride, 10 mM EDTA, and 2 mg/ml BSA (10x prep) 
DTNB (lypophilized): 5,5’-dithiobis (2-nitrobenzoic) acid dissolved into 0.9 ml Assay Buffer 
(sufficient for 100 assays) 
NADPH (lypophilized): dissolved with 0.22 ml dH2O (sufficient for 100 assays) 
TNB Standard (2.5 µM; lypophilized): dissolve in 0.5 ml Assay buffer generating 5 mM TNB 
standard 
TrxR Positive control (~ 20 mU; lypophilized): dilute 10 µl TrxR with 90 µl Assay Buffer 
TrxR Inhibitor (lypophilized): dissolve into 1.2 ml Assay Buffer (sufficient for 100 assays) 
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APPENDIX 10 
PRESENTATIONS 
Oral Communications: 
• Prasad R., Chan L.F., Hughes C.R., Kaski J.P., Kowalczyk J., Savage M.O., Peters C.J., Nathwani N., 
Clark A.J., Storr H.L., Metherell L.A. A mutation in thioredoxin reductase 2 (TXNRD2) is associated 
with familial glucocorticoid deficiency.  
ESPE, Milan, Sep 2013 
• Prasad R., Hughes C.R., Chan L.F., Peters C.J., Nathwani N., Clark A.J., Storr H.L., Metherell L.A. 
Thioredoxin reductase 2 mutation associated with familial glucocorticoid deficiency.  
William Harvey Research Institute, June 2013; shortlisted for Young Investigator of The Year 
• Prasad R., Hughes C.R., Chan L.F., Peters C.J., Nathwani N., Clark A.J., Storr H.L., Metherell L.A. 
Thioredoxin reductase 2 mutation associated with familial glucocorticoid deficiency.  
 ENDO, San Francisco, June 2013 
• Prasad R., Hughes C.R., Chan L.F., Peters C.J., Nathwani N., Clark A.J., Storr H.L., Metherell L.A. A 
mutation in thioredoxin reductase 2 (TXNRD2) is associated familial glucocorticoid deficiency. 
ESPE adrenal development seminar, Bern, May 2013 
• Prasad R., Hughes C.R., Chan L.F., Peters C.J., Nathwani N., Clark A.J., Storr H.L., Metherell L.A. A 
mutation in thioredoxin reductase 2 (TXNRD2) is associated with a predominantly adrenal 
phenotype in humans.  
British Endocrine Society Meeting, Harrogate, March 2013 
• Prasad R., Clark A.J.L., Storr H.L. Deficiency of ALADIN, the AAAS gene product, renders human 
adrenal and neuronal cells susceptible to oxidative stress.  
William Harvey Research Institute Annual Research Review, London, Jul 2012 
• Prasad R., Clark A.J.L., Storr H.L. Deficiency of ALADIN, the AAAS gene product, renders human 
adrenal and neuronal cells susceptible to oxidative stress.  
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European Society of Paediatric Endocrinology, Leipzig, Sep 2012 
• Prasad R., Clark A.J.L., Storr H.L. Deficiency of ALADIN, the triple A syndrome gene product, 
renders human adrenal cells susceptible to oxidative stress with subsequent impact on 
steroidogenesis  
British Society for Paediatric Endocrinology and Diabetes Annual Meeting, Leeds, Nov 2012 
 
Poster Presentations: 
• Prasad R., Clark A.J.L., Storr H.L. Oxidative stress in the pathogenesis of Triple A Syndrome.  
39th Meeting of the British Society for Paediatric Endocrinology and Diabetes, London, Nov 2011 
• Prasad R., Clark A.J.L., Storr H.L. Oxidative stress in the pathogenesis of Triple A Syndrome.  
British Endocrine Society Meeting, Harrogate, March 2012 
• Prasad R., Clark A.J.L., Storr H.L. Oxidative stress and the regulation of ALADIN and its interacting 
protein partner, Ferritin Heavy Chain 
Endocrine Society Meeting, Houston, Jun 2012 
• Prasad R., Clark A.J.L., Storr H.L. Deficiency of ALADIN, the AAAS gene product, renders human 
adrenal and neuronal cells susceptible to oxidative stress.  
Society for Free Radical Research International, London, Sep 2012 
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